

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

PCT/SE 2005 / 0 0 0 0 9 7

**Intyg
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) Sökande Medivir AB, Huddinge SE
Applicant (s)

(21) Patentansökningsnummer 0401288-6
Patent application number

(86) Ingivningsdatum 2004-05-19
Date of filing

Stockholm, 2005-04-20

*För Patent- och registreringsverket
For the Patent- and Registration Office*


Görel Gustafsson

Avgift
Fee

BEST AVAILABLE COPY

R² is C₁-C₆alkyl, C₀-C₃alkylcarbocyclyl, C₀-C₃alkylheterocyclyl;

R^3 is C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, $-OC_1$ - C_6 alkyl, $-OC_0$ - C_3 alkylcarbocyclyl, $-OC_0$ - C_3 alkylheterocyclyl;

R^4 is $=O$, halo, amino, or OH ;

$R^{4'}$ is C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl; wherein

5 R^2 , R^3 , and $R^{4'}$ are each optionally substituted with from 1 to 3 times with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-R_b$, $Y-C(=O)R_b$, $Y-(C=O)NRaR_b$, $Y-NRaC(=O)R_b$, $Y-NHSO_pR_b$, $Y-S(=O)_pR_b$, $Y-S(=O)_pNRaR_b$, $Y-C(=O)OR_b$, $Y-NRaC(=O)OR_b$;

10 where Y is a bond or C_1 - C_3 alkyl;

R_a is H or C_1 - C_3 alkyl;

R_b is H , C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl or C_0 - C_3 heterocyclyl;

p is 1 or 2;

15 R^7 is C_1 - C_6 alkyl, C_1 - C_3 alkyl C_3 - C_7 cycloalkyl, or C_2 - C_6 alkenyl, any of which is optionally substituted with 1-3 halo atoms, amino or $-SH$;

$R^{7'}$ is H or taken together with R^7 to form a C_3 - C_6 cycloalkyl ring optionally substituted with $R^{7'a}$ wherein;

$R^{7'a}$ is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_6 alkenyl or J ; any of which may be optionally substituted with halo;

20 q is 0 to 3 and k is 0 to 3; where $q+k \geq 1$;

W is $-CH_2-$, $-O-$, $-OC(=O)NH-$, $-OC(=O)-$, $-S-$, $-NH-$, $-NR^8$, $-NHSO_2-$, $-NHC(=O)NH-$ or $-NHC(=O)-$;

25 R^8 is a ring system containing 1 or 2 saturated or unsaturated rings each of which has 4-7 ring atoms and 0 to 2 hetero atoms selected from S , O and N , the ring system being optionally spaced from W by a C_1 - C_3 alkyl group; or R^8 is C_1 - C_6 alkyl, any of which R^8 groups can be optionally mono, di, or tri substituted with R^9 , wherein

30 R^9 is independently halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-R_b$, $Y-C(=O)R_b$, $Y-(C=O)NRaR_b$, $Y-NRaC(=O)R_b$, $Y-NHSO_pR_b$, $Y-S(=O)_pR_b$, $Y-S(=O)_pNRaR_b$, $Y-C(=O)OR_b$, $Y-NRaC(=O)OR_b$; wherein the carbocyclyl or heterocyclyl is optionally substituted with R^{10} ; wherein

R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or di- substituted with C_1 - C_6 -alkyl, sulfonyl, (C_1 - C_3 alkyl)sulfonyl, NO_2 , OH, SH, halo, haloalkyl, carboxyl, amide, (C_1 - C_3 alkyl)amide, or heteroaryl optionally substituted with C_1 - C_6 alkyl;

5 R^8 is H, C_1 - C_3 alkyl;

E is $-C(=O)-$, $-C(=S)-$, $-S(=O)_2-$, $-S=O-$, $-C=N-R_f$;

R_f is H, $-CN$, $-C(=O)NRaRa$; $-C(=O)C_1$ - C_3 alkyl

X is $-NR_x-$ where R_x is H, or C_1 - C_5 alkyl; or in the case where where E is $-(C=O)-$, X can also be $-O-$ or $-NR_jNR_j-$; wherein one of R_j is H, the other is H or J;

10 R^{11} is H, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-R_b$, $Y-C(=O)R_b$, $Y-(C=O)NRaR_b$, $Y-NRaC(=O)R_b$, $Y-NHSO_pR_b$, $Y-S(=O)_pR_b$, $Y-S(=O)_pNRaR_b$, $Y-C(=O)OR_b$, $Y-NRaC(=O)OR_b$;

15 when R^7 taken together with R^7 forms a C_3 - C_6 cycloalkyl, then one of R_j , R_x , R_y or R^{11} can also be J;

J is a 3 to 10-membered saturated or unsaturated alkylene chain extending from the R^7/R^7 cycloalkyl to R_j , R_x , R_y or R^{11} to form a macrocycle, which chain is optionally interrupted by one to three heteroatoms independently selected from: $-O-$, $-S-$ or $-$

20 $NR^{12}-$ wherein 0 to 3 carbon atoms in the chain are optionally substituted with R^{14} ; wherein;

R^{12} is H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or COR^{13} ;

R^{13} is C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl;

R^{14} is independently selected from H, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, hydroxy, halo, amino, oxo, thio, or C_1 - C_6 thioalkyl;

25

Ru and Rz are independently H or C_1 - C_3 alkyl;

m is 0 or 1; n is 0 or 1;

U is $=O$ or is absent;

30 R^{16} is H, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-R_b$, $Y-C(=O)R_b$, $Y-(C=O)NRaR_b$, $Y-$

M183-2

4

NRaC(=O)R_b , $\text{Y-NHSO}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{NRaR}_b$, Y-C(=O)OR_b , Y-NRaC(=O)OR_b ;


G is $-\text{O}-$, $-\text{NR}_y-$, $-\text{NR}_j\text{NR}_j-$,

where R_y is H, $\text{C}_1\text{-C}_3$ alkyl or J;

- 5 R^{16} is H; or $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, $\text{NH}_2\text{CO}-$, Y-NRaR_b , Y-O-R_b , Y-C(=O)R_b , Y-(C=O)NRaR_b , Y-NRaC(=O)R_b , $\text{Y-NHSO}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{NRaR}_b$, Y-C(=O)OR_b , Y-NRaC(=O)OR_b ;

- 10 or a pharmaceutically acceptable salt or prodrug thereof.

A second aspect of the invention provides compounds of the formula VI:



- 15 wherein

R^7 , $\text{R}^{7'}$, R^8 , R^{11} , R^{15} , R^{16} , R_j , R_u , R_x , R_y , A , G , k , m , n , U are as defined above;

q' is 0 or 1;

R_z is H, or together with the asterisked carbon forms an olefinic bond;

R_q is H or $\text{C}_1\text{-C}_4$ -alkyl;

- 20 T is $-\text{CHR}^{11}-$ or $-\text{NR}_d-$, where R_d is H or $\text{C}_1\text{-C}_3$ alkyl;

in the case where R^7 taken together with $\text{R}^{7'}$ forms a $\text{C}_3\text{-C}_6$ cycloalkyl, one of R_j , R_x , R_y , R_d or R^{11} can be J;

M183-2

5

J is a 5 to 10 membered saturated or unsaturated alkylene chain extending from the $R^7/R^{7'}$ cycloalkyl to R_d , R_j , R_x , R_y , or R^{11} to form a macrocycle, which chain is otherwise as defined above;
and pharmaceutically acceptable salts and prodrugs thereof.

5

Without in any way wishing to be bound by theory, or the ascription of tentative binding modes for specific variables, the notional concepts P1, P2, P3 and P4 as used herein are provided for convenience only and have substantially their conventional meanings and denote those portions of the inhibitor believed to fill the S1, S2, S3 and S4 subsites respectively of the enzyme, where S1 is adjacent the cleavage site and S4 remote from the cleavage site. Regardless of binding mode, the components defined by Formula I, VI etc are intended to be within the scope of the invention. For example it is expected that capping group R^{16} -G may interact with the S3 and S4 subsites.

15

The compounds of the present invention, can be briefly represented as R^{16} -G-P4-P3-link-P2-P1, wherein P3 and/or P4 may be absent, and P1, P3 and P4 each represents a building block constituted of a derivative of a natural or unnatural amino acid, P2 is a cyclic residue and G and R^{16} are capping groups. The link is a carbonyl or other function as defined for E. The P1 and P2 building blocks and the P3 and P4 building blocks are thus typically linked together by amide bonds whereas the P2 and P3 building blocks are linked through the above described link. The amide bonds are thereby typically reversed relative to each other on each side of the link in the compounds of the invention

25

Additional aspects of the invention include a pharmaceutical composition comprising a compound of the invention as defined above and a pharmaceutically acceptable carrier or diluent therefore.

30


The compounds and compositions of the invention have utility in methods of medical treatment or prophylaxis of HCV infections in humans. Accordingly, a further aspect

M183-2

6

of the invention is the use of a compound as defined above in the manufacture of a medicament for the prophylaxis or treatment of flavivirus infections in humans or animals. Exemplary flavivirus include BVDV, dengue and especially HCV.

- 5 Preferred values for q and k in Formula I include 2:1, 2:2, 2:3, 3:2, 3:3, more preferably 1:2 and 1:0; and most preferably 1:1, in which case preferred compounds have the partial structure:




where e is 1 or 2.

10

It is currently preferred that E is $-C(=O)-$ or $-C=N-R_f$, for example where R_f is $-CN$ or $-C(=O)NH_2$

- 15 Preferred values for q' and k in formula VI include 1:1, 1:2, 1:3, 2:2, 2:3, more preferably 0:2 and 0:0; and most preferably 0:1, in which case preferred compounds have one of the partial structures:




especially where R_z is H or R_q is H or methyl.

20


Compounds of the invention may comprise both a P3 and a P4 function, viz m and n are each 1. Favoured embodiments within formula I include formula I da-l dd below:

M183-2


7




Ida



Idb




Idc




Idde

Favoured embodiments within Formula VI comprising both a P3 and P4 function include formula VIda-VIdb below:



VIda




VIdb


M183-2

8


Alternative configurations of the compounds of the invention comprise a P3, but no P4 function, viz m is 1 and n is zero. Preferred embodiments within Formula I include formulae lea-lee below:




lea




leb



lec



led




lee

5

Favoured embodiments within Formula VI comprising a P3, but no P4 include formula VI ea-Vleb below:

M183-2

9




Still further alternative configurations of the compounds of the invention include those where m and n are zero and thus groups R¹⁶-G about P2, but as mentioned

5 above, the capping group R¹⁶-G may interact favourably with S3 and/or S4.


Favoured embodiments within Formula I include formulae Ifa-lfe below:

M183-2


10




Ifa




Ifb



Ifc




Ifd



Ife

Favoured embodiments within Formula VI wherein m and n are zero include those of formula VIfa below:



VIfa





- 5 The compounds of the invention may comprise linear molecules, as depicted above. Alternatively, in embodiments wherein R^7 and $R^{7'}$ together define a spiro cycloalkyl group, such as spiro-cyclopropyl, the compounds of the invention may be configured as macrocycles, wherein a linking group J extends between R_j , R_x , R_y or R^{11} of formula I or R_j , R_x , R_y , R_d or R^{11} of Formula VI.

10



Favoured embodiments of such macrocyclic structures within formula I wherein m is 0 and n is 1 include those of Formulae Iga-Igd below:

M183-2

11



Additional favoured embodiments of such macrocyclic structures within formula I wherein m is 0 and n is 1 include those of Formulae Ige-Igf below:




5

Favoured macrocyclic structures within Formula I, comprising both a P3 and P4 function, ie wherein m and n are each 1, include those of the formulae Iha-Ihd below.

M183-2




12




Favoured embodiments of macrocyclic structures within formula VI comprising a P3 function, but no P4 include those of the formula VIga- VIgc below:

M183-2

13



Favoured embodiments of macrocyclic structures within formula VI comprising both a P3 and P4 functions, include those of the formula VIha- VIhc below:



In general, in the optionally macrocyclic structures such as those illustrated above, linker J is a 3 to 10 chain atom, preferably 5 to 8 chain atom, such as 6 or 7 chain atom, saturated or unsaturated alkylene chain. The length of the chain will, of course, depend on whether J extends from R_d, R_j, R_x, R_y or R¹¹. Suitable chains are described in detail in WO 00/59929.

Conveniently, the J chain contains one or two heteroatoms selected from: O, S, NH, NC₁-C₆ alkyl or N-C(=O)C₁-C₆alkyl. More preferably, the J chain optionally contains one heteroatom selected from: NH, or N-C(=O)C₁-C₆alkyl, most preferably N(Ac). Most preferably, the chain containing a nitrogen atom is saturated. Alternatively, J

contains one heteroatom selected from: O, or S. Preferably, this chain is substituted with R^{14} , such H or methyl. Even more preferably, J is saturated.

Alternatively, J contains a double bond, typically spaced one carbon from the cycloalkyl R^7 function. The double bond may be cis or trans.

Representative examples of J thus include pentanyl, hexanyl, heptanyl, any of which are substituted with C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, hydroxyl, halo, amino, oxo, thio or C_1 - C_6 thioalkyl; penten:3:yl, hexen:4:yl, hepten:5 yl, where 3, 4 or 5 refers to a double bond between 3 carbon atoms 3 and 4, 4 and 5 etc.

10

Convenient R^7 and $R^{7'}$ groups include those wherein $R^{7'}$ is H and R^7 is n-ethyl, n-propyl, cyclopropylmethyl, cyclobutylmethyl, 2,2-difluoroethyl, or mercaptomethyl. Preferred embodiments include those wherein R^7 is n-propyl or 2,2-difluoroethyl.

Alternatively, R^7 and $R^{7'}$ together define a spiro-cycloalkyl function, such as a spiro-cyclobutyl ring, and more preferably a spiro-cyclopropyl ring. The ring is substituted or unsubstituted. Preferred substituents include mono or di-substitutions with $R^{7'a}$ wherein $R^{7'a}$ is C_1 - C_6 alkyl, C_3 - C_5 cycloalkyl, or C_2 - C_6 alkenyl, any of which is optionally substituted with halo. Alternatively the substituent may be a J linker as described above.

20

Particularly preferred substituents include $R^{7'a}$ as ethyl, vinyl, cyclopropyl, 1- or 2-bromoethyl, 1-or 2-fluoroethyl, 2-bromovinyl or 2-fluorethyl. Currently preferred stereochemistries for a spiro-cyclopropyl ring are defined below.

25

A favoured configuration for A is $-CR^4R^{4'}$ as illustrated in detail in PCT/EP03/10595, the contents of which are incorporated by reference.

30

Convenient $R^{4'}$ groups thus include C_1 - C_6 alkyl, such as methyl, ethyl, propyl, ethenyl and $-\text{CHCHCH}_3$. Alternative preferred $R^{4'}$ groups include aryl or heteroaryl such as optionally substituted phenyl, pyridyl, thiazolyl or benzimidazolyl or C_1 - C_3 alkylaryl or

C₁-C₃alkylheteroaryl, where the alkyl moiety is methyl, ethyl, propyl, ethenyl and -CHCHCH₃. Preferred aryl moieties include optionally substituted phenyl, benzothiazole and benzimidazole.

- 5 Favoured R⁴ groups include -NH₂, fluoro or chloro. Alternative preferred R₄ groups include -OH and especially =O.

- An alternative favoured configuration for A is CONHR³, where R³ is optionally substituted C₀-C₃alkylaryl, C₀-C₃alkylheteroaryl, OC₀-C₃alkylaryl or OC₀-C₃alkylheteroaryl.
- 10

- An alternative favoured configuration for A is CONHSO₂R², especially where R² is optionally substituted C₁-C₆ alkyl, preferably methyl, or optionally substituted C₃-C₇cycloalkyl, preferably cyclopropyl, or optionally substituted C₀-C₆alkylaryl, preferably optionally substituted phenyl.
- 15


A particularly preferred configuration for A is COOR¹, especially where R¹ is C₁-C₆ alkyl, such as methyl, ethyl, or tert-butyl and most preferably hydrogen.

- 20 Substituent -W-R₈ to the cyclic P₂ group can employ any of the proline substituents which are extensively described in WO 00/59929, WO 00/09543, WO 00/09558, WO 99/07734, WO 99/07733, WO 02/60926, WO 03/53349, WO03064416, WO03064455, WO03064456, WO0 03/99274, WO03/99316 and the like,

- 25 Preferred W functions include W is -OC(=O)NH-, -OC(=O)-, -NH-, -NR⁸-, -NHS(O)₂- or -NHC(=O)-, especially -OC(=O)NH- or -NH-. Favoured R⁸ groups for such W functions include optionally substituted C₀-C₃-alkylcarbocyclyl or C₀-C₃-alkylheterocyclyl, including those described in WO0009543, WO0009558 and WO 00/174768. For example ester substituents include those disclosed in WO 01/74768
- 30 such as C₁-C₆ alkyl, C₀-C₃aryloyl, particularly (optionally substituted) benzoyl or C₀-C₃ het-oyl, especially

M183-2

17



This publication also describes alternative $-W-R^8$ possibilities such as C_1-C_6 alkyl, such as ethyl, isopropyl, C_0-C_3 -cycloalkyl such as cyclohexyl, 2,2-difluoroethyl, $-C(=O)NR^c$, where R^c is C_1-C_6 alkyl, C_0-C_3 -cyclopropyl, C_0-C_3 -aryl or C_0-C_3 -heterocyclyl.

Currently preferred W functions include $-S-$ and especially $-O-$. Convenient values for R^8 in such embodiments include C_0-C_3 alkylaryl, or C_0-C_3 alkylheteroaryl either of which is optionally mono, di, or tri substituted with R^9 , wherein;

R^9 is C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2 , OH , halo, trifluoromethyl, amino or amido optionally mono- or di-substituted with C_1-C_6 alkyl, C_0-C_3 alkylaryl, C_0-C_3 alkylheteroaryl, carboxyl, aryl or heteroaryl being optionally substituted with R^{10} ; wherein

R^{10} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, amino optionally mono- or di-substituted with C_1-C_6 alkyl, C_1-C_3 alkyl amide), sulfonyl C_1-C_3 alkyl, NO_2 , OH , halo, trifluoromethyl, carboxyl, or heteroaryl.

Preferred R^9 is C_1-C_6 alkyl, C_1-C_6 alkoxy, amino, di- $(C_1-C_3$ alkyl)amino, C_1-C_3 alkylamide, aryl or heteroaryl, the aryl or heteroaryl being optionally substituted with

R^{10} ; wherein

R^{10} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, amino, mono- or di- C_1-C_3 alkylamino, amido, C_1-C_3 alkylamide, halo, trifluoromethyl, or heteroaryl.

Preferred R^{10} include C_1-C_6 alkyl, C_1-C_6 alkoxy, amino optionally mono- or di substituted with C_1-C_3 alkyl, amido, C_1-C_3 -alkylamide, halo, or heteroaryl.


Particularly preferred R^{10} include methyl, ethyl, isopropyl, tert-butyl, methoxy, chloro, amino optionally mono- or di substituted with C_1-C_3 alkyl, amido, C_1-C_3 alkylamide, or C_1-C_3 alkyl thiazole.

M183-2

18

Especially preferred R^8 include 1-naphthylmethyl, 2-naphthylmethyl, benzyl, 1-naphthyl, 2-naphthyl, or quinolyl unsubstituted, mono, or disubstituted with R^9 as defined, in particular 1-naphthylmethyl, or quinolyl unsubstituted, mono, or disubstituted with R^9 as defined.

A currently preferred R^8 is:






10

wherein R^{9a} is C_1-C_6 alkyl; C_1-C_6 alkoxy; thio C_1-C_3 alkyl; amino optionally substituted with C_1-C_6 alkyl; C_0-C_3 alkylaryl; or C_0-C_3 alkylheteroaryl, C_0-C_3 alkylheterocyclyl, said aryl, heteroaryl or heterocycle being optionally substituted with R^{10} wherein

R^{10} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, amino optionally mono- or di-substituted with C_1-C_6 alkyl, amido, C_1-C_3 alkyl amide, heteroaryl or heterocyclyl; and

R^{9b} is C_1-C_6 alkyl, C_1-C_6 -alkoxy, amino, di(C_1-C_3 alkyl)amino, (C_1-C_3 alkyl) amide, NO_2 , OH, halo, trifluoromethyl, carboxyl.

Convenient R^{9a} include aryl or heteroaryl, all optionally substituted with R^{10} as defined, especially where R^{9a} is selected from the group consisted of :




wherein R^{10} is H, C_1-C_6 alkyl, or C_0-C_3 alkyl- C_3-C_6 cycloalkyl, amino optionally mono- or di-substituted with C_1-C_6 alkyl, amido, (C_1-C_3 alkyl)amide, heteroaryl or heterocyclyl.

M183-2

19


R^{9a} is conveniently phenyl and thus R^8 is:



- 5 wherein R^{10a} is H, C_1 - C_6 alkyl; C_1 - C_6 alkoxy; or halo; and R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl)amide, NO_2 , OH, halo, trifluoromethyl, carboxyl.

An alternative preferred R^8 is:

10



- 15 wherein R^{10a} is H, C_1 - C_6 alkyl, or C_0 - C_3 alkyl- C_3 - C_6 cycloalkyl, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, amido, (C_1 - C_3 alkyl)amide, heteroaryl or heterocyclyl; and R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl)amide, NO_2 , OH, halo, trifluoromethyl, or carboxyl.


In the immediately above described embodiments R^{9b} is conveniently C_1 - C_6 -alkoxy, preferably methoxy.

20

A further ether substituent R^8 has the formula

M183-2

20



where W is N or CH, r is 0 or 1, Ra is H, C₁-C₆ alkyl, C₀-C₃cycloalkyl, C₁-C₆ alkyloxy, hydroxy or amine and Rb is H, halo, C₁-C₆ alkyl, C₀-C₃cycloalkyl, C₁-C₆ alkyloxy, C₁-C₆ thioalkyl, cycloalkylC₀-C₃alkyloxy, C₁-C₃alkyloxyC₁-C₃alkyl, C₀-C₃aryl or C₀-C₃heterocyclyl. A particularly preferred ether substituent is 7-methoxy-2-phenyl-quinolin-4-yl oxy.


Preferred P3 groups resemble natural or unnatural amino acids, especially aliphatic amino acids, such as L-valyl, L-leucyl, L-isoleucyl or L-t-leucyl. Further preferred P3 groups, as shown in WO 02/01898 include C₀-C₃ cycloalkyl, especially cyclohexylalanine, optionally substituted with CO₂Rg, where Rg is H, is C₁-C₆ alkyl, C₀-C₃-alkylaryl, C₀-C₃alkylhet, C₀-C₃alkylcycloalkyl or amine; or N-acetylpiperidine or tetrahydropyran. Preferred R¹¹ groups thus include C₁-C₆alkyl, C₀-C₃ alkylC₃-C₇ cycloalkyl, C₀-C₃alkylaryl or C₀-C₃ alkylheteroaryl, any of which is optionally substituted with hydroxy, halo, amino, C₁-C₆alkoxy, C₁-C₆thioalkyl, COOR¹⁴, carboxyl, (C₁-C₆alkoxy)carbonyl, aryl, heteroaryl or heterocyclyl, especially where the substituent is hydroxy or COOR¹⁴.

Particularly preferred R¹¹ include tert-butyl, iso-butyl, cyclohexyl, phenylethyl, 2,2-dimethyl-propyl, cyclohexylmethyl, phenylmethyl, 2-pyridylmethyl, 4-hydroxy-phenylmethyl, or carboxylpropyl. The most preferred R¹¹ values are currently tert-butyl, iso-butyl, or cyclohexyl.

Favoured embodiments of the invention include those wherein P4 is absent (ie n is 0) and wherein the P3 function lacks a carbonyl, ie U is absent. Currently preferred substructures include those of formula li below:

M183-2

21



II

wherein

Rx and Ry are as defined above, preferably H,

R¹¹ is C₁-C₆ alkyl, preferably C₃-C₅ branched alkyl such as the side chains of L-valyl,


- 5 L-leucyl, L-isoleucyl, L-t-leucyl; or C₀-C₂alkyl/C₃-C₇ cycloalkyl such as cyclohexyl or cyclohexylmethyl;

R^{16a} is -Rba, -S(=O)pRba, -(=O)Rba


Rba is C₁-C₆ alkyl, C₀-C₃-alkylheterocyclyl, C₀-C₃-alkylcarbocyclyl.

- 10 Alternatively, compounds of partial structure II may be macrocyclised between an appropriate value of R⁷ and one of Rx, Ry or R¹¹.


Representative embodiments of P3 groups which lack a carboxy function (ie variable U is absent) include those of formula Iia-Iid below:




Iia



Iib



Iic



Iid

- 15 where Ar is carbocyclyl or heterocyclyl, especially aryl or heteroaryl, any of which is optionally substituted with R⁹. Although the partial structures of Formulae Iia - Iid



have been illustrated in the context of a compound within Formula I, it will be apparent that such configurations of Formula II apply also to Formula VI, and to other values of q, q' and k . Similarly, although the partial structures of formulae Iic and IId show an R11 group corresponding to leucine, it will be apparent that these configurations will be applicable to other R11 groups, especially those resembling the side chains of natural or unnatural L-amino acids, for example t-butyl alanine/t-leucine.

R¹⁵ in those compounds of the invention wherein n is 1, is preferably optionally substituted C₁-C₆alkyl, C₃-C₇cycloalkyl or C₀-C₃alkylC₃-C₇cycloalkyl, any of which may be optionally substituted. Preferred P4 groups are typically analogues of natural or unnatural amino acids, especially aliphatic amino acids such as L-valyl, L-leucyl, L-isoleucyl, L-t-leucyl or L-cyclohexylalanine and thus favoured R¹⁵ groups include cyclohexyl, cyclohexylmethyl, tert-butyl, iso-propyl, or iso-butyl.

Preferred G values include -NR_y-, especially wherein R_y is methyl or preferably H, or hydrazine.



A further preferred G value is O thereby defining an ester with the carbonyl of P4 (if present) or the carbonyl of P3 (if present) or an ether in the case of variants wherein group U is absent. Conventional pharmaceutically acceptable ethers or esters capping groups for R¹⁶ include C₁-C₆alkyl (especially methyl or t-butyl), C₀-C₃alkylheterocyclyl (especially pyridyl, benzimidazolyl, piperidyl, morpholinyl, piperazinyl) or C₀-C₃alkylcarbocyclyl (especially phenyl, benzyl, indanyl) any of which is optionally substituted with hydroxy, halo, amino, or C₁-C₆alkoxy.

Favoured compounds of the invention can comprise a hydrazine functionality, for example where X is -NHNH- and m is 1; with n being zero or 1. Alternatively, especially where m is zero, G can be -NHNH-. Compounds will generally not comprise a hydrazine at both G and X. Typical hydrazines within Formula I, wherein m and n are zero include compounds of the partial structures Ija- Ijb below:



R^{16} in formulae Ija and Ijb can be regarded as an alkyl (or C_1 - C_3 -alkylheterocyclyl or C_1 - C_3 alkyl carbocyclyl) wherein the first alkyl carbon is substituted with an oxo group to defined the keto function and R^{16} is the remainder of the alkyl, alkylheterocyclyl or alkylcarbocyclyl moiety. Formula Ijb depicts a variant where R^{16} is a methylene group whose carbon is substituted with an oxo substituent and also $-OR_b$, where R_b is as defined above, typically, C_1 - C_6 alkyl, such as t-butyl, C_0 - C_3 alkylheterocyclyl such as pyridyl, or C_0 - C_3 -carbocyclyl, such as benzyl or phenyl, any of which is optionally substituted as defined above. Compounds of partial structures Ija and Ijb can be linear molecules as shown (both R_j are H), or preferably one of the depicted J groups can be macrocyclised to an appropriate R^7 group.

Alternative hydrazines of Formula I where m is 1 include those of partial structures Ijc and Ijd below:





where R^{16} , G, R^{11} R_j and Ru are as defined for formula I above. Compounds of partial structures Ijc and Ijd can be linear molecules as shown (both R_j are H), or preferably one of the depicted J groups, or the R_{11} group can be macrocyclised to an appropriate R^7 group

M183-2

24

Although formula Ija-Ijd are depicted with a proline analogue as P2, it will be apparent that this aspect of the invention is equally adapted to other configurations of q and k.




- 5 Favoured embodiments within formula VI include those with the substructures of formula VIja- VIjb:



- where Rq and Rz are as defined above and Q and K are $-(CH_2)_{q'}$ and $-(CH_2)_k$ respectively. Currently preferred embodiments within Formulae VIja and VIjb include those wherein q' is zero (ie Q is a bond) and k is 1, ie K is methylene, especially those wherein Rq is H or methyl and Rz is H or forms an olefinic bond. Compounds of partial structures VIja and VIjb can be linear molecules as shown (both Rj are H), or preferably one of the depicted J groups can be macrocyclised to an appropriate R⁷ group

15

- Alternative hydrazine-like configuration are found when G is amino, and m and n are 0, and R¹⁶ is an N-linked unsaturated heterocycle as defined below, for example pyridyl or pyrimidyl or a saturated heterocycle as defined below, such as piperazinyl, piperidinyl and especially morpholinyl. Examples of such embodiments include those of the formulae Ije and VIjc and VIjd:



20

Compounds of partial structures Ije, VIjc and VIjd can be linear molecules as shown or preferably Rx can be macrocyclised to an appropriate R^7 group. Although these partial structures are depicted with a five membered ring for P2, it will be readily
5 apparent that this configuration extends to other values of q, q' and k. Similarly these configurations will be applicable to other N-linked heterocycles as R^{16} .

Returning now to Formulae I and VI in general, favoured R^{16} groups for the compounds of the invention include 2-indanol, indanyl, 2-hydroxy-1-phenyl-ethyl, 2-
10 thiophenemethyl, cyclohexylmethyl, 2,3-methylenedioxybenzyl, cyclohexyl, phenyl, benzyl, 2-pyridylmethyl, cyclobutyl, iso-butyl, n-propyl, methyl, or 4-methoxyphenylethyl.

Currently preferred R^{16} groups include 2-indanol, indan, 2-hydroxy-1-phenyl-ethyl, 2-
15 thiophenemethyl, 2,3-methylenedioxybenzyl, or cyclohexylmethyl.

Unnatural amino acids include L-amino acids wherein the side chain is not one of the
20 naturally occurring amino acids. Examples of non-natural amino acids include L-beta-methylsulfonylmethylalanine, L-cyclohexylalanine, L-tertiary-leucine, L-norleucine, L-norvaline, L-ornithine, L-sarcosine, L-citulline, L-homophenylalanine, L-homoserine, L-beta-(1-naphthyl)alanine, L-beta-(2-naphthyl)alanine etc. Non natural amino acids also include the D-amino acids corresponding to the 20 natural amino acids and D-amino acids bearing other side chains, such as those listed above.

25 'C₁-C₆-alkyl' (also abbreviated as C₁-C₆-alk in compound expressions such as C₁-C₆-alkyloxy etc) as applied herein is meant to include straight and branched chain aliphatic carbon chains such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, heptyl and any simple isomers thereof. The alkyl group
30 may have an unsaturated bond. Additionally, any C atom in C₁-C₆-alkyl may optionally be substituted by one, two or where valency permits three halogens and/or

a heteroatom S, O, NH. If the heteroatom is located at a chain terminus then it is appropriately substituted with one or 2 hydrogen atoms.

'C₁-C₃-alkyl' as applied herein includes methyl, ethyl, propyl, isopropyl, cyclopropyl, any of which may be optionally substituted as described in the paragraph above or in the case of C₂ or C₃, bear an unsaturated bond such as CH₂=CH.

'Amine' includes NH₂, NHC₁-C₃-alkyl or N(C₁-C₃-alkyl)₂.

10 'Halo' or halogen as applied herein is meant to include F, Cl, Br, I, particularly chloro and preferably fluoro.

15 "C₀-C₃-aryl" as applied herein is meant to include a phenyl, naphthyl or phenyl fused to C₃-C₇ cyclopropyl such as indanyl, which aryl is directly bonded (ie C₀) or through an intermediate methyl, ethyl, propyl, or isopropyl group as defined for C₀-C₃-alkyl above. Unless otherwise indicated the aryl and/or its fused cycloalkyl moiety is substituted with 1-3 substituents selected from halo, hydroxy, nitro, cyano, carboxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkanoyl, amino, azido, oxo, mercapto, nitro C₀-C₃carbocyclyl, C₀-C₃-heterocyclyl. "Aryl" has the
20 corresponding meaning.

25 'C₀-C₃-carbocyclyl' as applied herein is meant to include C₀-C₃-aryl and C₀-C₃ alkyl C₃-C₇ cycloalkyl. Unless otherwise indicated the aryl or cycloalkyl group is substituted with 1-3 substituents selected from halo, hydroxy, nitro, cyano, carboxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkanoyl, amino, azido, oxo, mercapto, nitro, C₀-C₃carbocyclyl and/or C₀-C₃-heterocyclyl. "Carbocyclyl" has the corresponding meaning, i.e. where the C₀-C₃ alkyl linkage is absent

30 'C₀-C₃-heterocyclyl' as applied herein is meant to include a monocyclic, saturated or unsaturated, heteroatom-containing ring such as piperidinyl, morpholinyl, piperazinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazinyl, Isothiazinyl, thiazolyl,

oxadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, furanyl, thienyl, pyridyl, pyrimidyl, pyridazinyl, pyrazolyl, or any of such groups fused to a phenyl ring, such as quinolinyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazinyl, benzisothiazinyl, benzothiazolyl, benzoxadiazolyl, benzo-1,2,3-triazolyl, benzo-1,2,4-triazolyl, benzotetrazolyl, benzofuranyl, benzothienyl, benzopyridyl, benzopyrimidyl, benzopyridazinyl, benzopyrazolyl etc, which ring is bonded directly ie (C₀), or through an intermediate methyl, ethyl, propyl, or isopropyl group as defined for C₀-C₃-alkyl above. Any such non-saturated rings having an aromatic character may be referred to as heteroaryl herein. Unless otherwise indicated the hetero ring and/or its fused phenyl moiety is substituted with 1-3 substituents selected from halo, hydroxy, nitro, cyano, carboxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkanoyl, amino, azido, oxo, mercapto, nitro, C₀-C₃ carbocyclyl, C₀-C₃-heterocyclyl. "Heterocyclyl" and "Heteroaryl" has the corresponding meaning, i.e. where the C₀-C₃ alkyl linkage is absent.

15

Typically heterocyclyl and carbocyclyl groups are thus a monocyclic ring with 5 or especially 6 ring atoms, or a bicyclic ring structure comprising a 6 membered ring fused to a 4, 5 or 6 membered ring.

20 Typical such groups include C₃₋₈ cycloalkyl, phenyl, benzyl, tetrahydronaphthyl, indenyl, indanyl, heterocyclyl such as from azepanyl, azocanyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, pyranlyl, tetrahydropyranlyl, tetrahydrothiopyranlyl, thiopyranlyl, furanyl, tetrahydrofuranyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, tetrazolyl, pyrazolyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, quinazolinyl, tetrahydroquinazolinyl and quinoxalinyl, any of which may be substituted as defined herein.

30

The saturated heterocycle thus includes radicals such as pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl, indolinyl, azetidyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, hexahydropyrimidinyl, hexahydropyridazinyl, 1,4,5,6-
 5 tetrahydropyrimidinylamine, dihydro-oxazolyl, 1,2-thiazinanyl-1,1-dioxide, 1,2,6-thiadiazinanyl-1,1-dioxide, isothiazolidinyl-1,1 -dioxide and imidazolidinyl-2,4-dione, whereas the unsaturated heterocycle include radicals with an aromatic character such as furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl,
 10 pyrimidinyl, pyrazinyl, indoliziny, indolyl, isoindolyl. In each case the heterocycle may be condensed with a phenyl ring to form a bicyclic ring system.

In general preferred monocyclic rings include substituted pyridyl, substituted pyrimidyl, substituted phenyl, particularly phenyl substituted with a cyclic group such
 15 as pyrrolidine-1-yl, piperidine-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, 2-morpholin-4-yl-ethylamino, and piperazin-1-yl, piperid-4-yl or N-piperazinyl, N-substituted with Ra or piperidin-1-yl which is 4-substituted with -NRaRb.

Synthesis of the compounds of the present invention can be performed by different
 20 chemical strategies in solution or solid phase or a combination of both. The suitably protected individual building blocks can first be prepared and subsequently coupled together i.e. $P2+P1 \rightarrow P2-P1$. Alternatively, precursors of the building blocks can be coupled together and modified at a later stage of the synthesis of the inhibitor sequence. Further building blocks, precursors of building blocks or prefabricated
 25 bigger fragments of the desired structure, can then be coupled to the growing chain, e.g. $R^{16}-G-P3+ E-P2-P1 \rightarrow R^{16}-G-P3-P2-P1$ or $R^{16}-G-P4-P3+E-P2-P1 \rightarrow R^{16}-G-P4-P3-E-P2-P1$.

Coupling between two amino acids, an amino acid and a peptide, or two peptide
 30 fragments can be carried out using standard coupling procedures such as the azide method, mixed carbonic-carboxylic acid anhydride (isobutyl chloroformate) method,

carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble carbodiimide) method, active ester (p-nitrophenyl ester, N-hydroxysuccinic imido ester) method, Woodward reagent K-method, carbonyldiimidazole method, phosphorus reagents or oxidation-reduction methods. Some of these methods (especially the carbodiimide method) can be enhanced by adding 1-hydroxybenzotriazole or 4-DMAP. These coupling reactions can be performed in either solution (liquid phase) or solid phase.

More explicitly, the coupling step involves the dehydrative coupling of a free carboxyl of one reactant with the free amino group of the other reactant in the presence of a coupling agent to form a linking amide bond. Descriptions of such coupling agents are found in general textbooks on peptide chemistry, for example, M. Bodanszky, "Peptide Chemistry", 2nd rev ed., Springer-Verlag, Berlin, Germany, (1993) hereafter simply referred to as Bodanszky, the contents of which are hereby incorporated by reference. Examples of suitable coupling agents are N,N'-dicyclohexylcarbodiimide, 1-hydroxybenzotriazole in the presence of N,N'-dicyclohexylcarbodiimide or N-ethyl-N'-[(3-dimethylamino) propyl] carbodiimide. A practical and useful coupling agent is the commercially available (benzotriazol-1-yloxy) tris-(dimethylamino) phosphonium hexafluorophosphate, either by itself or in the presence of 1-hydroxybenzotriazole or 4-DMAP. Another practical and useful coupling agent is commercially available 2-[(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate. Still another practical and useful coupling agent is commercially available O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

The coupling reaction is conducted in an inert solvent, e. g. dichloromethane, acetonitrile or dimethylformamide. An excess of a tertiary amine, e. g. diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine or 4-DMAP is added to maintain the reaction mixture at a pH of about 8. The reaction temperature usually ranges between 0 °C and 50 °C and the reaction time usually ranges between 15 min and 24 h.

The functional groups of the constituent amino acids generally must be protected during the coupling reactions to avoid formation of undesired bonds. The protecting groups that can be used are listed in Greene, "Protective Groups in Organic Chemistry", John Wiley & Sons, New York (1981) and "The Peptides: Analysis, Synthesis, Biology", Vol. 3, Academic Press, New York (1981), hereafter referred to simply as Greene, the disclosures of which are hereby incorporated by reference.

The α -carboxyl group of the C-terminal residue is usually protected as an ester that can be cleaved to give the carboxylic acid. Protecting groups that can be used include 1) alkyl esters such as methyl, trimethylsilyl and t.butyl, 2) aralkyl esters such as benzyl and substituted benzyl, or 3) esters that can be cleaved by mild base or mild reductive means such as trichloroethyl and phenacyl esters.

The α -amino group of each amino acid to be coupled must be protected. Any protecting group known in the art can be used. Examples of such groups include: 1) acyl groups such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate groups such as benzyloxycarbonyl (Cbz or Z) and substituted benzyloxycarbonyls, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate groups such as tertbutyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate groups such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl groups such as triphenylmethyl and benzyl; 6) trialkylsilyl such as trimethylsilyl; and 7) thiol containing groups such as phenylthiocarbonyl and dithiasuccinoyl. The preferred α -amino protecting group is either Boc or Fmoc. Many amino acid derivatives suitably protected for peptide synthesis are commercially available.

The α -amino protecting group is cleaved prior to the next coupling step. When the Boc group is used, the methods of choice are trifluoroacetic acid, neat or in dichloromethane, or HCl in dioxane or in ethyl acetate. The resulting ammonium salt is then neutralized either prior to the coupling or in situ with basic solutions such as aqueous buffers, or tertiary amines in dichloromethane or acetonitrile or

dimethylformamide. When the Fmoc group is used, the reagents of choice are piperidine or substituted piperidine in dimethylformamide, but any secondary amine can be used. The deprotection is carried out at a temperature between 0 °C and room temperature usually 20-22 °C.

5

Any of the natural or non-natural amino acids having side chain functionalities will typically be protected during the preparation of the peptide using any of the above described groups. Those skilled in the art will appreciate that the selection and use of appropriate protecting groups for these side chain functionalities depend upon the amino acid and presence of other protecting groups in the peptide. In the selection of such protecting groups it is desirable that the group is not removed during the deprotection and coupling of the α -amino group.

For example, when Boc is used as the α -amino protecting group, the following side chain protecting groups are suitable: p-toluenesulfonyl (tosyl) moieties can be used to protect the amino side chain of amino acids such as Lys and Arg; acetamidomethyl, benzyl (Bn), or tert-butylsulfonyl moieties can be used to protect the sulfide containing side chain of cysteine; benzyl (Bn) ethers can be used to protect the hydroxy containing side chains of serine, threonine or hydroxyproline; and benzyl esters can be used to protect the carboxy containing side chains of aspartic acid and glutamic acid.

When Fmoc is chosen for the α -amine protection, usually tert. butyl based protecting groups are acceptable. For instance, Boc can be used for lysine and arginine, tert.butyl ether for serine, threonine and hydroxyproline, and tert-butyl ester for aspartic acid and glutamic acid. Triphenylmethyl (Trityl) moiety can be used to protect the sulfide containing side chain of cysteine.

Once the inhibitor sequence is completed any protecting groups are removed in whatever manner is dictated by the choice of protecting groups. These procedures

M183-2

32

are well known to those skilled in the art.


In compounds of Formula I, the P2 unit comprises a nitrogen-containing ring residue which is substituted with the W and R⁸ moieties.

5

Synthesis of heterocyclic P2 building blocks

Compounds wherein W is O and R⁸ is alkyl, C₀-C₃ carbocyclyl, C₀-C₃-heterocyclyl can be prepared according to the procedure described by E. M. Smith et al. (J. Med. Chem. (1988), 31, 875-885), as depicted in Scheme 1, which illustrates the technique in a moiety wherein q and k are 1.

10



Scheme 1

Commercially available Boc-4-(R)-hydroxyproline, or any suitable hydroxy substituted proline analogue, such as an hydroxypiperidoic acid is treated with a base such as sodium hydride or potassium t.butoxide in a solvent like dimethylformamide and the resulting alkoxide is reacted with an alkylating agent, R⁸-X, wherein X is a suitable leaving group such as a halide like chloride, bromide or iodide, providing the desired substituted proline derivative.


20

Alternatively, when W is O or S and R⁸ is carbocyclyl such as phenyl or heterocyclyl such as heteroaryl, the P2 building blocks can also be prepared via a Mitsunobu reaction (Mitsunobu, 1981, Synthesis, January, 1-28; Rano et al., Tetrahedron Lett., 1995, 36, 22, 3779-3792; Krchnak et al., Tetrahedron Lett., 1995, 36, 5, 6193-6196; Richter et al., Tetrahedron Lett., 1994, 35, 27, 4705-4706) as shown in Scheme 2, which illustrates the technique in a moiety wherein q and k are 1.

25

M183-2

33



Scheme 2


- 5 Treatment of the appropriate hydroxy substituted proline analogue, such as a hydroxypiperidoic acid, here shown as commercially available Boc-4-hydroxyproline methyl ester, with the desired alcohol or thiol (R⁸-WH) in the presence of triphenylphosphine and an activating agent like diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD) or the like, provides the ester compound (2b).
- 10 Hydrolysis of the ester to the acid by standard procedures provides the P2 building block (2c).

- 15 Alcohol (2a) can alternatively be treated with phosgene thus providing the corresponding chloroformate which upon reaction with an amine, R⁸NH₂, in the presence of a base like sodium hydrogen carbonate or triethylamine, provides carbamates i.e. W is -OC(=O)NH-, whereas reaction of alcohol (2a) with an acylating agent, R⁸-CO-X, like an acid anhydride or acid halide for instance the acid chloride, to provide esters, i.e. W is -OC(=O)-.

- 20 Various alcohols R⁸-OH, and alkylating agents R⁸-X are described in WO 00/09543 and WO00/59929. An example of the synthesis wherein R⁸ is a substituted quinoline derivative is shown in Scheme 3.

M183-2

34




Scheme 3

- Friedel-Craft acylation of a suitable substituted aniline (3a), available either commercially or in the literature, using an acylating agent like acetyl chloride or the like in the presence of boron trichloride and aluminium trichloride in a solvent like dichloromethane provides (3b). Coupling of (3b) to a heterocyclic carboxylic acid (3c) under basic conditions, such as in pyridine, in the presence of an activating agent for the carboxylate group, for instance POCl_3 , followed by ring closure and dehydration under basic conditions like potassium tert.butoxide in tert.butanol provides quinoline derivative (3e). Quinoline derivative (3e) can be coupled in a Mitsunobu reaction to an alcohol as described above, or the hydroxy group can be displaced by a suitable leaving group such as a halide like chloride, bromide or iodide, by treatment of quinoline (3e) with an appropriate halogenating agent for example phosphoryl chloride or the like.

A variety of carboxylic acids with the general structure (3c) can be used in Scheme 3. These acids are available either commercially or in the literature. An example of the preparation of 2-(substituted)-amino-carboxy-aminothiazole derivatives, following the procedure by Berdikhina et al. Chem. Heterocycl. Compd. (Engl. Transl.) (1991), 427-433, is shown below.

M183-2

35




Scheme 4

- Thiourea (4c) with different alkyl substituents R' can be formed by reaction of the appropriate amine (4a) with tert.butylisothiocyanate in the presence of a base like diisopropylethylamine in a solvent like dichloromethane followed by removal of the tert. butyl group under acidic conditions. Subsequent condensation of thiourea derivative (4c) with 3-bromopyruvic acid provides the acid (4d).
- 10 P2 building blocks wherein the R^8 substituent is attached via a nitrogen atom i.e. W is amine, amide or sulphonamide, can be prepared from aminoproline analogues achieved either from a suitable commercially available aminoproline, etc derivative or by transforming the hydroxy group of the corresponding hydroxy derivative into an azide group for example by transforming the hydroxy group into a suitable leaving group such as a mesylate or halogen like chloride, followed by substitution of the leaving group with azide or by the use of an azide transfer agent like
- 15 diphenylphosphoryl azide (DPPA). Reduction of the azide by catalytic hydrogenation or any other suitable reduction method provides the amine. The amino derivative can be reacted with an alkylating agent of the general formula R^8-X wherein R^8 and X are as described for scheme 1, to form compounds wherein W is $-\text{NH}-$. Reaction of the aminoproline analogue with an acid of the general formula R^8-COOH under standard amide coupling conditions provides compounds wherein W is $-\text{NHC}(=\text{O})-$, whereas reaction of the aminoproline analogue with an appropriate derivative of sulphonic acid, $\text{R}^8-\text{S}(\text{O})_2-\text{X}$ where X is a leaving group for example chloride, in the presence of
- 20 a base, provides sulphonamides. It will be apparent that corresponding reactions will be available for P2 groups with other ring sizes and substitution pattern.
- 25

M183-2

36

4-Substituted heterocyclyl derivatives such as 4-substituted proline for use as P2 building blocks where W is -CH₂- can be prepared as shown in Scheme 5, which illustrates the technique on a moiety where q and k is 1, according to the procedures described by J. Ezquerra et al., Tetrahedron, 1993, 38, 8665-8678 and C. Pedregal et al. Tetrahedron Lett., 1994, 35, 2053-2056.



Scheme 5

10

Treatment of suitably acid protected pyrrolidone or piperidinone such as commercially available Boc-pyrroglutamic acid (5a) with a strong base such as lithium diisopropylamide in a solvent like tetrahydrofuran followed by addition of an alkylating agent R⁸-CH₂-X where X is a suitable leaving group such as a halide like chloride or bromide, followed by reduction of the amide and deprotection of the ester gives the desired compound (5d).

15

Compounds with alternative ring size and/or position of the W-R⁸ substituent of the proline derivatives in scheme 1, 2 and 5 may also be used in the preparation of compounds according to the present invention. For example, alkylation of commercially available 3-hydroxyproline provides compounds of the general formula (I) wherein k is 0 and q is 2. Correspondingly, alkylation of 5-hydroxyproline, prepared for example as described by Hallberg et al., J. Med. Chem. (1999), 4524-4537, provides compounds of the general formula (I) wherein k is 2 and q is 0.

20

25

Various methods for the preparation of hydroxylated 2-piperidine carboxylic acids are described in the literature se for instance Celestini et al., Org. Lett., (2002), 1367-


1370, Hoarau et al., *Tetrahedron: Asymmetry*, (1996), 2585-2594, Zhu et al., *Tetrahedron Lett.*, 41, (2000), 7033-7036. For example, the corresponding pyridine carboxylic acids can be reduced to provide hydroxylated 2-piperidine carboxylic acids. Enzymatical methods can also be used for the preparation of hydroxylated proline analogues. For example, a 3-hydroxy substituent can be introduced on commercially available 4, 5, and 6 membered heterocyclic acids by the use of proline 3-hydroxylase as described by Ozaki et al., *Tet. Letters*, 40, (1999), 5227-5230.

Additional P2 building blocks, especially for compounds of formula VI are described in Schemes 11-15 below.

Synthesis and introduction of P1 building blocks.

The amino acids used in the preparation of P1 fragments are available either commercially or in the literature, see for example WO 00/09543 and WO00/59929 from Boehringer-Ingelheim.

Scheme 6 shows an example of the preparation of a sulphonamide derivative to be used as a P1 fragment, and the subsequent coupling to a Boc protected P2 building block.



Scheme 6

The sulphonamide group can be introduced on a suitably protected amino acid (6a) by treatment of the amino acid with a coupling agent, for example N,N'-carbonyldiimidazole (CDI) or the like, in a solvent like THF followed by reaction with the desired sulphonamide (6b) in the presence of a strong base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). Alternatively the amino acid can be treated with the desired sulphonamide (6b) in the presence of a base like diisopropyl ethylamine followed by treatment with a coupling agent like PyBOP® to effect the introduction of the sulphonamide group. Removal of the amino protecting group by standard methods and subsequent coupling to a P2 building block, prepared as described above, using standard methods for amide bond formation, like with a coupling agent as O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) in the presence of a base such as diisopropylamine in a solvent like dimethylformamide, gives Boc protected P2-P1 construct (6e).

Alternatively, the sulphonamide group can be introduced at a later stage of the synthesis, for example as the last step. In this case the carboxylic acid is appropriately protected, for example as the methyl ester, and appropriately deprotected prior to the coupling of the sulphonamide group, for example with aqueous lithium hydroxide.

20


P1 building blocks for the preparation of compounds according to general formula I and VI wherein A is an ester or an amide can be prepared by reacting amino acid (6a) with the appropriate amine or alcohol respectively under standard conditions for amide bond or ester formation. P1 building blocks wherein A is CR^4R^4 are described in Oscarsson et al Bioorg Med Chem 2003 11(13) 2955-2963 and PCT/EP03/10595 filed 23.09.2003, the contents of which are incorporated by reference.

25

Synthesis of capped building blocks

30

The building blocks R^{16} -G-P3 and R^{16} -G-P4-P3 can be prepared as generally depicted in scheme 7.




Scheme 7

A suitable N-protected amino acid (7a) can be coupled with an amino capping group (R¹⁶-NHRy) using standard peptide coupling conditions like with coupling agents such as HATU, DCC, HOBT or the like in the presence of a base such as DIEA or DMAP in a solvent like dichloromethane, chloroform or dimethylformamide or a mixture thereof and ester formation conditions like providing amides i.e. G is NHRy (7b). Alternatively, reaction of amino acid (7a) with a compound of general formula R¹⁶-X where R¹⁶ is as defined above and X is a leaving group such as a halide, in the presence of a base like cesium carbonate or silver (I) oxide provides esters, i.e. G is O (7b). On the other hand, amino acid (7a) can be coupled to a second, suitably O-protected, amino acid (7d) using standard peptide coupling conditions as described above, providing (7e). Displacement of the ester group with a suitable capping group (7b) provides fragment (7f) useful for the preparation of compounds according to the present invention wherein m and n are 1.

When G is N-Ry, the capped P3 or P2 building block can also be prepared on solid support as exemplified in Scheme 8.

M183-2

40



Scheme 8

An appropriate N-protected, for example Boc protected, amino acid (8a) can be
 5 immobilized on a solid support, here exemplified by Agronaut resin PS-TFP, by
 reacting the amino acid with the desired solid support in the presence of coupling
 reagent like N,N'-diisopropylcarbodiimide and a base like DMAP in a solvent like
 dichloromethane and dimethylformamide. The immobilized amino acid can then be
 10 cleaved from the support with a suitable capping group (8c) thus giving fragments
 useful for the preparation of compounds according to the present invention wherein
 m or n is 1. Optionally the amino protecting group can be removed followed by
 coupling of an appropriate amino acid using standard methods thus providing
 fragments useful for the preparation of compounds according to the present
 invention wherein m and n are 1.


15

Coupling of a capping group or a capped building block to the P2-P1 construct

The R¹⁶-G, R¹⁶-G-P3 or R¹⁶-G-P4-P3 building block linked via a urea functionality to
 the P2-P1 construct, can be introduced as depicted in scheme 9, which illustrates
 the technique with a variant in which P2 is a heterocyclic residue.

M183-2

41



Rx' and R11' have the same definitions as Rx and R11 respectively but are not part of a macrocycle.
A' is a protected carboxylic acid, substituted amide or CR₄R₄'.

Scheme 9


- A chlorocarbamate group can be formed onto the ring amine of the P2-P1 construct (9a) by removal of the amine protection group by standard procedures, like acidic treatment with for example TFA in dichloromethane or the like when the Boc group is used, followed by reaction of the free amine with phosgene in toluene in the presence of a base such as sodium hydrogen carbonate or triethylamine in a solvent like tetrahydrofuran. Subsequent reaction of the formed electrophilic center with the amino group of a R¹⁶-NH₂, R¹⁶-NH-NH₂, R¹⁶-G-P3 or R¹⁶-G-P4-P3 building block (9c) in a solvent like dichloromethane in the presence of a base like sodium hydrogen carbonate provides (9d). Compounds of general formula (I) wherein E is C=S, S(=O) or S(=O)₂ can be prepared according to the above procedure but with the use of reagents like thiocarbonyl diimidazole, thionyl chloride or sulphuryl chloride respectively instead of phosgene.

Compounds containing a hydrazine moiety in the P3 unit, *i.e.* X is -NR_jNR_j- in general formula I, can be prepared as depicted below. Scheme 9A shows the

M183-2

42

introduction of a hydrazine derivative wherein Rj is H to a 5-membered heterocyclic P2 building block.



5

Scheme 9A



Reaction of tert. butyl carbazate with p-nitrophenyl chloroformate in the presence of a base like sodium hydrogen carbonat followed by addition of the P2 building block (9Ac) provides 9Ab. Removal of the boc group by standard procedures like acidic treatment with for example TFA in a suitable solvent such as dichloromethane, provides the hydrazine containing derivative (9Ac). Alternatively, any appropriate hydrazine derivative, such as morpholin-1-ylamine, piperidin-1-ylamine or the like can be used instead of tert.butyl carbazate in the reaction with 9Aa.

15



M183-2

43




R11' has the same definition as R11 but is not part of a macrocycle.
A' is a protected carboxylic acid, substituted amine or CR4R4'

Scheme 9B

- 5 Treatment of the α -amino compound (9Ba) with sodium nitrite, potassium bromide and sulphuric acid (Yang *et al.* J. Org. Chem. (2001), 66, 7303-7312) provides the corresponding α -bromo compound (9Bb) which upon reaction with the above described derivative (9Ab) provides the hydrazine containing derivative (9Bc).
- 10 The linkage between the P2 and P3 building blocks can also be via a carbamate group and a general route to such compounds is depicted in Scheme 10, which illustrates the technique with a variant in which P2 is a proline derivative.

M183-2

44




Scheme 10

The desired, optionally protected, amino capping group (10a) is coupled to a hydroxy acid (10b) using standard peptide coupling techniques followed by reaction with the electrophilic P2 building block (10d) described above and optional deprotection provides construct (10e).

Compounds lacking a carboxy group in the P3 unit can be prepared as illustrated in Scheme 11, which illustrates the technique as applied to a compound of Formula I

M183-2

45



R11' has the same definition as R11 but is not part of a macrocycle.
A' is a protected carboxylic acid, substituted amide or CR₄R₄'.


Scheme 11

- Chlorocarbamoyl derivative (11a) can be reacted in a displacement reaction with an
 5 azide derivative (11b), prepared by methods known from the literature, in the
 presence of a base like sodium hydrogen carbonate to give (11c). X is as described
 for general formula (I). Reduction of the azide function for example by polymer
 bound triphenyl phosphine in a solvent like methanol or any other suitable reduction
 method provides intermediate (11d) which subsequently can be reacted with an acid
 10 under peptide coupling conditions or with an amine in a reductive amination reaction
 providing amides and secondary amines respectively.

Scheme 11A shows an alternative route towards compounds lacking a carboxy
 group in the P3 unit

M183-2

46



Scheme 11A


Instead of using the azide derivative (11b) in scheme 11 the corresponding, optionally protected, hydroxy derivative (11Ab) can be used in the displacement reaction with the chlorocarbamate (11Aa) and thus introducing a primary alcohol. The alcohol (11Ac) can then, after optional deprotection, be oxidized with a suitable oxidizing agent like for example Dess-Martin periodinane to form the corresponding aldehyde. Reaction of the aldehyde with a desired amine in a reductive amination reaction using a reagent like for example polystyrene bound cyanoborohydride in a solvent like THF provides amine derivatives (11Ae).

Alternatively alcohol (11Ac) can be reacted with a suitable acylating or alkylating agent under the appropriate conditions to provide ester and ether compounds respectively, i.e. G is O in general formula (I).

Subsequent reaction of the formed alcohol with a suitable acylating or alkylating agent using the appropriate conditions provides the ester and ether compounds respectively, i.e. G is O in general formula (I).

Although Figure 11 and 11 A have been described with reference to a compound of Figure I, it will be readily apparent that corresponding methodology is applicable for compounds of the Formula VI.

- 5 Alternatively the linkage between the P2 and P3 building blocks can be via a guanidine group and a general route to such compounds is depicted in Scheme 12.



$R^{11'}$ has the same definition as R^{11} but is not part of a macrocycle.
 A' is a protected carboxylic acid, substituted amide or CR_4R_4' .

10 Scheme 12

- 15 Treatment of the P2-building block (12a) with thiocarbonyl diimidazole or the like in a solvent like dimethylformamide followed by condensation with sodium cyanamide in a solvent like ethanol affords the thiolate intermediate (12b). Reaction of intermediate (12b) with the desired building block, here shown as a capped P3 building block (12c) provides the cyanoguanidine derivative (12d). Other building blocks, $R^{16}-G$ or $R^{16}-G-P_4-P_3$, can alternatively be coupled to the intermediate (12b). Hydrolysis of the cyano group by treatment of (12d) with diluted hydrochloric acid gives the guanylurea derivative (12e).


When R7, R7' and A' contains functional groups, these are suitably protected by methods recognized by persons skilled in the art, see for example Bodanzky or Greene cited above.

5

Carbocyclic P2 building blocks

A typical route to saturated, carbocyclic P2 building blocks towards compounds of formula VI is shown in Scheme 13, which illustrates the technique with a variant wherein q' is 0 and k is 1.

10



Rx' and T' have the same definitions as Rx and T respectively but are not part of a macrocycle.
A' is a protected carboxylic acid, substituted amide or CR₄R₄'.

Scheme 13


- 15 The saturated cycloalkyl scaffold (13b) can be prepared, for example, from 3,4-bis(methoxycarbonyl)cyclopentanone (13a), described by Rosenquist et al. in Acta Chem. Scand. 46 (1992) 1127-1129 by reduction of the keto group with a reduction agent like sodium borohydride in a solvent like methanol followed by hydrolysis of the esters and finally ring closure in acetic anhydride in the presence of pyridine. The provided bicyclic acid (13b) can then be coupled to the amine function of the desired P3 fragment (13c), P3-P4 fragment or capping group R¹⁶-NHRy, using conventional
- 20

peptide coupling conditions like with HATU and diisopropyl amine in a solvent like dimethyl formamide, giving (13d). Lactone opening of (13d) with for example lithium hydroxide provides the acid which subsequently can be coupled to the amino group of a P1 building block or a precursor of a desired P1 fragment (13e), using

5 conventional peptide coupling conditions. The R⁸-substituent of the carbocycle can be introduced for example by a Mitsunobu reaction with the appropriate alcohol as described above or by any other suitable method previously described. When R⁷, R^{7'} and A' contains functional groups, these are optionally suitably protected by methods recognized by persons skilled in the art, se for example Bodanzky or Greene cited

10 above.

Scheme 14 shows an alternative route towards saturated compounds of formula VI where the building blocks are introduced in the reversed order, i.e. the P1 fragment is introduced before the capping group, P3 or P3-P4 building block.



15 Rx' and T' have the same definitions as Rx and T respectively but are not part of a macrocycle.
A' is a protected carboxylic acid, substituted amide or CR⁴R^{4'}.

Scheme 14

Protection of the acid group of (14a) for example as the tert. butyl ester by treatment with di-tert. butyl dicarbonate in the presence of a base like dimethylaminopyridine and triethylamine in a solvent like dichloromethane provides ester (14b). Lactone

20


opening and coupling of a P1 building block (14c) as described in scheme 13 or directly by the amine group of the P1 fragment provides (14d). Introduction of R⁸-substituent as described above followed by removal of the acid protection group by subjecting the ester to acidic conditions like trifluoroacetic acid and triethylsilane in a solvent like methylene chloride and finally coupling of the P3 building block (14e), P3-P4 building block or capping group R¹⁶-NHRy, as described above provides (f). When R⁷, R^{7'} and A' contain functional groups, these are optionally suitably protected by methods recognized by persons skilled in the art, see for example Bodanzky or Greene cited above.

10

An unsaturated P2 building block towards the preparation of compounds of formula VI can be prepared as illustrated with cyclopentene below.

The cyclopentene scaffold is typically prepared as described in scheme 15.

15



Scheme 15

20


A bromination-elimination reaction of 3,4-bis(methoxycarbonyl)cyclopentanone (15a) as described by Dolby et al. in J. Org. Chem. 36 (1971) 1277-1285 followed by reduction of the keto functionality with a reduction agent like sodium borohydride provides the unsaturated hydroxy compound (15b). Selective ester hydrolysis using for example lithium hydroxide in a solvent like a mixture of dioxane and water provides hydroxy substituted cyclopentene derivative (15c).

25

A P2 building block wherein Rq is other than hydrogen, such as a methylated cyclopentene scaffold can be prepared as shown in scheme 16.

M183-2

51



Scheme 16


- 5 Oxidation of commercially available 3-methyl-3-buten-1-ol (16a) by the use of an oxidation agent like pyridinium chlorochromate followed by treatment with acetyl chloride, bromine and methanol provides the α-bromo ester (16c). The afforded ester (16c) can then be reacted with the enolate (16e), achieved for example by treatment of the corresponding tert.butyl ester with a base such as lithium diisopropyl amide in
- 10 a solvent like tetrahydrofuran, to give the alkylated compound (16f). The tert-butyl ester (16e) can be prepared by treatment of the corresponding commercially available acid (16d) where k' is 1 to 3 with di-tert.butyl dicarbonate in the presence of a base like dimethylaminopyridine. Cyclisation of (16f) by an olefin metathesis reaction performed as described above provides cyclopentene derivative (16g).
- 15 Stereoselective epoxidation of (16g) can be carried out using the Jacobsen asymmetric epoxidation method to furnish the epoxide (16h). Finally, addition of a base like DBN (1,5-diazabicyclo-[4.3.0]non-5-ene) yields the alcohol (16i). Optionally the double bond of compound (16i) can be reduced for example by catalytic hydrogenation using a catalyst like palladium on carbon which provides the
- 20 corresponding saturated compound.

M183-2

52

The afforded cyclic scaffolds can then be used, as described above, to complete the inhibitor sequence. An example is shown in scheme 17.

5



Rx' and T' have the same definitions as Rx and T respectively but are not part of a macrocycle. A' is a protected carboxylic acid, substituted amide or $\text{CR}_4\text{R}_4'$.

Scheme 17

10 The amino group of a P1-building block or a suitable precursor thereof (17b) can be coupled to the acid of the cyclopentene derivative (17a) using standard amide coupling conditions followed by introduction of the R^8 -substituent for example by Mitsunobu conditions as described above to provide (17d). Hydrolysis of the remaining ester and subsequent amide coupling of a desired P3 or P3-P4 building block (17e) optionally followed by manipulations of the P1 part provides


15 cyclopentene containing compounds (17f) according to general formula VI. When R^7 , $\text{R}^{7'}$ and A' contain functional groups, these are optionally suitably protected by methods recognized by persons skilled in the art, see for example Bodanzky or Greene cited above.

Formation of macrocyclic compounds

Compounds according to the present invention wherein an alkylene chain extending from the $R^7/R^{7'}$ cycloalkyl to R_x , R_d or R^{11} thus forming a macrocycle, can be prepared as described below. Suitable P1, P2 and P3 building blocks, or precursors thereof, are coupled together using the strategies described above, followed by a ring-closing reaction (macrocyclization). The substituent $W-R^8$ of the P2 building block can be incorporated via a Mitsunobu reaction as described above, before or after formation of the macrocycle or the assembly can be done with the required substituted proline analogue or carbocycle. For macrocyclic structures extending


5 from the $R^7/R^{7'}$ cycloalkyl to R^{11} , P3 amino acids containing the appropriate side chain can be prepared as described in WO00/59929.

A typical route to macrocyclic compounds is shown in Scheme 18 which illustrates the technique applied to a compound having a heterocyclic P2 and a spiro-cyclopropyl P1, where the macrocycle incorporates the P3 side chain.



Scheme 18

- Oxidation of the appropriate alcohol (19a) using a suitable oxidation method like for example with N-methyl morpholine oxide and tetrapropylammonium perruthenate in a solvent like dichloromethane provides ketone (19b). Reductive alkylation of
- 5 tert.butyl carbazate with the afforded ketone gives the P3 building block (19c) useful for the preparation of compounds wherein the macrocycle is extending from the "inner" nitrogen as shown in compounds 20c and 20d in scheme 20. Alternatively,
- any appropriate hydrazine derivative such as morpholin-1-ylamine, piperidin-1-ylamine can be used instead of tert.butyl carbazate in the reaction with aldehyde
- 10 19b. Alternatively removal of the boc group from compound 19c by standard procedures like acidic treatment with for example TFA in a suitable solvent like THF, provides building blocks useful for the preparation of compounds wherein the macrocycle is extending from the other, "outer", nitrogen of the hydrazine group .
- 15 The P3 building block can then be coupled to any of the described P2-P1 building blocks. Scheme 20 exemplifies the coupling of a hydrazine containing P3 building block to a cyclopentane scaffold followed by macrocyclisation.




M183-2

56

Scheme 20

Coupling of the carbazate derivative (20b) to the P2-P1 building block (20a) using standard peptide coupling conditions provides intermediate (20c). Ring closure of (20c) by an olefin metathesis reaction as described above gives the macrocyclic compound (20d).

Scheme 20A shows a route towards hydrazine containing compounds wherein the macrocycle is extending from the "outer" nitrogen. The coupling is exemplified with a 5-membered heterocyclic P2-building block.



Scheme 20A

Coupling of the hydrazine compound described above (20Aa) to the P2 building block (20Ab) via a urea linkage can be effected for example by treatment of (20Aa) with *p*-nitrophenyl chlorocarbamate in a solvent like acetonitrile in the presence of a base like sodium hydrogen carbonate followed by addition of the P2-building block (20Ab) in a solvent such as acetonitrile in the presence of a base like

diisopropylamine. Ring closing methatesis of 20Ac, as described above in scheme 20, provides the macrocyclic derivative 20Ad.

The term "N-protecting group" or "N-protected" as used herein refers to those groups intended to protect the N-terminus of an amino acid or peptide or to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis" (John Wiley & Sons, New York, 1981), which is hereby incorporated by reference. N-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl, and the like, carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, α,α -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl, cyclohexylloxycarbonyl, phenylthiocarbonyl, and the like; alkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like; and silyl groups such as trimethylsilyl and the like. Favoured N-protecting groups include formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butoxycarbonyl (BOC) and benzyloxycarbonyl (Cbz).

Hydroxy protecting group as used herein refers to a substituent which protects hydroxyl groups against undesirable reactions during synthetic procedures such as those O-protecting groups disclosed in Greene, "Protective Groups In Organic

Synthesis," (John Wiley & Sons, New York (1981)). Hydroxy protecting groups comprise substituted methyl ethers, for example, methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, t-butyl and other lower alkyl ethers, such as isopropyl, ethyl and especially methyl, benzyl and triphenylmethyl; 5 tetrahydropyranyl ethers; substituted ethyl ethers, for example, 2,2,2-trichloroethyl; silyl ethers, for example, trimethylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl; and esters prepared by reacting the hydroxyl group with a carboxylic acid, for example, acetate, propionate, benzoate and the like.

10 In treating conditions caused by flavivirus such as HCV, the compounds of formula I or VI are typically administered in an amount to achieve a plasma level of around 100 to 5000 nM, such as 300 to 2000 nM. This corresponds to a dosage rate, depending on the bioavailability of the formulation, of the order 0.01 to 10 mg/kg/day, preferably 0.1 to 2 mg/kg/day. A typical dosage rate for a normal adult will be around 15 0.05 to 5 g per day, preferably 0.1 to 2 g such as 500-750 mg, in one to four dosage units per day. As with all pharmaceuticals, dosage rates will vary with the size and metabolic condition of the patient as well as the severity of the infection and may need to be adjusted for concomitant medications.

20 As is good prescribing practice with antiviral therapy, the compounds of formula I are typically coadministered with other HCV therapies to avoid the generation of drug escape mutants. Examples of such additional HCV antiviral therapies include ribavirin, interferons, including pegylated interferons. Additionally a number of nucleoside analogues and protease inhibitors are in the development and will be 25 amenable to co-administration with the compounds of the invention.

While it is possible for the active agent to be administered alone, it is preferable to present it as part of a pharmaceutical formulation. Such a formulation will comprise the above defined active agent together with one or more acceptable carriers or 30 excipients and optionally other therapeutic ingredients. The carrier(s) must be

M183-2

59

acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient.

5 The formulations include those suitable for rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration, but preferably the formulation is an orally administered formulation. The formulations may conveniently be presented in unit dosage form, e.g. tablets and sustained release capsules, and may be prepared by any methods well known in the art of pharmacy.

10

Such methods include the step of bringing into association the above defined active agent with the carrier. In general, the formulations are prepared by uniformly and intimately bringing into association the active agent with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. The invention extends to methods for preparing a pharmaceutical composition comprising bringing a compound of Formula I or VI or its pharmaceutically acceptable salt in conjunction or association with a pharmaceutically acceptable carrier or vehicle. If the manufacture of pharmaceutical formulations involves intimate mixing of pharmaceutical excipients and the active ingredient in salt form, then it is often preferred to use excipients which are non-basic in nature, i.e. either acidic or neutral. Formulations for oral administration in the present invention may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active agent; as a powder or granules; as a solution or a suspension of the active agent in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water in oil liquid emulsion and as a bolus etc.

25

With regard to compositions for oral administration (e.g. tablets and capsules), the term suitable carrier includes vehicles such as common excipients e.g. binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone (Povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose and starch; fillers and carriers, for example

30

corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid; and lubricants such as magnesium stearate, sodium stearate and other metallic stearates, stearic acid, glycerol stearate, silicone fluid, talc waxes, oils and colloidal silica. Flavouring agents
 5 such as peppermint, oil of wintergreen, cherry flavouring or the like can also be used. It may be desirable to add a colouring agent to make the dosage form readily identifiable. Tablets may also be coated by methods well known in the art.

A tablet may be made by compression or moulding, optionally with one or more
 10 accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active agent in a free flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Moulded tablets may be made by moulding in a
 15 suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active agent.

Other formulations suitable for oral administration include lozenges comprising the
 20 active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active agent in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active agent in a suitable liquid carrier.

The compounds of formula I or VI can form salts which form an additional aspect of
 the invention. Appropriate pharmaceutically acceptable salts of the compounds of
 25 formula I include salts of organic acids, especially carboxylic acids, including but not limited to acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, isethionate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate,
 30 heptanoate, hexanoate, fumarate, nicotinate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, proprionate, tartrate, lactobionate, pivalate, camphorate, undecanoate and succinate, organic sulphonic acids such as

methanesulphonate, ethanesulphonate, 2-hydroxyethane sulphonate, camphorsulphonate, 2-napthalenesulphonate, benzenesulphonate, p-chlorobenzenesulphonate and p-toluenesulphonate; and inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, hemisulphate, thiocyanate, persulphate, phosphoric and sulphonic acids.

Prodrugs of the compounds of formula I are those compounds which following administration to a patient release a compound of the formula I in vivo generally following hydrolysis in the gut, liver or plasma. Typical prodrugs are pharmaceutically acceptable ethers and especially esters (including phosphate esters) of hydroxy functions, pharmaceutically acceptable amides or carbamates of amine functions or pharmaceutically acceptable esters of carboxy functions. Preferred pharmaceutically acceptable esters include alkyl esters, including acetyl, ethanoyl, butyryl, t-butyryl, stearyl and pivaloyl, phosphate esters and sulphonic esters (ie those derived from RSO_2OH , where R is lower alkyl or aryl). Pharmaceutically acceptable esters include lower alkyl ethers and the ethers disclosed in WO00/47561, especially methoxyaminoacyl and ethoxyaminoacyl.

The compounds of the invention have various steric centres and the invention extends to racemates and enantiomers at each of these steric centres.




Typically, the stereochemistry of the groups corresponding to the P3 and P4 side chains (ie R^{15} and/or R^{11}) will correspond to an L-amino acid configuration, although the invention also extends to D-isomers at one or both of these centres.

25


The stereochemistry of the backbone component of the cyclic P2 group (i.e. spanning the carbonyl of the P1 amide bond and the carbonyl or E extending of P3 will typically correspond to L-proline. The stereochemistry of the P2 ring atom to which W is bonded is typically as shown:

M183-2


62




In compounds of the invention wherein R7 and R7' together define a spiroalkyl group, such a spiro-cycloalkyl will typically comprise an R^{7'a} substituent on the spiro-cyclopropyl ring which is orientated syn to A:



or anti to A:




Conveniently, the spiro carbon of such a spiro-cyclopropyl ring has the R configuration:



Conveniently an R^{7'a} substituent on a spiro-cyclopropyl ring adjacent to A is in a syn orientation in the following absolute configuration:

M183-2

63




Particularly preferred variants have $R^{7'a}$ include ethyl, hence the asymmetric carbon atoms at position 1 and 2 have the R, R configuration.

5

Alternative preferred $R^{7'a}$ include vinyl, hence the asymmetric carbon atoms at position 1 and 2 have the R, S configuration.

Where the compound of the invention is a macrocycle comprising a J group, J is preferably a diastereomer represented by partial structures (i) or (ii):

10



especially where J is syn to A.

15 Detailed description of the embodiments

Various embodiments of the invention will now be described by way of illustration only with reference to the following non-limiting examples.

20 Example 1

7-Methoxy-2-phenyl-quinolin-4-ol (1).

To a stirred round bottled flask with toluene (100 mL) ethyl benzoyl acetate (18.7 g, 97 mmol) and *m*-anisidine (12 g, 97 mmol) was added. 4 M HCl in dioxane (0.5 mL) was added and the reaction mixture was refluxed for 6 h (140 °C). The mixture was

25

M183-2

64

co-evaporated with toluene. To the crude mixture diphenyl ether (50 mL) was added and the mixture was heated to 280 °C for 2 h. When the theoretical amount ethanol (6 mL) was collected in a Dean Stark trap the heating was stopped and the mixture was cooled to rt. The crude mixture was dissolved in CH₂Cl₂ (100 mL) and stirred for 5 30 min. The formed precipitate was filtered off and dried which gave 1 (4.12 g, 16.4 mmol, 17 %): pale yellow powder.

¹H (300 MHz, DMSO-D₆): δ 3.8 (s, 3H), 6.24 (s, 1H), 6.88-6.96 (dd, 1H, *J* = 9.07 Hz, *J* = 2.47 Hz), 7.19 (d, 1H, *J* = 2.19 Hz), 7.56 (t, 3H, *J* = 2.19 Hz), 7.8 (dd, 2H, *J* = 7.14 Hz, *J* = 2.19 Hz), 8.0 (d, 1H, *J* = 9.06 Hz); ¹³C (75.5 MHz, DMSO-D₆): δ 55.3, 99.6, 10 106.9, 113.1, 119.1, 126.4, 127.5, 128.8, 130.2, 134.1, 142.2, 149.4, 161.8, 176.4.

Example 2

(Rac)-4-oxocyclopent-2-ene-1, 2-dicarboxylic acid dimethyl ester (2).


15

(1*R*, 2*S*)-4-oxo-cyclopentane-1, 2-dicarboxylic acid dimethyl ester (4.8 g, 23.8 mmol) and CuBr₂ (11.9 g, 53.2 mmol) were dissolved in dry THF (70 mL) and the mixture was refluxed for two hours at 90 °C. The formed CuBr was filtrated off and the organic phase was concentrated. CaCO₃ (2.7 g, 27.2 mmol) and DMF (70 mL) were 20 added and the mixture was held at 100 °C for one hour. The dark brown mixture was poured over ice (35 g) and the formed precipitate was filtrated off. The aqueous layer was extracted with ethyl acetate (1 x 300mL + 3 x 150 mL). The organic phases were dried, filtrated and concentrated. Purification by flash chromatography (toluene/EtOAc 9:1) gave 2 (2.1 g, 45 %) as yellow crystals

25

Example 3





((1*S*,4*R*) & (1*R*,4*S*))-4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid dimethyl ester (3).

- 5 To a cold solution (-30 °C) of 2 (3.18 g, 16.1 mmol) dissolved in MeOH (23 mL), NaBH₄ (0.66 g, 17.5 mmol) was added. After nine minutes the excess of NaBH₄ was destroyed by adding brine (80 mL). The mixture was concentrated and extracted with ethyl acetate (4 x 80 mL). The organic phases were dried, filtrated and concentrated and gave 3 (3.0 g, 92 %) as a yellow oil.

10

Example 4

(1*S*,4*R*) & (1*R*,4*S*)-4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid 2-methyl ester (4).

- 15 To an ice-cold solution of 3 (3.4 g, 22 mmol) dissolved in dioxane and water (1:1, 110ml), LiOH (0.52 g, 22 mmol) was added. After two and a half hours the mixture was co-evaporated with toluene and methanol. Purification by flash chromatography (toluene/Ethyl acetate 3:1 + 1 % HOAc) gave the title compound (1.0 g, 27 %) as yellow-white crystals.

20


¹H-NMR (300 MHz, CD₃OD): δ 1.78-1.89 (m, 1H), 2.70-2.84 (m, 1H), 3.56-3.71 (m, 1H), 3.76 (s, 3H), 4.81-4.90 (m, 1H), 6.76-6.81 (m, 1H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 38.0, 48.0, 52.4, 75.7, 137.0, 146.2, 165.0 178.4.

25

Example 5

M183-2

66



((3*S*,5*R*) & (3*R*,5*S*))-5-((*S*)-1-*tert*-Butoxycarbonyl-butylcarbamoyl)-3-hydroxy-cyclopent-1-enecarboxylic acid methyl (5).


- 5 To an ice cooled solution of 4 (0.20 g, 1.1 mmol) and 2-amino-pentanoic acid *tert*.butyl ester (0.24 g, 1.4 mmol) in DMF (7 mL), DIPEA (0.18 g, 1.4 mmol) and HATU (0.53 g, 1.4 mmol) were added. After two hours the solution was concentrated and purified using column chromatography (toluene/ethyl acetate 3:1). This gave the title compound as a yellow oil (0.22 g, 63 %).

10

¹H-NMR (300 MHz, CDCl₃): δ 0.84-0.96 (m, 3H), 1.14-1.39 (m, 2H), [(1.44 & 1.49) s, 9H], 1.50-1.60 (m, 1H), 1.61-1.85 (m, 1H), 1.97-2.10 (m, 1H), 2.11-2.28 (m, 1H), 3.57-3.68 (m, 1H), [(3.73 & 3.76) s, 3H], 4.30-4.50 (m, 1H), 4.63-4.73 (m, 1H), 6.80-6.95 (m, 1H), 6.95-7.00 (m, 1H).

15

Example 6



((3*S*,5*R*) & (3*R*,5*S*))-5-((*S*)-1-*tert*-Butoxycarbonyl-propylcarbamoyl)-3-hydroxy-cyclopent-1-enecarboxylic acid methyl ester (6).

20

Reaction of 4 (141 mg, 76 mmol) according to the method described for the preparation of 5 using L-2-amino-N-butyric acid *tert*.butyl ester instead of 2-amino-pentanoic acid *tert*.butyl ester gave the title compound as a slightly yellow oil (171 mg, 69 %).


25

M183-2

67

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.89-0.98 (m, 3H), [(1.42 & 1.44) s, 9H], 1.60-1.78 (m, 1H), 1.79-1.95 (m, 1H), 1.99-2.11 (m, 1H), 2.18-2.30 (m, 1H), 3.58-3.65 (m, 1H), [3.75 & 3.78) s, 3 H], 4.22-4.39 (m, 1H), 4.61-4.66 (m, 1H), 6.77-6.90 (m, 1H), 6.91-6.92 (m, 1H).


5

Example 7

((3S,5R) & (3R,5S))-5-(((1R,2S)-1-*tert*-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-hydroxy-cyclopent-1-enecarboxylic acid methyl ester (7).

- 10 Reaction of 4 (50 mg, 37 mmol) according to the method described for the preparation of 5 using (1R, 2S)-1-amino-2-vinyl-cyclopropane carboxylic acid *tert*.butyl ester instead of 2-amino-pentanoic acid *tert*.butyl ester provided the title compound as a slightly yellow oil (50 mg, 38 %).

- 15 $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ [(1.38 & 1.42) s, 9H], 1.75-1.83 (m, 1H), 2.00-2.21 (m, 3H), 3.55-3.63 (m, 1H), [(3.77 & 3.82) s, 3H], 4.20-4.38 (m, 1H), 4.65-4.80 (m, 1H), 5.13-5.20 (m, 1H), 5.22-5.38 (m, 1H), 5.60-5.82 (m, 1H), 6.95-6.96 (m, 2H).

Example 8

20

M183-2

68

((3*R*,5*R*) & (3*S*,5*S*))-5-((*S*)-1-*tert*-Butoxycarbonyl-butylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (8).


To an ice cooled solution of 5 (0.23 g, 0.67 mmol) in dry THF, 7-methoxy-2-phenyl-quinolin-4-ol (0.22 g, 0.88 mmol) and triphenylphosphine (0.23 g, 0.88 mmol) were added. Then DIAD (0.19 g, 0.92 mmol) was dissolved in THF (2 mL) and added dropwise to the solution. After one hour the mixture was concentrated and purified using flash chromatography (toluene/ethyl acetate 3:1). This gave the title compound as a white powder (0.30 g, 77 %).

10

¹H-NMR (300 MHz, CDCl₃): δ 0.88-1.00 (m, 3H), 1.18-1.43 (m, 2H), [(1.45 & 1.50) s, 9H], 1.53-1.65 (m, 1H), 1.66-1.85 (m, 1H), 2.29-2.43 (m, 1H), 3.10-3.25 (m, 1H), [(3.79 & 3.83) s, 3H], 3.97 (s, 3H), 4.05-4.20 (m, 1H), 4.38-4.50 (m, 1H), 6.03-6.13 (m, 1H), 6.65-6.90 (m, 1H), 7.04-7.18 (m, 3H), 7.40-7.56 (m, 4H), 8.00-8.12 (m, 3H).

15

Example 9



((3*R*,5*R*) & (3*S*,5*S*))-5-((*S*)-1-*tert*-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (9).

20

Reaction of 6 (132 mg, 40 mmol) according to the method described for the preparation of 8 gave the title compound as a yellow oil (137 mg, 61 %).


25

¹H-NMR (300 MHz, CDCl₃): δ 0.83-0.98 (m, 3H), [(1.42 & 1.44) s, 9H], 1.65-1.78 (m, 1H), 1.80-1.97 (m, 1H), 2.30-2.40 (m, 1H), 3.05-3.20 (m, 1H), [(3.78 & 3.80) s, 3H],

M183-2

69

3.94 (s, 3H), 3.95-4.01 (m, 1H), 4.38-4.44 (s, 1H), 6.05-6.15 (m, 1H), 6.80-6.94 (m, 1H), 7.02-7.15 (m, 3H), 7.38-7.55 (m, 4H), 7.97-8.18 (m, 3H).

Example 10


5

((3*R*,5*R*) & (3*S*,5*S*))-5-((1*R*,2*S*)-1-*tert*-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (10).

- 10 Reaction of 7 (41 mg, 116 mmol) according to the method described for the preparation of 8 provided the title compound as a yellow oil.

¹H-NMR (300 MHz, CDCl₃): δ 1.52-1.57 (m, 1H), 1.58 (m, 9H), 1.80-1.83 (m, 1H), 2.00-2.17 (m, 1H), 2.20-2.38 (m, 1H), 3.20-3.37 (m, 1H), 3.80 (s, 3H), 3.81-3.98 (m, 1H), 3.99 (s, 3H), 5.12-5.20 (m, 1H), 5.22-5.40 (m, 1H), 5.63-5.80 (m, 1H), 6.05-6.20 (m, 1H), 7.00-7.21 (m, 4H), 7.40-7.58 (m, 4H), 8.02-8.18 (m, 3H).

15

Example 11


M183-2

70

((3*R*,5*R*) & (3*S*,5*S*))-5-((*S*)-1-*tert*-Butoxycarbonyl-butylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid (11).

The methyl ester 8 (0.35 g, 0.61 mmol) was dissolved in dioxane/water (1:1, 7ml) and LiOH (0.031 g, 1.3 mmol) was added. The reaction was stirred over night and then co-concentrated. This gave the lithium salt of 11 (0.32 g, 90 %) as a brown powder.


Example 12



((3*R*,5*R*) & (3*S*,5*S*))-5-((*S*)-1-*tert*-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid (12)

Reaction of 9 (225 mg, 40 mmol) according to the method described for the preparation of 11 provided the title compound as a yellow salt (157 mg, 72 %).

Example 13




((3*R*,5*R*) & (3*S*,5*S*))-5-((1*R*,2*S*))-1-*tert*-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid (13).

M183-2

71

Reaction of 10 (35 mg, 59 μ mol) according to the method described for the preparation of 11 (33 mg, 97 %) provided the title compound as a yellow salt.

Example 14



5

(*S*)-2-[[[(1*S*,4*S*) & (1*R*,4*R*))-2-[(*S*)-1-[(*S*)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric acid *tert*-butyl ester (14).

- 10 The acid 12 (38.4 mg, 0.070 μ mol) and (2-amino-3-methyl-butrylamino)-cyclohexyl acetic acid methyl ester (26.6 mg, 0.098 μ mol) were dissolved in DMF (1.5 mL) and cooled in an ice-bath. DIPEA (17.1 μ L, 0.098 μ mol) and HATU (37.4 mg, 0.098 μ mol) were added. After ninety minutes the mixture was co-concentrated with toluene and methanol and then purified by flash column chromatography
- 15 (toluene/ethyl acetate 6:1). Further purification was performed on HPLC (90 % MeOH + 0.2 % TEA). The diastereomeric mixture 14 was concentrated and gave a slightly yellow oil (20.6 mg, 37 %). After lyophilisation 14 was collected as a white powder.


- 20 $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.93-1.02 (m, 9H), 1.03-1.25 (m, 4H), 1.44 (s, 9H), 1.65-1.86 (m, 9H), 2.05-2.10 (m, 1H), 2.22-2.40 (m, 1H), 3.05-3.20 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.18-4.22 (m, 1H), 4.38-4.60 (m, 3H), 6.01-6.10 (m, 1H), 6.61-6.70 (m, 2H), 6.80-6.85 (m, 1H), 7.05-7.18 (m, 2H), 7.40-7.58 (m, 5H), 8.00-8.13 (m, 3H).

M183-2

72

¹³C-NMR (75.5 MHz, CDCl₃): δ 9.7, 18.4, 19.2, [25.9 & 26.1], [28.2 & 28.5], 29.6, 32.0, 37.3, 41.0, 46.2, 50.7, 52.4, 54.4, 55.8, 57.2, 58.5, 82.0, 82.8, 98.4, 110.2, 118.4, 120.1, 123.2, 127.9, 128.2, 128.9, 129.5, 131.2, 135.1, 135.2, 142.7, 144.2, 161.6, 164.3, 164.7, 170.9, 171.4, 172.4. MALDI-TOF *m/z* 821.56 [(M + Na)⁺ calcd for C₄₅H₅₈N₄NaO₉⁺ 821.41].

Example 15



(S)-2-[[[(1R,4R) & (1S,4S)]-2-[(R)-1-[(R)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric acid *tert*-butyl ester (15).

Reaction of 12 (20 mg, 37 mmol) according to the method described for the preparation of 14 using (2-amino-3-methyl-butrylamino)-(R)-cyclohexyl acetic acid methyl ester instead of (2-amino-3-methyl-butrylamino)-(S)-cyclohexyl acetic acid methyl ester, gave the title compound (19 mg, 66 %) as a white powder.


¹H-NMR (300 MHz, CDCl₃): δ 0.91-0.98 (m, 3H), 0.99-1.10 (m, 6H), 1.11-1.38 (m, 4H), [(1.43 & 1.45) s, 9H], 1.45-1.94 (m, 9H), 2.05-2.18 (m, 1H), 2.22-2.40 (m, 1H), 3.16-3.24 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.04-4.18 (m, 1H), 4.36-4.57 (m, 3H), 6.00-6.08 (m, 1H), 6.13-6.21 (m, 1H), 6.62-6.70 (m, 1H), 6.81-6.85 (m, 1H), 7.05-7.18 (m, 3H), 7.41-7.57 (m, 4H), 8.02-8.13 (m, 3H). ¹³C-NMR (75.5 MHz, CDCl₃): δ 9.3, 18.2, 19.0, [25.5 & 25.9], [28.0 & 28.3], 29.4, 31.4, 32.1, 35.7, 40.7, 50.4, 52.2,

M183-2

73

54.2, 55.5, 57.0, 58.2, 81.8, 82.4, 98.2, 107.5, 115.0, 118.1, 122.9, 127.6, 128.7, 128.8, 128.9, 129.2, 135.1, 140.4, 142.2, 151.4, 161.3, 163.9, 170.4, 170.9, 171.2, 172.0. MALDI-TOF m/z 821.60 $[(M + Na)^+]$ calcd for $C_{45}H_{58}N_4NaO_9^+$ 821.41].

5 Example 16



(S)-2-((((3R,5R) & (3S,5S))-5-((S)-1-*tert*-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarbonyl]-amino)-3-methylbutyric acid methyl ester (16).

10

Reaction of 12 (24 mg, 44 μ mol) according to the method described for the preparation of 14 using D-valine methyl ester instead of (2-amino-3-methylbutyrylamino)cyclohexyl acetic acid methyl ester, gave the title compound (27 mg, 97 %) as a white powder.


15

1H -NMR (300 MHz, $CDCl_3$): δ 0.82-0.99 (m, 9H), [(1.42 & 1.44) s, 9H] 1.65-1.95 (m, 2H), 2.18-2.25 (m, 1H), 2.26-2.40 (m, 1H), 3.20-3.25 (m, 1H), 3.75 (s, 3H), 3.97 (s, 3H), 4.15-4.19 (m, 1H), 4.36-4.43 (m, 1H), 4.64-4.75 (m, 1H), 6.03-6.15 (m, 1H), 6.80-6.85 (m, 2H), 7.10-7.20 (m, 3H), 7.42-7.58 (m, 4H), 8.0-8.10 (m, 3H). ^{13}C -NMR (75.5 MHz, $CDCl_3$): δ 9.7, [18.2 & 19.1], 25.7, [28.1 & 28.2], 32.0, 35.6, 50.4, 52.4, 54.5, 55.7, 57.6, 81.7, 82.7, 98.4, 107.7, 115.2, 118.4, 123.2, 127.8, 129.0, 129.2, 129.5, 134.8, 135.0, 140.4, 142.5, 151.6, 159.6, [161.1 & 161.5], 164.6, 171.1, 172.2. MALDI-TOF m/z 682.51 $[(M + Na)^+]$ calcd for $C_{37}H_{45}N_3NaO_8^+$ 682.31].

25 Example 17

M183-2

74



(S)-2-[[[(1*R*,4*R*) & (1*S*,4*S*))-2-[(*S*)-1-[(2,5-Dimethoxy-phenyl)-ethyl-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-butyric acid *tert*-butyl ester (17).

5

Compound 17 (28.6 mg, 59 %) was prepared from 12 (33 mg, 60 mmol) according to the method for the preparation of 14 using 2-amino-N-(2,5-dimethoxy-phenyl)-N-ethyl-3-methyl butyramide instead of (2-amino-3-methyl-buteryl-amino)-cyclohexyl acetic acid methyl ester. This gave the title compound as a white powder.

10

¹H-NMR (300 MHz, CDCl₃): δ 0.75-0.95 (m, 9H) 1.05-1.18 (m, 3H), [(1.42 & 1.44) s, 9H], 1.60-1.95 (m, 3H), 2.20-2.40 (m, 1H), 3.20-3.34 (m, 1H), 3.60-3.80 (m, 2H), [3.62-3.65 (m, 3H)], [3.79-3.82 (m, 3H)], 3.98 (s, 3H), 4.02-4.18 (m, 1H), 4.30-4.44 (m, 2H), 6.05-6.18 (m, 1H), 6.60-6.63 (m, 1H), 6.77-6.80 (m, 2H), 6.85-6.93 (m, 2H), 7.12-7.20 (m, 2H), 7.35-7.60 (m, 5H), 8.02-8.20 (m, 3H). ¹³C-NMR (75.5 MHz, CDCl₃): δ [9.6 & 9.7], [12.5 & 12.8], [17.1 & 17.5], [19.4 & 19.5], 25.6, [28.0 & 28.1], 32.4, 35.8, 43.0, 44.3, [50.2 & 50.3], 54.3, [54.8 & 55.0 & 55.2 & 55.5], [55.6 & 55.7 & 55.9 & 56.0], 81.7, 82.8, 98.4, 106.9, [112.4 & 112.5], 113.7, 115.0, 115.2, 115.9, 116.3, 118.4, [123.0 & 123.1], [127.7 & 127.8], 128.8, 128.9, 129.5, 130.1, [134.1 & 134.2], 142.6, 149.1, 149.4, 153.4, 158.9, [161.4 & 161.6], [163.2 & 163.5], 170.9, [171.3 & 171.5], 172.3. MALDI-TOF *m/z* 831.62 [(M + Na)⁺ calcd for C₄₆H₅₆N₄NaO₉⁺ 831.39].


15

20

Example 18

M183-2

75





(S)-2-[[[(1R,4R) & (1S,4S)]-2-[(S)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric acid *tert*-butyl ester (18).

5

Compound 18 (16.1 mg, 26 %) was prepared from 12 (43.2 mg, 0.077 mmol) according to the method for the preparation of 14 using (2-amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester instead of (2-amino-3-methyl-butyrylamino)-cyclohexyl acetic acid methyl ester. Flash column chromatography was performed in toluene/ethyl acetate 3:1 instead of 6:1: This gave the title compound as a white powder.

¹H-NMR (300 MHz, CDCl₃): δ 0.77-0.83 (m, 3H), [(0.92 & 0.93) s, 9H] 0.94-1.20 (m, 4 H), [(1.36 & 1.38) s, 9H], 1.42-1.76 (m, 8H), 2.20-2.38 (m, 1H), 2.81-2.96 (m, 1H), 3.20-3.22 (m, 1H), 2.78 (s, 3H), [(3.83 & 3.85) s, 3H], 3.97-4.02 (m, 1H), 4.17-4.21 (m, 1H), 4.22-4.37 (m, 2H), 5.85-5.97 (m, 1H), [6.76-6.78 (m, 0.5H)], [6.80-6.82 (m, 0.5H)], 6.98-7.05 (m, 3H), 7.23-7.41 (m, 6H), 7.82-7.99 (m, 3H). ¹³C-NMR (75.5 MHz, CDCl₃): δ [9.4 & 9.5], [25.4 & 25.5], 25.8, [26.5 & 26.6], [27.9 & 28.0], [28.4 & 28.5], 29.3, [35.4 & 35.7], [36.0 & 36.4], [40.5 & 40.7], [50.2 & 50.5], [52.1 & 52.2], [54.1 & 54.3], 55.5, [57.0 & 57.3], [60.4 & 60.7], [81.8 & 82.0], [82.4 & 82.5] 98.1, 107.5, 115.0, 118.1, 123.0, 127.5, 128.7, 128.8, 129.2, 134.9, 135.8, 141.9, 142.5, 151.3, 159.4, [160.9 & 161.3], [163.7 & 163.9], [169.9 & 170.0] [170.0 & 171.3], [172.5 & 172.4]. MALDI-TOF *m/z* 835.68 [(M + Na)⁺ calcd for C₄₆H₆₀N₄NaO₉⁺ 835.43].

25

Example 19

(S)-2-[[[(1R,4R)-2-[(S)-1-[[[(S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic acid tert-butyl ester (19a) and
 (S)-2-[[[(1S,4S)-2-[(S)-1-[[[(S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic acid tert-butyl ester (19b).



The acid 11 (0.051 g, 0.087 mmol) and (2-amino-3-methyl-butrylamino)-cyclohexyl-acetic acid methyl ester (0.054 g, 0.21 mmol) were dissolved in DMF (1.5 mL) and cooled in an ice-bath. DIPEA (16 mg, 0.12 mmol) and HATU (47 mg, 0.13 mmol) were added. After two and a half hours the mixture was co-concentrated with toluene and methanol and then purified by flash column chromatography (toluene/ethyl acetate 3:1). Further purification was performed on HPLC (90 % MeOH + 0.2 % TEA). This gave after co-concentration the two diastereomers 19a (9.4 mg, 13 %) and 19b (5.3 mg, 7 %) as slightly yellow syrups. After lyophilisation 19a and 19b were collected as white powders:

¹H-NMR (300 MHz, CDCl₃): δ 0.86-0.93 (m, 3H), 0.94-1.00 (m, 6H), 1.00-1.41 (m, 7H), 1.46 (s, 9H), 1.50-1.88 (m, 8H), 2.05-2.20 (m, 1H), 2.20-2.37 (m, 1H), 3.12-3.25 (m, 1H), 3.73 (s, 3H), 3.97 (s, 3H), 4.05-4.20 (m, 1H), 4.40-4.55 (m, 3H), 6.02-6.18 (m, 1H), 6.30 (d, J = 8.52 Hz, 1H), 6.63 (s, 1H), 6.76 (d, J = 8.51 Hz, 1H), 7.06-7.16 (m, 2H), 7.42-7.56 (m, 5H), 8.00-8.12 (m, 3H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 14.0,

M183-2

77

18.4, 19.3, 26.1, 28.3, 28.5, 29.7, 31.9, 34.9, 36.0, 41.0, 50.7, 52.4, 53.3, 55.7, 57.2, 58.6, 82.0, 82.7, 98.4, 105.7, 107.7, 115.2, 118.4, 123.2, 125.3, 127.9, 129.0, 129.1, 135.1, 138.0, 142.4, 151.6, 159.4, 161.6, 164.3, 170.7, 171.2, 172.3. 19b: ¹H-NMR (300 MHz, CDCl₃): δ 0.90-1.04 (m, 9H), 1.04-1.43 (m, 7H), 1.47 (s, 9H), 1.50-1.87 (m, 8H), 2.10-2.27 (m, 1H), 2.33-2.45 (m, 1H), 3.10-3.20 (m, 1H), 3.73 (s, 3H), 3.96 (s, 3H), 4.02-4.10 (m, 1H), 4.36-4.53 (m, 3H), 6.00-6.16 (m, 1H), 6.30 (d, *J* = 8.52 Hz, 1H), 6.73 (s, 1H), 6.86 (d, *J* = 7.96 Hz, 1H), 7.08-7.16 (m, 2H), 7.36-7.56 (m, 5H), 8.03-8.11 (m, 3H). ¹³C-NMR (75.5 MHz, CD₃OD): δ 14.0, 18.6, 19.2, 26.1, 28.2, 28.7, 29.7, 34.5, 36.1, 36.6, 40.8, 50.5, 52.4, 53.4, 55.7, 57.3, 59.1, 64.8, 82.3, 98.4, 105.8, 107.8, 115.3, 118.4, 123.2, 127.8, 129.0, 129.4, 135.2, 142.2, 144.9, 151.0, 151.6, 159.2, 164.3, 164.3, 170.2, 171.6, 171.9

Example 20

- 15 (S)-2-[[[(1R,4R)-2-[(R)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid tert-butyl ester (20a) and
 (S)-2-[[[(1S,4S)-2-[(R)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid tert-butyl ester (20b).
 20

Method A: The carboxylic acid 11 (57 mg, 0.10 mmol) was dissolved in warm (50 °C) dry THF (2 mL). (2-Amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (50 mg, 0.12 mmol), DIPEA (30 mg, 0.23 mmol), DCC (25 mg, 0.12 mmol) and

HOBt (17 mg, 13 mmol) were added. After two hours the mixture was concentrated and added to a short column (toluene/Ethyl acetate 1:3 + 3 % AcOH). Then it was further purified on HPLC using 90 % MeOH + 0.2 % TEA. The diastereomeric products were not separated. After HPLC the solution was co-concentrated with
5 toluene and methanol to give 20 (28 mg, 34%).


Method B: To an ice-cold solution of 11 (60 mg, 0.10 mmol) and (2-amino-3,3-dimethyl-butrylamino)-cyclohexyl-acetic acid methyl ester (42 mg, 0.15 mmol) DIPEA (19 mg, 0.15 mmol) and HATU (62 mg, 0.16 mmol) were added. After two
10 and a half hours the mixture was concentrated and purified using column chromatography. (toluene/Ethyl acetate 3:1). The diastereomeric mixture was separated using HPLC (90 % MeOH + 0.2 % TEA). This gave 20a (6 mg, 6 %) and 20b (9 mg, 10%).

15 20a: ¹H-NMR (300 MHz, CDCl₃): δ 0.82-0.90 (m, 3H), 1.01 (s, 9H), 1.05-1.40 (m, 7H), 1.46 (s, 9H), 1.50-1.80 (m, 8H), 2.20-2.35 (m, 1H), 3.07-3.25 (m, 1H), 3.73 (s, 3H), 3.97 (s, 3H), 4.11 (d, J = 7.96 Hz, 1H), 4.38-4.52 (m, 3H), 6.03-6.12 (m, 1H), 6.24 (d, J = 8.79 Hz, 1H), 6.63 (s, 1H), 6.82 (d, J = 9.06 Hz, 1H), 7.07-7.27 (m, 2H), 7.36 (d, J = 7.96 Hz, 1H), 7.41-7.55 (m, 4H), 8.01-8.10 (m, 3H); ¹³C-NMR (75.5 MHz,
20 CD₃OD): δ 14.0, 18.8, 26.1, 26.8, 28.2, 28.6, 29.6, 34.9, 35.6, 36.2, 40.9, 50.7, 52.4, 53.3, 55.7, 57.3, 60.8, 82.0, 82.7, 98.4, 105.2, 107.7, 115.2, 118.4, 123.2, 127.9, 129.0, 129.4, 131.1, 135.1, 138.4, 142.4, 153.3, 159.6, 161.6, 164.2, 170.1, 171.3, 172.2. 20b: ¹H-NMR (300 MHz, CDCl₃): δ 0.90-0.98 (m, 3H), 1.04 (s, 9H), 1.08-1.40 (m, 7H), 1.44 (s, 9H), 1.55-1.90 (m, 8H), 2.20-2.38 (m, 1H), 3.10-3.22 (m, 1H), 3.73 (s, 3H), 3.97 (s, 3H), 4.02-4.15 (m, 1H), 4.35-4.48 (m, 3H), 6.00-6.08 (m, 1H), 6.72 (s, 1H), 6.90 (d, J = 9.06 Hz, 1H), 7.09-7.20 (m, 3H), 7.44-7.55 (m, 5H), 8.03-8.11 (m, 3H).
25

Example 21

M183-2

79



(1*R*,2*S*)-1-[[[(1*R*,4*R*) & (1*S*,4*S*))-2-[(*S*)-1-[(*S*)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid *tert*-butyl ester (21).

The acid 13 (35 mg, 0.060 mmol) and (2-amino-3,3-dimethyl-butrylamino)-cyclohexyl-acetic acid methyl ester (22 mg, 0.080 mmol) were dissolved in dry THF (1.5 mL) and warmed to 50 °C. HOBt (11 mg, 0.080 mmol) and DCC (31 mg, 0.15 mmol) were added. After one hour the mixture was co-concentrated with toluene and methanol and then purified by flash column chromatography (toluene/ethyl acetate 1:1). Further purification was performed on HPLC (80 % MeOH + 0.2 % TEA. The diastereomeric mixture 21 was concentrated and gave a slightly yellow oil (26.4 mg, 53 %). After lyophilisation 21 was collected as a white powder.

15

¹H-NMR (300 MHz, CDCl₃): δ [(0.98 & 1.00), s, 9H], 1.01-1.38 (m, 5H), [(1.39 & 1.40) s, 9H], 1.52-1.63 (m, 4H), 1.65-1.80 (m, 4H), 1.90-2.05 (m, 1H), 2.20-2.40 (m, 1H), 3.02-3.20 (m, 1H), [(3.66 & 3.67) s, 3H], 3.98 (s, 3H), 3.99-4.02 (m, 1H), 4.30-4.45 (m, 2H), 5.05-5.11 (m, 1H), 5.20-5.30 (m, 1H), 5.60-5.81 (m, 1H), 6.03-6.17 (m, 1H), 6.77-6.82 (m, 1H), 6.95-7.22 (m, 5H), 7.40-7.50 (m, 4H), 8.01-8.10 (m, 3H). ¹³C-NMR (75.5 MHz, CDCl₃): δ 22.3, [25.7 & 25.8], [26.4 & 26.5], [28.0 & 28.4] 29.2, 32.7, 33.3, [35.3 & 35.4], 36.0, [40.2 & 40.3], 40.7, 52.0, 55.4, [57.2 & 57.4] [60.4 & 60.5], [87.6 & 87.7], [82.3 & 82.5], 98.4, 107.0, 114.9, [117.4 & 117.5], 118.1, 122.9, 127.6, 128.6, 128.9, 129.2, [133.6 & 133.8], 135.9, 136.9, 140.1, [141.4 & 141.6],



M183-2

80

151.1, 159.6, [160.9 & 161.3], [164.2 & 164.6], 168.9, 170.3, [172.1 & 172.6].

MALDI-TOF m/z 859.77 $[(M + Na)^+]$ calcd for $C_{48}H_{60}N_4NaO_9^+$ 859.43].

Example 22



(S)-2-[[[(1R,4R)-2-[(R)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid (22a) and
(S)-2-[[[(1S,4S)-2-[(R)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid (22b).



The tert.butyl ester 20 (28 mg, 0.034 mmol), TES (8.7 mg, 0.075 mmol), DCM (1 mL) and TFA (1 mL) were mixed in a round bottomed flask. Two hours later the mixture was concentrated and the diastereomers were separated on HPLC using 65 % MeOH + 0.2 % TEA as mobile phase. This gave 22a (15 mg, 55 %) and 22b (12 mg, 45 %) as slightly yellow syrups. After lyophilisation the title compounds were collected as white powders.

22a: $[\alpha]^{22}_D + 155.8$; 1H -NMR (300 MHz, CD_3OD): δ 0.90-0.97 (m, 3H), 1.03 (s, 9H), 1.05-1.50 (m, 7H), 1.50-1.80 (m, 8H), 2.43-2.55 (m, 1H), 2.77-2.90 (m, 1H), 3.68 (s, 3H), 3.96 (s, 3H), 4.20-4.30 (m, 2H), 4.31-4.40 (m, 1H), 4.45-4.50 (m, 1H), 6.03-6.11 (m, 1H), 6.98 (s, 1H), 7.12-7.19 (m, 1H), 7.36 (s, 1H), 7.41 (d, $J = 2.2$ Hz, 1H), 7.50-7.60 (m, 3H), 8.03-8.10 (m, 3H); ^{13}C -NMR (75.5 MHz, CD_3OD): δ 13.1, 19.1, 26.1,

M183-2

81

28.7, 28.9, 29.5, 34.3, 34.8, 35.9, 40.1, 50.8, 51.2, 54.8, 55.0, 57.9, 60.7, 83.5, 99.1, 106.0, 115.2, 118.2, 123.3, 127.8, 128.0, 128.7, 128.8, 129.7, 135.2, 139.8, 143.7, 150.6, 160.1, 162.2, 165.2, 171.7, 172.2, 173.4. 22b: $[\alpha]^{22}_D$ -72.3; $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 0.90-0.97 (m, 3H), 1.02 (s, 9H), 1.07-1.35 (m, 7H), 1.53-1.90 (m, 8H), 2.46-2.61 (m, 1H), 2.76-2.88 (m, 1H), 3.69 (s, 3H), 3.96 (s, 3H), 4.15-4.35 (m, 2H), 4.37-4.41 (m, 1H), 4.42-4.47 (m, 1H), 6.02-6.12 (m, 1H), 7.02 (s, 1H), 7.16 (dd, $J = 2.47, 9.34$ Hz, 1H), 7.32 (s, 1H), 7.40 (d, $J = 2.47$ Hz, 1H), 7.48-7.58 (m, 3H), 8.03-8.12 (m, 3H); $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD): δ 13.0, 18.8, 25.9, 26.0, 28.8, 29.4, 34.2, 34.8, 36.3, 39.9, 48.8, 50.5, 51.1, 54.8, 57.9, 60.5, 82.8, 99.0, 106.0, 115.1, 118.2, 123.1, 127.8, 127.9, 128.7, 129.0, 129.5, 136.7, 139.8, 142.8, 150.6, 160.1, 162.0, 162.2, 164.7, 172.1, 173.5.

Example 23

- 15 (S)-2-(((1*R*,4*R*)-2-((*R*)-1-(((*R*)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid (23a) and (S)-2-(((1*S*,4*S*)-2-((*R*)-1-(((*R*)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid (23b).

20


Compound 23a (6.6 mg, 50 %) and compound 23b (1.3 mg, 10 %) were prepared from 15 (14 mg, 0.018 mmol) according to the method for the preparation of 22a and 22b. This gave the title compounds as white powders.

M183-2

82

23a: $^1\text{H-NMR}$ (300 MHz, CD_3OD): 0.88-1.02 (m, 9H), 1.02-1.40 (m, 7H), 1.55-1.97 (m, 6H), 2.01-2.10 (m, 1H), 2.38-2.52 (m, 1H), 2.88-3.00 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.08-4.20 (m, 1H), 4.22-4.40 (m, 3H), 6.03-6.18 (m, 1H), 6.86-6.99 (m, 1H), 7.08-7.20 (m, 1H), 7.23 (s, 1H), 7.40-7.43 (m, 1H), 7.45-7.70 (m, 3H), 8.02-8.20 (m, 3H). $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD): δ 9.0, 17.6, 18.2, 24.5, 25.3, 28.1, 28.8, 30.9, 35.4, 39.4, 49.6, 51.1, 54.7, 57.2, 58.0, 82.4, 98.5, 105.5, 114.5, 117.7, 122.7, 127.2, 127.3, 128.2, 129.0, 135.6, 136.4, 141.7, 149.9, 159.5, 161.2, 161.4, 164.0, 171.0, 171.7, 172.4. 23b: $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 0.9-1.20 (m, 9H), 1.21-1.53 (m, 7H), 1.55-1.93 (m, 6H), 2.05-2.20 (m, 1H), 2.41-2.50 (m, 1H), 2.96-3.05 (m, 1H), 3.77 (s, 3H), 4.00 (s, 3H), 4.05-4.40 (m, 4H), 6.05-6.18 (m, 1H), 6.90-6.95 (m, 1H), 7.05-7.22 (m, 2H), 7.50-7.65 (m, 4H), 8.01-8.16 (m, 3H).

Example 24



15 (S)-2-[[[(1R,4R) & (1S,4S)]-2-[(S)-1-[(S)-Carboxy-cyclohexyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid (24).


20 The tert.butyl ester 14 (13.4 mg, 0.017 mmol), TES (4.83 mg, 0.042 mmol), DCM (2 mL) and TFA (2 mL) were mixed in a round bottomed flask. One hour later the mixture was concentrated and purified by HPLC using 65 % MeOH + 0.2 % TEA as mobile phase. This gave 24 (4.3 mg, 34 %) as a slightly yellow syrup. After lyophilisation 24 was collected as a white powder.

M183-2

83

¹H-NMR (300 MHz, CD₃OD): δ 0.91-0.99 (m, 9H), 1.00-1.28 (m, 4H), 1.55-1.78 (m, 9H), 1.92-1.95 (m, 1H), 2.00-2.05 (m, 1H), 2.93-3.01 (m, 1H), 3.75 (s, 3H), 3.97 (s, 3H), 4.10-4.40 (m, 4H), 6.05-6.15 (m, 1H), 6.88-6.94 (m, 1H), 7.05-7.10 (m, 2H), 7.41-7.43 (m, 1H), 7.44-7.55 (m, 2H), 8.62-8.68 (m, 1H), 8.69-8.79 (m, 1H), 7.97-8.05 (m, 2H). ¹³C-NMR (75.5 MHz, CD₃OD): δ 9.2, 18.5, 25.5, [29.0 & 29.2], [30.0 & 30.5], 35.3, 37.7, 39.7, 46.2, 50.0, [51.4 & 51.5], 53.6, 55.1, 57.1, 58.4, 83.1, 98.9, 104.9, 114.6, 118.3, 123.0, 123.4, 127.5, 128.4, 128.5, 129.7, 135.0, 142.1, 145.7, 146.2, 159.2, 161.9, 164.3, 171.5, 171.9, 172.2. MALDI-TOF *m/z* 791.27 [(M + K)⁺ calcd for C₄₂H₄₈KN₄O₉⁺ 791.31].

10

Example 25

(S)-2-(((3R,5R) & (3S,5S))-5-((S)-1-Carboxy-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarbonyl]-amino)-3-methyl-butyl ester (25).

15

Compound 25 (8.0 mg, 60 %) was prepared from 16 (13.8 mg, 0.022 mmol) according to the method for the preparation of 24 which gave the title compound as a white powder.


20

¹H-NMR (300 MHz, CD₃OD): δ 0.83-1.02 (m, 9H), 1.68-1.80 (m, 1H), 1.82-2.02 (m, 1H), 2.10-2.22 (m, 1H), 2.40-2.60 (m, 1H), 2.81-2.95 (m, 1H), 3.75 (s, 3H), 4.00 (s, 3H), 4.18-4.22 (m, 1H), 4.27-4.40 (m, 2H), 6.05-6.12 (m, 1H), 6.99-7.02 (m, 1H),

M183-2

84

7.16-7.21 (m, 1H), 7.38 (s, 1H), 7.40-7.43 (m, 1H), 7.48-7.61 (m, 3H), 7.98-8.12 (m, 3H).

Example 26

5


(S)-2-[[[(1R,4R) & (1S,4S)]-2-[(S)-1-[(2,5-Dimethoxy-phenyl)-ethyl-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-butyric acid (26).

- 10 Compound 26 (5.7 mg, 36 %) was prepared from 17 (16.7 mg, 0.021 mmol) according to the method for the preparation of 24 which gave the title compound as a white powder.

¹H-NMR (300 MHz, CD₃OD): δ 0.75-0.81 (m, 6H), 0.82-0.98 (m, 3H), 1.00-1.10 (m, 3H), 1.60-2.00 (m, 3H), 2.40-2.56 (m, 1H), 2.80-2.88 (m, 1H), 3.18-3.24 (m, 1H), 3.40-3.46 (m, 1H), [3.67-3.80 (m, 6H)], 3.97 (s, 3H), 4.10-4.20 (m, 1H), 4.21-4.40 (m, 2H), 6.02-6.17 (m, 1H), 6.75-6.82 (m, 1H), 6.84-7.01 (m, 3H), 7.10-7.20 (m, 1H), 7.30-7.37 (m, 1H), 7.40-7.43 (m, 1H), 7.50-7.60 (m, 3H), 8.00-8.17 (m, 3H). ¹³C-NMR (75.5 MHz, CD₃OD): δ 9.6, [11.8 & 12.0], [17.2 & 17.4], 18.9, 25.0, 32.3, 35.7, 43.3, 44.2, [50.3 & 50.5], [54.5 & 54.8 & 54.9 & 55.0], [55.1 & 55.2 & 55.3 & 56.0], 58.7, 83.6, 99.3, 105.5, [112.5 & 112.7], 114.3, [15.1 & 115.2], 115.7, 116.1, 118.4, [123.3 & 123.4], 125.2, [128.0 & 128.1, 128.8, 129.1, 129.8, [135.1 & 135.3], 139.2, [143.3 & 144.4], 149.2, [149.6 & 149.9], 153.8, 159.9, 162.4, [163.9 & 164.5], 172.1, 172.8, [173.6 & 173.7]. MALDI-TOF *m/z* 775.30 [(M + Na)⁺ calcd for C₄₂H₄₈N₄NaO₉⁺ 775.33].

M183-2

85

Example 27

(S)-2-[[[(1R,4R) & (1S,4S)]-2-[(S)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-
 5 carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-
 cyclopent-2-enecarbonyl]-amino]-butyric acid (27).


Compound 27 (6.0 mg, 72 %) was prepared from 18 (8.6 mg, 0.011 mmol) according
 to the method for the preparation of 24. Purification by HPLC (60 % methanol + 0.2
 10 % TEA) gave the title compound as a white powder.

¹H-NMR (300 MHz, CD₃OD): δ 0.88-0.95 (m, 3H), 0.96 (s, 9H), 0.97-1.24 (m, 4H),
 1.57-1.62 (m, 3H), 1.58-1.78 (m, 4H), 1.79-1.99 (m, 1H), 2.35-2.44 (m, 2H), 2.85-
 2.98 (m, 1H), [(3.67 & 3.69) s, 3H], 3.94 (s, 3H), 4.10-4.20 (m, 1H), 4.30-4.40 (m,
 15 3H), 6.00-6.09 (m, 1H), [6.80-6.82 (m, 0.5H)] [6.85-6.87 (m, 0.5H)], 7.05-7.19 (m,
 2H), 7.38-7.55 (m, 4H), 7.95-8.07 (m, 3H). ¹³C-NMR (75.5 MHz, CD₃OD): δ [9.1 &
 9.2], [24.7 & 24.9], [25.4 & 25.5], [25.9 & 26.0], [28.3 & 28.4], 28.9, [34.8 & 34.9],
 [35.6 & 35.9], [39.6 & 39.7], [49.9 & 50.1], [51.4 & 51.2], [53.9 & 54.0] 55.0, [57.2 &
 57.4], 60.0, [82.1 & 82.5], 98.6, 106.2, 114.7, 117.8, 122.7, 127.5, 127.7, [128.4 &
 20 128.5], 129.1, 135.3, 136.3, 141.6, 142.0, 150.5, 159.8, [161.0 & 161.3] [164.0 &
 164.1], [171.6 & 171.9], [172.2 & 172.3], [173.0 & 173.2]. MALDI-TOF *m/z* 779.43 [(M
 +Na)⁺ calcd for C₄₂H₅₂N₄NaO₉⁺ 779.36].

Example 28

M183-2

86



(S)-2-[[[(1R,4R)-2-[(S)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid tert-butyl ester (28).

5

The tert.butyl ester 19a (7.6 mg, 0.0094 mmol) and TES (2.4 mg, 0.021 mmol) were dissolved in DCM (1 mL) and the mixture was cooled in an ice-bath. TFA (1 mL) was added. After two hours the mixture was concentrated and purified on HPLC using 60 % MeOH + 0.2 % TEA as mobile phase. This gave 28 (6.1 mg, 86 %) as a slightly yellow syrup. After lyophilisation the title compound was collected as white powder.

10


¹H-NMR (300 MHz, CD₃OD + CDCl₃ (1:1)): δ 0.90-1.00 (m, 9H), 1.00-1.30 (m, 7H), 1.50-1.90 (m, 8H), 2.00-2.10 (m, 1H), 2.40-2.50 (m, 1H), 2.85-2.98 (m, 1H), 3.65-3.72 (s, 3H), 3.99 (s, 3H), 4.15-4.22 (m, 1H), 4.24-4.35 (m, 2H), 4.38-4.44 (m, 1H), 6.10-6.20 (m, 1H), 6.95-6.96 (m, 1H), 7.16-7.23 (m, 1H), 7.31 (s, 1H), 7.42 (d, *J* = 2.47 Hz, 1H), 7.53-7.72 (m, 3H), 7.97-8.16 (m, 3H); ¹³C-NMR (75.5 MHz, CD₃OD + CDCl₃ 1:1): δ 13.5, 18.3, 19.0, 26.0, 29.0, 29.7, 31.0, 34.1, 35.8, 40.2, 51.9, 55.9, 57.7, 58.9, 63.5, 68.4, 84.0, 99.6, 104.8, 105.7, 115.1, 119.0, 123.7, 128.1, 128.9, 129.1, 130.4, 131.3, 135.3, 138.0, 142.9, 159.5, 162.8, 164.8, 172.2, 172.2, 172.4

20

Example 29

M183-2

87





(S)-2-[[[(1S,4S)-2-[(S)-1-[[[(S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid tert-butyl ester (29).

5

Compound 29 (1.3 mg, 26 %) was prepared from 19b (5.3 mg, 0.065 mmol) according to the method for the preparation of 28. This gave the title compound as a white powder.

- 10 ¹H-NMR (300 MHz, CD₃OD): δ 0.85-1.00 (m, 9H), 1.00-1.23 (m, 7H), 1.50-1.78 (m, 8H), 2.05-2.23 (m, 1H), 2.50-2.66 (m, 1H), 2.70-2.85 (m, 1H), 3.69 (s, 3H), 3.92 (s, 3H), 4.02-4.16 (m, 1H), 4.20-4.25 (m, 1H), 4.35-4.40 (m, 2H), 6.09 (m, 1H), 7.00 (s, 1H), 7.12-7.18 (dd, J = 2.47, 2.19 Hz, 1H), 7.30 (s, 1H), 7.40 (d, J = 2.42 Hz, 1H), 7.48-7.74 (m, 3H), 8.03-8.10 (m, 3H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 11.7, 16.5,
- 15 17.0, 24.4, 27.2, 27.9, 29.0, 29.1 37.5, 41.8, 49.7, 50.5, 53.3, 56.3, 63.5, 66.5, 81.0, 100.3, 101.0, 105.7, 113.6, 121.6, 126.3, 127.1, 127.9, 130.1, 131.4, 135.6, 138.7, 141.1, 150.4, 160.2, 160.5, 165.3, 173.0, 173.6, 173.7

Example 30



(1*R*,2*S*)-1-[[[(1*R*,4*R*)-2-[(*S*)-1-[(*S*)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (30a) and

5 (1*R*,2*S*)-1-[[[(1*S*,4*S*)-2-[(*S*)-1-[(*S*)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-2-vinyl-cyclopropane-carboxylic acid (30b).

10 Compound 30a (6.3 mg, 49 %) and compound 30b (5.6 mg, 43 %) were synthesized from 21 (13.8 mg, 0.0016 mmol) according to the method of the preparation of 22a and 22b. 30a and 30b: White powder.

15 30a: ¹H-NMR (300 MHz, CD₃OD): δ 1.02 (s, 9H), 1.03-1.43 (m, 5H), 1.61-1.95 (m, 8H), 2.11-2.21 (m, 1H), 2.43-2.58 (m, 1H), 2.97-3.04 (m, 1H), 3.78 (s, 3H), 4.01 (s, 3H), 4.02-4.17 (m, 1H), 4.25-4.40 (m, 2H), 5.10-5.20 (m, 1H), 5.27-5.40 (m, 1H), 6.77-6.94 (m, 1H), 6.10-6.20 (m, 1H), 6.97 (s, 1H), 7.18 (dd, *J* = 2.5, 9.2 Hz, 1H), 7.22 (s, 1H), 7.46 (d, *J* = 2.5 Hz, 1H), 7.52-7.65 (m, 3H), 8.00-8.18 (m, 3H). ¹³C-NMR (75.5 MHz, CD₃OD): δ 13.5, 25.3, 25.7, 28.3, 28.7, 29.0, 32.8, 34.6, 35.3, 39.3, 49.7, 51.1, 54.6, 57.2, 59.8, 82.1, 98.4, 105.8, 114.5, 116.3, 117.6, 122.6, 127.2, 128.1, 128.2, 128.8, 130.2, 133.7, 136.0, 139.5, 141.5, 150.3, 159.7, 161.0, 161.2, 163.4, 171.6, 172.5. MALDI-TOF *m/z* 803.56 [(*M* + Na)⁺ calcd for C₄₄H₅₂N₄NaO₉⁺ 803.36].


20 30b: ¹H-NMR (300 MHz, CD₃OD): δ 1.03 (s, 9H), 1.04-1.42 (m, 5H), 2.60-2.90 (m, 8H), 2.17-2.22 (m, 1H), 2.40-2.55 (m, 1H), 2.96-3.10 (m, 1H), 3.77 (s, 3H), 4.01 (s, 3H), 4.05-4.16 (m, 1H), 4.30-4.40 (m, 2H), 5.15-5.20 (m, 1H), 5.25-5.40 (m, 1H),

M183-2

89

5.78-5.95 (m, 1H), 6.10-6.20 (m, 1H), 6.98 (s, 1H), 7.17 (dd, $J = 2.5, 9.1$ Hz, 1H),
7.26 (s, 1H), 7.46 (d, $J = 2.5$ Hz, 1H), 7.50-7.65 (m, 3H), 8.03-8.28 (m, 3H). ^{13}C -NMR
(75.5 MHz, CD_3OD): δ 13.7, 26.0, 26.3, 28.8, 29.4, 29.6, 34.0, 35.2, 35.8, 40.1, 50.6,
51.7, 55.3, 57.8, 60.6, 83.0, 99.1, 106.3, 115.2, 117.0, 118.3, 123.2, 127.9, 128.0,
128.8, 129.6, 130.6, 134.4, 136.1, 140.0, 142.5, 150.8, 160.3, 161.8, 162.0, 165.7,
172.3, 173.0

Example 31



trans-(3*R*,4*R*)-Bis(methoxycarbonyl)cyclopentanol (31).

Sodium borohydride (1.11 g, 0.029 mol) was added to a stirred solution of (1*R*, 2*S*)-
4-oxo-cyclopentane-1,2-dicarboxylic acid dimethyl ester (4.88 g, 0.0244 mol) in
methanol (300 mL) at 0 °C. After 1 h the reaction was quenched with 90 mL brine,
concentrated and extracted with ethyl acetate. The organic phases were pooled,
dried, filtered and concentrated. The crude product was purified by flash column
chromatography (toluene/ethyl acetate 1:1) to give 31 (3.73 g, 76%) as a yellow oil.

Example 32



3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid (32).

Sodium hydroxide (1M, 74 mL, 0.074 mol) was added to a stirred solution of 31 (3.73
g, 0.018 mol) in methanol (105 mL) at room temperature. After 4 h, the reaction
mixture was neutralized with 3M HCl, evaporated and co-evaporated with toluene
several times. Pyridine (75 mL) and Ac_2O (53 mL) were added and the reaction
mixture was allowed to shake overnight at room temperature. The mixture was then


M183-2

90

co-evaporated with toluene and purified by flash column chromatography (ethyl acetate + 1% acetic acid) to give 32 (2.51 g, 88%) as a yellow oil.

Example 33

5




3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid *tert*-butyl ester (33)

10 DMAP (14 mg, 0.115 mmol) and Boc_2O (252 mg, 1.44 mmol) was added to a stirred solution of 32 (180 mg, 1.15 mmol) in 2 mL CH_2Cl_2 under inert argon atmosphere at 0 °C. The reaction was allowed to warm to room temperature and was stirred overnight. The reaction mixture was concentrated and the crude product was purified by flash column chromatography (toluene/ethyl acetate gradient 15:1, 9:1, 6:1, 4:1, 2:1) to give 33 (124 mg, 51%) as white crystals.

15

^1H -NMR (300 MHz, CD_3OD) δ 1.45 (s, 9H), 1.90 (d, J = 11.0 Hz, 1H), 2.10-2.19 (m, 3H), 2.76-2.83 (m, 1H), 3.10 (s, 1H), 4.99 (s, 1H); ^{13}C -NMR (75.5 MHz, CD_3OD) δ 27.1, 33.0, 37.7, 40.8, 46.1, 81.1, 81.6, 172.0, 177.7.

20 Example 34



(1R,2R,4S)-2-((1R,2S)-1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-hydroxy-cyclopentanecarboxylic acid *tert*-butyl ester (34)


25 Compound 33 (56 mg, 0.264 mmol) was dissolved in dioxane/ water 1:1 (5 mL) and the mixture was cooled to 0 °C. 1 M lithium hydroxide (0.52 mL, 0.520 mmol) was

M183-2

91

added and the mixture was stirred at 0 °C for 45 minutes, after which the mixture was neutralized with 1M hydrochloric acid and evaporated and coevaporated with toluene. The residue was dissolved in DMF (5 mL) and (1*R*,2*S*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride (60 mg, 0.313 mmol) and diisopropylethylamine (DIEA) (138 μ L, 0.792 mmol) were added and the solution was cooled to 0 °C. HATU (120 mg, 0.316 mmol) was added and the mixture was stirred for 0.5 h at 0 °C and for an additional 2 h at room temperature. The mixture was then evaporated and extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification by flash column chromatography (toluene/ EtOAc 1:1) provided compound 34 (86 mg, 89 %) as a colorless oil.

Example 35




(1*R*,2*R*,4*R*)-2-(((1*R*,2*S*)-1-Ethoxycarbonyl-2-vinyl-cyclopropyl)carbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid *tert*-butyl ester (35)

Compound 34 (73 mg, 0.199 mmol) was dissolved in dry THF (4 mL) and 2-phenyl-7-methoxy-4-quinolinol (86 mg, 0.342 mmol) and triphenylphosphine (141 mg, 0.538 mmol) were added. The mixture was cooled to 0°C and DIAD (0.567 mmol) dissolved in 1 mL THF was added dropwise. The mixture was stirred for 48 h at room temperature. The solvent was evaporated and the crude product was purified by flash column chromatography gradient elution (toluene/ EtOAc 9:1, 6:1, 4:1) to give compound 35 (81 mg, 68 %).

Example 36

M183-2

92




Boc-L-*tert*-leucine-OH (36).

Triethylamine (890 μ L, 6.40 mmol) was added dropwise to a stirred solution of L-*tert*-leucine (300 mg, 2.29 mmol) and di-*tert*-butyl dicarbonate (599 mg, 2.74 mmol) in dioxane/ water 1:1 (8 mL) and the solution was stirred overnight. The mixture was extracted with petroleum ether (2 \times) and the aqueous phase was cooled to 0 $^{\circ}$ C and carefully acidified to pH 3 by slow addition of 4M NaHSO₄·H₂O. The acidified water phase was extracted with EtOAc (3 \times) and the combined organic phases were washed with brine (2 \times) and was then dried, filtered and concentrated to give compound 36 (522 mg, 99 %) as a colorless powder. No further purification was needed.

¹H-NMR (300 MHz, CD₃OD) δ 0.99 (s, 9H), 1.44 (s, 9H), 3.96 (s, 1H); ¹³C-NMR (75.5 MHz, CD₃OD) δ 27.1, 28.7, 34.9, 68.0, 80.5, 157.8, 174.7.

Example 37



((S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamic acid *tert*-butyl ester (37).


20

Boc-Chg-OH (387 mg, 1.50 mmol) was coupled to methylamine hydrochloride (111 mg, 1.65 mmol) using the same HATU coupling conditions as in the synthesis of compound 34. The crude product was extracted with EtOAc, washed with brine and concentrated. Purification by flash column chromatography (EtOAc) provided compound 37 (307 mg, 76 %) as a colorless solid.

25

¹H-NMR (300 MHz, CDCl₃) δ 0.91-1.13 (m, 2H), 1.14-1.31 (m, 3H), 1.44 (s, 9H), 1.61-1.80 (m, 6H), 2.80 (d, *J* = 4.7 Hz, 3H), 3.91 (dd, *J* = 7.1, 9.1 Hz, 1H), 5.23 (b, 1H), 6.52 (bs, 1H); ¹³C-NMR (75.5 MHz, CDCl₃) δ 25.9, 26.0, 26.1, 28.3, 28.5, 29.6, 40.5, 59.5, 79.7, 155.9, 172.4.

Example 38




10 **{{(S)-1-(((S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl)-2,2-dimethyl-propyl)-**
 carbamic acid *tert*-butyl ester (38)

To a solution of compound 37 (98 mg, 0.362 mmol) in methylene chloride (3 mL) were added triethylsilane (115 mL, 0.742 mmol) and TFA (3 mL). The mixture was stirred for 2 h at room temperature and was then evaporated and coevaporated with toluene. The deprotected amine was dissolved in DMF (5 mL) and coupled to compound 36 (84 mg, 0.363 mmol) using the same HATU coupling conditions as in the synthesis of 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification by flash column chromatography (toluene/ EtOAc 1:1) provided compound 38 (128 mg, 92 %) as a colorless solid.

M183-2

94

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 0.99 (s, 9H), 1.02-1.30 (m, 5H), 1.44 (s, 9H), 1.58-1.77 (m, 4H), 1.78-1.89 (m, 2H), 2.79 (d, $J = 4.7$ Hz, 3H), 4.11 (d, $J = 9.3$ Hz, 1H), 4.33 (app. t, $J = 8.5$ Hz, 1H), 5.65 (b, 1H), 7.25 (b, 1H), 7.39 (b, 1H); $^{13}\text{C-NMR}$ (75.5 MHz, CDCl_3) δ 25.9, 25.9, 26.0, 26.2, 26.8, 28.4, 29.0, 29.7, 34.5, 39.7, 58.4, 62.4, 79.4, 156.0, 171.4, 171.8.

Example 39

(1*R*,2*S*)-1-[[[(1*R*,2*R*,4*S*)-2-[(*S*)-1-[[(*S*)-Cyclohexyl-methylcarbamoyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (39)

To a solution of compound 35 (30 mg, 0.050 mmol) in methylene chloride (1.5 mL) were added triethylsilane (21 μL , 0.132 mmol) and TFA (1.5 mL). The mixture was stirred for 2 h at room temperature and was then evaporated and coevaporated with toluene. The amine 38 (1.3 eq) was deprotected in the same manner as compound 35 and was then coupled to deprotected compound 35 using the same HATU coupling conditions as in the synthesis of 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification using HPLC (MeOH/ water 9:1 + 0.2% triethylamine) provided compound 39 (30 mg, 74%) as a colorless solid.


$^1\text{H-NMR}$ (300 MHz, CD_3OD) δ 0.81-1.14 (m, 4H), 0.99 (s, overlapped, 9H), 1.21 (t, $J = 7.1$ Hz, 3H), 1.35-1.51 (m, 4H), 1.52-1.65 (m, 3H), 1.66-1.72 (m, 2H), 2.03-2.20 (m,

M183-2

95

2H), 2.24-2.39 (m, 1H), 2.46-2.56 (m, 1H), 2.66 (s, 3H), 2.72-2.85 (m, 1H), 3.39-3.48 (m, 2H), 3.90 (s, 3H), 4.03-4.15 (m, 3H), 4.44 (s, 1H), 5.09 (dd, $J = 1.9, 10.3$ Hz, 1H), 5.19-5.27 (m, 1H), 5.25 (dd, overlapped, 1H), 5.79 (ddd, $J = 8.8, 10.3, 17.2$ Hz, 1H), 6.99 (s, 1H), 7.07 (dd, $J = 2.5, 9.1$, Hz, 1H), 7.29 (d, $J = 2.5$ Hz, 1H), 7.43-7.52 (m, 3H), 7.86-7.98 (m, 2H), 8.05 (d, $J = 9.3$ Hz, 1H); ^{13}C -NMR (75.5 MHz, CD_3OD) δ 14.7, 23.4, 26.0, 26.9, 27.1, 27.3, 30.1, 30.7, 35.0, 35.4, 38.3, 38.8, 40.9, 41.0, 47.9, 55.9, 59.6, 62.0, 62.4, 79.8, 99.9, 107.3, 116.4, 118.0, 119.1, 124.4, 128.9, 129.8, 130.5, 135.3, 141.3, 152.1, 161.1, 162.4, 163.0, 171.6, 172.5, 173.7, 175.2, 176.8. Maldi-TOF-spectrum: $(\text{M}+\text{H})^+$ calcd: 810.4, found: 810.5; $(\text{M}+\text{Na})^+$ calcd: 832.4, found: 832.4; $(\text{M}+\text{K})^+$ calcd: 848.5, found: 848.4.

Example 40



(1*R*,2*S*)-1-[[[(1*R*,2*R*,4*S*)-2-[(*S*)-1-[[(*S*)-Cyclohexyl-methylcarbamoyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (40)

To a solution of compound 39 (20 mg, 0.025 mmol) in THF/MeOH/water 2:1:1 (2 mL) at 0 °C was added 1M LiOH (175 μL , 0.175 mmol) and the solution was allowed to attain room temperature and was stirred for 48 h. The solution was acidified to pH 3 with 1M HCl and was then evaporated and coevaporated with toluene. The crude product was purified by HPLC (MeOH/ water 6:4 + 0.5% TFA followed by MeOH/ water 4:1 + 0.2% TFA) to give compound 40 (13 mg, 67 %) as a colorless solid.

^1H -NMR (300 MHz, CD_3OD) δ 0.82-0.98 (m, 1H), 1.01 (s, 9H), 1.05-1.26 (m, 3H), 1.34-1.43 (m, 1H), 1.49-1.77 (m, 8H), 2.10-2.21 (m, 1H), 2.28-2.42 (m, 2H), 2.50-

M183-2

96

2.61 (m, 1H), 2.64 (s, 3H), 2.68-2.81 (m, 1H), 3.36-3.45 (m, 2H), 4.04-4.11 (m, 1H),
 4.06 (s, overlapped, 3H), 4.27 (d, $J = 8.8$ Hz, 1H), 5.10 (dd, $J = 1.8, 10.3$ Hz, 1H),
 5.28 (dd, $J = 1.8, 17.2$ Hz, 1H), 5.59-5.68 (m, 1H), 5.82 (ddd, $J = 9.1, 10.3, 17.2$ Hz,
 1H), 7.44 (dd, $J = 2.5, 11.8$ Hz, 1H), 7.50 (s, 1H), 7.53 (d, $J = 2.5$ Hz, 1H), 7.69-7.78
 5 (m, 3H), 8.02-8.07 (m, 2H), 8.39 (d, $J = 9.3$ Hz, 1H); ^{13}C -NMR (75.5 MHz, CD_3OD) δ
 23.5, 26.0, 26.9, 27.2, 27.3, 30.0, 30.7, 34.7, 35.3, 37.0, 38.7, 41.0, 41.3, 47.4, 56.9,
 59.4, 62.7, 83.9, 100.4, 102.2, 116.2, 117.7, 121.7, 126.7, 129.8, 130.8, 133.4,
 133.9, 135.6, 143.5, 158.0, 166.6, 168.6, 172.5, 173.4, 173.6, 175.4, 176.4. Maldi-
 TOF-spectrum: $(\text{M}+\text{H})^+$ calcd: 782.4, found: 782.2; $(\text{M}+\text{Na})^+$ calcd: 804.4, found:
 10 804.2; $(\text{M}+\text{K})^+$ calcd: 820.5, found: 820.2.

Example 41




15

3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid methyl ester (41)

Compound 32 (1.014 g, 6.50 mmol) was dissolved in acetone (35 mL) before methyl
 iodide (13.68 g, 96.4 mmol) and silver(I)oxide (1.61 g, 6.95 mmol) were added. After
 20 stirring for 3h the mixture was filtered through celite and the filtrate was evaporated
 before purification by flash column chromatography (toluene/ethyl acetate 4:1) was
 performed yielding the methyl ester 41 (702 mg, 64 %) as white crystals.

^1H -NMR (300 MHz, CDCl_3): δ 1.96 (d, $J = 10.7$ Hz, 1H), 2.21-2.25 (m, 3H), 2.91-2.95
 25 (m, 1H), 3.16 (s, 1H), 3.75 (s, 3H), 4.98 (app. s, 1H).

Example 42




M183-2

97

(1*R*,2*R*,4*S*)-2-((*S*)-1-*tert*-Butoxycarbonyl-butylcarbamoyl)-4-hydroxy-cyclopentanecarboxylic acid methyl ester (42)

- Compound 41 (263 mg, 1.55 mmol) and H-Nva-OfBu (420 mg, 2.42 mmol) were dissolved in dry THF (20 mL). DIEA (530 μ L, 3.04 mmol) and 2-hydroxypyridine (260 mg, 2.73 mmol) were added and the mixture was refluxed for five days. The solvent was evaporated and the crude product was purified by flash column chromatography (toluene/ EtOAc 1:2) to give 42 (510 mg, 96%).

10 Example 43




(1*R*,2*R*,4*R*)-2-((*S*)-1-*tert*-Butoxycarbonyl-butylcarbamoyl)-4-(7-methoxy-2-phenylquinolin-4-yloxy)-cyclopentanecarboxylic acid methyl ester (43)

- Compound 42 (249 mg, 0.725 mmol), 2-phenyl-7-methoxy-4-quinolinol (310 mg, 1.23 mmol) and PPh₃ (580 mg, 2.21 mmol) were dissolved in dry THF and the temperature was lowered to 0°C. DIAD (435 μ L, 2.21 mmol) dissolved in 2 mL dry THF, was added to the mixture during five minutes. After two hours the temperature was raised to room temperature and the solution was stirred overnight. Evaporation and purification by flash column chromatography (toluene/ EtOAc gradient 6:1 to 4:1) gave 43 (324 mg, 78%).

Example 44

M183-2

98



(S)-2-[[[(1R,2R,4S)-2-[(S)-1-[[[(S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid *tert*-butyl ester (44)

5

Compound 43 (38 mg, 0.066 mmol) was dissolved in dioxane/ water 1:1 (4 mL) and the solution was cooled to 0 °C and 1 M LiOH (132 μ l, 0.132 mmol) was added. The temperature was raised to room temperature and the solution was stirred for 2 hours after which it was neutralized by addition of 1M HCl and evaporated and

10 coevaporated with toluene. The residue and deprotected amine 38 (1.1 eq) was dissolved in DMF and coupled using the standard HATU coupling conditions as in the synthesis of compound 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification with HPLC (MeOH/ water 9:1 + 0.2% TEA) provided compound 44 (44 mg, 81 %) as a colorless solid.

15

$^1\text{H-NMR}$ (CDCl_3 , 300 MHz) rotamers (5:1) δ 0.79 (t, J = 7.3 Hz, 3H), 0.85-1.19 (m, 3H), 0.93 (s, overlapped, 9H), 1.20-1.35 (m, 2H), 1.39 (s, 1.5 H), 1.43 (s, 7.5 H), 1.54-1.79 (m, 6H), 2.06-2.28 (m, 3H), 2.39-2.51 (m, 2H), 2.66-2.78 (m, 1H), 2.74 (d, overlapped, J = 4.7 Hz, 3H), 3.42-3.68 (m, 2H), 3.84 (s, 2.5 H), 3.88 (s, 0.5 H), 4.19


20 (t, J = 8.9 Hz, 1H), 4.39-4.59 (m, 1H), 4.68 (d, J = 9.6 Hz, 1H), 5.04-5.14 (m, 1H), 6.77 (s, 1H), 6.88-7.06 (m, 2H), 7.26-7.47 (m, 6H), 7.53 (b, 1H), 7.85-7.97 (m, 3H); $^{13}\text{C-NMR}$ (75.5 MHz, CDCl_3) δ 13.7, 18.7, 25.6, 25.7, 26.0, 26.7, 28.0, 28.9, 29.7, 34.5, 34.7, 37.7, 38.0, 39.2, 46.6, 47.7, 52.7, 55.3, 58.5, 60.3, 77.9, 81.7, 98.0, 107.4, 115.0, 117.9, 122.8, 127.4, 128.6, 129.0, 140.2, 151.2, 158.9, 160.6, 161.1,

M183-2

99

170.9, 171.6, 171.8, 172.7, 173.3. Maldi-TOF-spectrum: (M+H)⁺ calcd: 828.5, found: 828.6; (M+Na)⁺ calcd: 850.5, found: 850.6; (M+K)⁺ calcd: 866.6, found: 866.6.

Example 45



(S)-2-[[[(1R,2R,4S)-2-[(S)-1-[[[(S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid (45)

10

Compound 44 (21 mg, 0.025 mmol) was dissolved in CH₂Cl₂ (1.5 mL) and triethylsilane (10 μL, 0.063 mmol) and TFA (1.5 mL) were added. The solution was stirred for 2 hours at room temperature after which the solvents were evaporated and coevaporated with toluene to provide compound 45 (20 mg, 100 %) as a colorless solid.

15

¹H-NMR (300 MHz, CD₃OD) δ 0.93 (t, overlapped, 3H), 0.98 (s, 9H), 0.99-1.25 (m, 4H), 1.30-1.49 (m, 3H), 1.50-1.90 (m, 8H), 2.25-2.39 (m, 2H), 2.54-2.62 (m, 1H), 2.64 (s, 3H), 2.72-2.87 (m, 1H), 3.34-3.57 (m, 3H), 4.02-4.13 (m, 1H), 4.06 (s, overlapped, 3H), 4.27-4.36 (m, 1H), 4.37-4.47 (m, 1H), 5.57-5.66 (m, 1H), 7.45 (dd, J = 2.3, 9.2 Hz, 1H), 7.48 (s, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.69-7.79 (m, 3H), 8.01-8.07 (m, 2H), 8.42 (d, J = 9.3 Hz, 1H); ¹³C-NMR (75.5 MHz, CD₃OD) δ 14.0, 20.2, 26.0, 26.9, 27.2, 30.1, 30.7, 34.6, 35.3, 37.2, 39.1, 41.2, 47.7, 53.7, 56.9, 59.4, 59.5, 62.5, 83.7, 100.4, 101.3, 102.2, 116.2, 121.7, 126.7, 129.8, 130.8, 133.3, 133.9, 143.5, 157.9, 166.6, 168.5, 172.5, 173.6, 175.3, 175.4, 175.5.

25

Maldi-TOF-spectrum: (M+H)⁺ calcd: 772.4, found: 772.6; (M+Na)⁺ calcd: 794.4, found: 794.6; (M+K)⁺ calcd: 810.5, found: 810.6.

5 Example 46

Hept-6-enal (46)

To a solution of hept-6-en-1-ol (1 mL, 7.44 mmol) and N-methylmorpholine N-oxide (1.308 g, 11.17 mmol) in DCM (17 mL) was added ground molecular sieves (3.5 g, 4
10 Å). The mixture was stirred for 10 min at room temperature under nitrogen atmosphere before tetrapropylammonium perruthenate (TPAP) (131 mg, 0.37 mmol) was added. After stirring for additional 2.5 h the solution was filtered through celite. The solvent was then carefully evaporated and the remaining liquid was purified by flash column chromatography (DCM) to give the volatile aldehyde 46 (620 mg, 74%)
15 as an oil.

Example 47

N-Hept-6-en-(*E*)-ylidene-hydrazinecarboxylic acid *tert*-butyl ester (47)

20 To a solution of 46 (68 mg, 0.610 mmol) and *tert*-butyl carbazate (81 mg, 0.613 mmol) in MeOH (5 mL) was added ground molecular sieves (115 mg, 3Å). The mixture was stirred for 3 h after which it was filtered through celite and evaporated. The residue was dissolved in dry THF (3 mL) and AcOH (3mL). NaBH₃CN (95 mg, 1.51 mmol) was added and the solution was stirred over night. The reaction mixture
25 was diluted with saturated NaHCO₃ solution (6 mL) and EtOAc (6 mL). The organic phase was washed with brine, saturated NaHCO₃, brine, dried over MgSO₄ and evaporated. The cyanoborane adduct was hydrolyzed by treatment with MeOH (3 mL) and 2 M NaOH (1.9 mL). The mixture was stirred for 2 h and the MeOH was evaporated. H₂O (5 mL) and DCM (5 mL) were added and the water phase was
30 extracted three times with DCM. The combined organic phases were dried and evaporated. Purification by flash column chromatography (toluene/ethyl acetate 9:1

M183-2

101

with 1 % triethylamine and toluene/ethyl acetate 6:1 with 1 % triethylamine) provided 47 (85 mg, 61 %) as an oil.

Example 48

- 5 (1*R*,2*S*)-1-[[[(1*R*,2*R*,4*R*)-2-(*N*-*tert*-Butoxycarbonyl-*N*-hept-6-enyl-hydrazinocarbonyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (48)

- 10 Scaffold molecule 35 (135 mg, 0.225 mmol) and triethylsilane (71 μ L, 0.447 mmol) was dissolved in DCM (2 mL) after which trifluoroacetic acid (TFA) (2 mL) was added. The mixture was stirred for 2 h and thereafter co-evaporated with toluene in order to remove the TFA. The residue was dissolved in DMF (3 mL) and 47 (60 mg, 0.263 mmol) and DIEA (118 μ L, 0.677 mmol) were added. The temperature was lowered to 0° C and the coupling reagent *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU) (94 mg, 0.247 mmol) was added.
- 15 The cold solution was allowed to stir for half an hour and then for additional 16 h in room temperature. The solvent was removed by heating the reaction flask in a water bath under diminished pressure. The residue was thereafter dissolved in ethyl acetate and the organic phase was washed three times with brine, dried, filtered and
- 20 evaporated. Purification by HPLC (MeOH/H₂O 90:10 with 0.2 % triethylamine) gave 48 (140 mg, 82 %) as an oil.

¹H-NMR (300 MHz, CDCl₃, 40° C): δ 1.22 (t, *J* = 7.1 Hz, 3H), 1.28-1.42 (m, 6H), 1.46 (s, 9H), 1.52-1.62 (m, 2H), 1.82-1.91 (m, 1H), 1.96-2.16 (m, 3H), 2.18-2.34 (m, 2H), 2.42-2.56 (m, 1H), 2.58-2.72 (m, 1H), 3.42 (app. bs, 3H), 3.66-3.84 (m, 1H), 3.92 (s, 3H), 4.15 (q, *J* = 7.1 Hz, 2H), 4.88-5.02 (m, 2H), 5.07-5.18 (m, 2H), 5.20-5.32 (m, 1H), 5.63-5.84 (m, 2H), 6.62 (bs, 1H), 6.94 (s, 1H), 7.09 (dd, *J* = 2.6, 9.2 Hz, 1H), 7.36-7.51 (m, 4H), 7.99-8.10 (m, 3H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 14.3, 23.0, 26.4, 26.6, 28.3, 28.6, 33.2, 33.5, 35.6, 37.6, 40.6, 44.7, 47.1, 48.6, 55.5, 61.5, 81.9, 98.4, 107.9, 114.5, 115.6, 118.1, 123.2, 127.6, 128.3, 128.7, 129.1, 133.5, 138.7, 140.7, 151.5, 154.5, 159.2, 160.9, 161.5, 170.5, 174.2, 176.3.

Example 49

(Z)-(1*R*,4*R*,6*S*,16*R*,18*R*)-14-*tert*-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.0^{4,6}]nonadec-7-ene-4-carboxylic acid ethyl ester (49)

A solution of 48 (158 mg, 0.209 mmol) in dry DCM (25 mL) was bubbled with argon for 5 min. To the stirred solution under argon atmosphere was then added a solution of Hoveyda-Grubbs catalyst 2nd generation (11 mg, 0.018 mmol) in dry DCM (5 mL). The mixture was stirred at reflux under argon atmosphere for 16 h. The solvent was evaporated and purification by HPLC (MeOH/H₂O 90:10 with 0.2 % triethylamine) yielded 49 (107 mg, 70 %) as a colorless solid.

¹H-NMR (300 MHz, CD₃OD): δ 1.03-1.22 (m, 1H), 1.28 (t, *J* = 7.1 Hz, 3H), 1.32-1.44 (m, 4H), 1.49 (s, 9H), 1.55-1.73 (m, 2H), 1.81-1.91 (m, 1H), 2.04-2.28 (m, 3H), 2.30-2.52 (m, 3H), 2.53-2.70 (m, 1H), 2.86-3.00 (m, 1H), 3.34-3.44 (m, 1H), 3.46-3.62 (m, 1H), 3.95 (s, 3H), 4.19 (q, *J* = 7.1 Hz, 2H), 4.32-4.48 (m, 1H), 5.20-5.33 (m, 1H), 5.34 (bs, 1H), 5.58-5.70 (m, 1H), 7.10 (s, 1H), 7.14 (dd, *J* = 2.5, 9.1 Hz, 1H), 7.39 (d, *J* = 2.5 Hz, 1H), 7.45-7.55 (m, 3H), 8.00 (d, *J* = 8.0 Hz, 2H), 8.17 (d, *J* = 9.3 Hz, 1H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 14.6, 23.4, 27.5, 27.7, 28.0, 28.5, 30.7, 36.1, 38.1, 42.5, 45.6, 56.0, 62.7, 79.9, 82.8, 100.2, 107.4, 116.6, 119.1, 124.5, 126.5, 128.9, 129.8, 130.5, 135.8, 141.5, 152.2, 156.4, 161.3, 162.5, 163.1, 171.9, 175.8, 179.0. MALDI-TOF-spectrum: (M+H)⁺ calcd: 727.4, found: 727.5.

Example 50

(Z)-(1*R*,4*R*,6*S*,16*R*,18*R*)-14-*tert*-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.0^{4,6}]nonadec-7-ene-4-carboxylic acid (50)

To a solution of 49 (27 mg, 0.037 mmol) in THF/MeOH/H₂O 2:1:1 (5 mL) was added 1 M LiOH (300 μL, 0.300 mmol). The solution was stirred for 24 h at room

temperature and finally for one hour at reflux. After acidification to pH 3-4 with 1 M HCl and evaporation the residue was purified by HPLC (MeOH/H₂O 80:20 and MeOH/H₂O 90:10) providing 50 (12 mg, 46 %) as a colorless solid.

5 ¹H-NMR (300 MHz, CD₃OD): δ 1.06-1.24 (m, 1H), 1.26-1.42 (m, 3H), 1.48 (s, 9H), 1.52-1.73 (m, 3H), 1.80-1.90 (m, 1H), 2.02-2.15 (m, 1H), 2.15-2.40 (m, 4H), 2.43-2.54 (m, 1H), 2.54-2.68 (m, 1H), 2.88-3.00 (m, 1H), 3.35-3.48 (m, 1H), 3.49-3.66 (m, 1H), 3.96 (s, 3H), 4.32-4.48 (m, 1H), 5.25-5.42 (m, 2H), 5.56-5.68 (m, 1H), 7.14 (s, 1H), 7.17 (dd, *J* = 2.5, 9.1 Hz, 1H), 7.40 (d, *J* = 2.2 Hz, 1H), 7.46-7.58 (m, 3H), 8.00
10 (d, *J* = 8.0 Hz, 2H), 8.19 (d, *J* = 9.1 Hz, 1H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 23.6, 26.8, 27.8, 28.3, 28.5, 30.5, 35.8, 38.1, 43.0, 45.5, 56.0, 80.2, 82.7, 100.4, 106.9, 116.6, 119.2, 124.7, 127.4, 129.0, 129.8, 130.7, 134.8, 140.9, 151.6, 156.5, 161.1, 163.0, 163.4, 173.8, 175.7, 179.3.

15 Example 51

((*S*)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propyl)-carbamic acid *tert*-butyl ester (51).

To a cold solution of 36 (133 mg, 0.575 mmol), cyclopentylamine (64 μL, 0.648 mmol) and DIEA (301 μL, 1.73 mmol) in DMF (3 mL) was added the coupling
20 reagent HATU (240 mg, 0.631 mmol). The mixture was stirred for half an hour and for additional two hours at room temperature. The solvent was removed by heating the reaction flask in a water bath under diminished pressure and the residue was dissolved in ethyl acetate, after which the organic phase was washed three times with brine, dried, filtered and evaporated. Purification by flash column
25 chromatography (toluene/ethyl acetate 4:1) provided 51 (140 mg, 82 %) as colorless crystals.

30 ¹H-NMR (300 MHz, CDCl₃): δ 0.95 (s, 9H), 1.28-1.48 (m, overlapped, 2H), 1.40 (s, 9H), 1.49-1.71 (m, 4H), 1.86-2.01 (m, 2H), 3.76 (b, 1H), 4.09-4.23 (m, 1H), 5.32 (b, 1H), 5.91 (b, 1H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 23.6, 23.7, 26.5, 28.3, 32.6, 33.1, 34.5, 51.0, 62.2, 79.4, 155.9, 170.3.

Example 52

(1*R*,2*S*)-1-[[[(1*R*,2*R*,4*S*)-2-[(*S*)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (52)

Compound 51 (298 mg, 0.048 mmol) and 35 (16 mg, 0.054 mmol) was deprotected and coupled according to the method for the preparation of 39. Purification by HPLC (MeOH/H₂O 90:10 with 0.2 % triethylamine) gave 52 (22 mg, 63 %) as a colorless solid.

¹H-NMR (CDCl₃, 300 MHz): δ 0.97 (s, 9H), 1.21 (t, *J* = 7.1 Hz, 3H), 1.26-1.37 (m, 1H), 1.38-1.46 (m, 2H), 1.48-1.58 (m, 4H), 1.78-1.85 (m, 1H), 1.86-2.02 (m, 3H), 2.03-2.19 (m, 1H), 2.28-2.40 (m, 2H), 2.41-2.54 (m, 1H), 2.64-2.78 (m, 1H), 3.10-3.24 (m, 1H), 3.30-3.44 (m, 1H), 3.95 (s, 3H), 4.04-4.21 (m, 3H), 5.12 (dd, *J* = 1.7, 10.3 Hz, 1H), 5.14-5.22 (m, 1H), 5.28 (dd, *J* = 1.7, 17.0 Hz, 1H), 5.59 (b, 1H), 5.75 (ddd, *J* = 8.8, 10.3, 17.0 Hz, 1H), 6.66-6.82 (m, 2H), 6.99 (s, 1H), 7.09 (dd, *J* = 2.5, 9.1 Hz, 1H), 7.41-7.55 (m, 4H), 7.99-8.09 (m, 3H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 14.3, 22.9, 23.6, 23.6, 26.7, 32.7, 33.2, 33.7, 34.8, 35.9, 36.6, 40.2, 46.4, 47.5, 51.3, 55.5, 61.1, 61.4, 78.0, 98.4, 107.1, 115.2, 117.9, 118.2, 123.1, 127.6, 128.8, 129.3, 133.5, 159.1, 161.4, 169.4, 169.9, 173.1, 174.0. MALDI-TOF-spectrum: (M+H)⁺ calcd: 725.4, found: 725.6; (M+Na)⁺ calcd: 747.4, found: 747.6; (M+K)⁺ calcd: 763.3, found: 763.5.

Example 53

(1*R*,2*S*)-1-[[[(1*R*,2*R*,4*S*)-2-[(*S*)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (53).

To a solution of 52 (14 mg, 0.019 mmol) in dioxane/H₂O 1:1 (4 mL) was added 1 M LiOH (115 μL, 0.115 mmol). The solution was stirred for 24 h at room temperature.

Thereafter an additional portion of LiOH (75 μ L, 0.075 mmol) was added and the solution was stirred for another 24 h. After acidification to approximately pH 3 with 1 M HCl and co-evaporation with toluene the residue was purified by HPLC (MeOH/H₂O 70:30 with 0.2 % TFA) yielding 53 (8 mg, 60 %) as a colorless solid.

5

¹H-NMR (300 MHz, CD₃OD): δ 0.98 (s, 9H), 1.28-1.48 (m, 3H), 1.49-1.76 (m, 5H), 1.78-1.94 (m, 2H), 2.10-2.24 (m, 1H), 2.26-2.45 (m, 2H), 2.50-2.62 (m, 1H), 2.66-2.79 (m, 1H), 3.35-3.48 (m, 2H), 3.94-4.03 (m, 1H), 4.06 (s, 3H), 4.16-4.24 (m, 1H), 5.10 (dd, J = 1.8, 10.3 Hz, 1H), 5.29 (dd, J = 1.8, 17.2 Hz, 1H), 5.62 (b, 1H), 5.82 (ddd, J = 9.1, 10.3, 17.2 Hz, 1H), 7.43 (dd, J = 2.5, 9.3 Hz, 1H), 7.50 (s, 1H), 7.50-7.69 (dd, overlapped, 1H), 7.67-7.80 (m, 3H), 8.01-8.11 (m, 2H), 8.39 (d, J = 9.3 Hz, 1H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 24.7, 24.7, 27.3, 33.1, 33.6, 34.7, 35.4, 36.9, 38.7, 41.0, 47.4, 52.3, 56.9, 62.3, 83.9, 100.4, 102.3, 116.2, 117.7, 121.6, 126.7, 129.8, 130.8, 133.4, 133.8, 135.6, 143.5, 158.0, 166.5, 168.6, 171.9, 173.4, 175.2, 176.4. MALDI-TOF-spectrum: (M+H)⁺ calcd: 697.4, found: 697.3; (M+Na)⁺ calcd: 718.7, found: 719.3; (M+K)⁺ calcd: 735.3, found: 735.3.

15

Example 54

(S)-*tert*-Butoxycarbonylamino-cyclohexyl-acetic acid methyl ester (54)

20

To a solution of Boc-Chg-OH (53 mg, 0.206 mmol) in acetone (3 mL) were added methyl iodide (195 μ L, 3.1 mmol) and silver (I) oxide (53 mg, 0.229 mmol). The mixture was allowed to stir over night in a reaction flask that was covered with aluminium foil. Thereafter the solution was filtered through celite and evaporated. Purification by flash column chromatography (toluene/ethyl acetate 15:1) provided methyl ester 54 (56 mg, 100 %) as a colorless oil.

25

¹H-NMR (300 MHz, CDCl₃): δ 1.00-1.34 (m, 5H), 1.44 (s, 9H), 1.54-1.82 (m, 6H), 3.73 (s, 3H), 4.20 (dd, J = 2.8, 5.0 Hz, 1H), 5.05 (bs, 1H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 26.0, 28.2, 28.3, 29.5, 41.1, 52.0, 58.3, 79.7, 155.6, 172.9.

30

Example 55

(S)-((S)-2-Benzoyloxycarbonylamino-3-methyl-butylamino)-cyclohexyl-acetic acid methyl ester (55)

Compound 54 (93 mg, 0.343 mmol) was deprotected and coupled to Z-Val-OH (95 mg, 0.378 mmol) according to the method for the preparation of 39. Flash column chromatography (toluene/ethyl acetate 4:1) gave 55 (131 mg, 94 %) as a colorless solid.

¹H-NMR (300 MHz, CDCl₃): δ 0.92-1.30 (m, 11H), 1.54-1.88 (m, 6H), 2.02-2.18 (m, 1H), 3.72 (s, 3H), 4.05-4.18 (m, 1H), 4.52 (dd, *J* = 3.0, 5.5 Hz, 1H), 5.12 (s, 2H), 5.49 (bs, 1H), 6.52 (bs, 1H), 7.34 (s, 5H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 17.8, 19.0, 25.8, 28.2, 29.3, 31.2, 40.5, 51.9, 56.8, 60.0, 66.8, 127.7, 127.9, 128.1, 128.3, 136.2, 156.3, 171.3, 172.2.

15 Example 56

(S)-2-[[[(1*R*,2*R*,4*S*)-2-[(S)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid *tert*-butyl ester (56).

20 To a solution of 55 (40 mg, 0.099 mmol) in ethanol (95%) (7.5 mL) was added palladium on active carbon (10 %, 40 mg) and the mixture was hydrogenated under pressure at room temperature for 2 h. The mixture was filtered through celite and evaporated. Compound 43 (38 mg, 0.083 mmol) was dissolved in dioxane/H₂O 1:1 (3 mL) and the mixture was cooled to 0° C before 1 M LiOH (140 μL, 0.140 mmol) was added to the stirred solution. After 1h the mixture was neutralized with 1 M hydrochloric acid and the solvent was evaporated and co-evaporated with toluene. The residue was coupled to deprotected 55 using the same HATU coupling conditions as in the synthesis of compound 48. Purification by HPLC (MeOH/H₂O 90:10 with 0.2 % triethylamine) gave 56 (56 mg, 88 %) as a colorless solid.

M183-2

107

¹H-NMR (300 MHz, CDCl₃): δ 0.82-0.96 (m, 9H), 0.82-1.22 (m, overlapped, 6H), 1.23-1.40 (m, 2H), 1.44 (s, 9H), 1.50-1.69 (m, 4H), 1.71-1.87 (m, 2H), 1.95-2.06 (m, 1H), 2.07-2.22 (m, 1H), 2.28-2.54 (m, 3H), 2.60-2.75 (m, 1H), 3.08-3.28 (m, 1H), 3.30-3.49 (m, 1H), 3.70 (s, 3H), 3.94 (s, 3H), 4.28-4.38 (m, 1H), 4.41-4.57 (m, 2H), 5.17 (b, 1H), 6.54-6.70 (m, 2H), 6.74 (b, 1H), 6.95 (s, 1H), 7.09 (dd, *J* = 2.5, 9.1 Hz, 1H), 7.39-7.55 (m, 5H), 7.98-8.10 (m, 3H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 13.7, 18.1, 18.6, 19.2, 25.9, 28.0, 28.2, 29.6, 30.7, 34.6, 36.5, 37.6, 40.8, 47.4, 47.5, 52.1, 52.8, 55.5, 56.8, 58.9, 77.8, 82.0, 98.3, 107.5, 115.3, 118.1, 123.1, 127.5, 128.7, 129.1, 140.5, 151.4, 159.2, 160.7, 161.3, 171.0, 171.5, 172.3, 172.8, 173.0. MALDI-TOF-spectrum: (M+H)⁺ calcd: 815.5, found: 815.7; (M+Na)⁺ calcd: 837.4, found: 837.6; (M+K)⁺ calcd: 853.4, found: 853.6.

Example 57

(S)-2-[[[(1*R*,2*R*,4*S*)-2-[(S)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid (57)

Tert.butyl ester 56 (28 mg, 0.034 mmol) and triethylsilane (14 μL, 0.088 mmol) was dissolved in DCM (2 mL) after which trifluoroacetic acid (2 mL) was added and the mixture was stirred for 2 h. Co-evaporation with toluene gave 57 (26 mg, 100 %) as a colorless solid.


¹H-NMR (300 MHz, CD₃OD): δ 0.86-1.00 (m, 9H), 1.01-1.24 (m, 4H), 1.36-1.46 (m, 2H), 1.48-1.75 (m, 8H), 1.70-1.89 (m, overlapped, 1H), 1.96-2.12 (m, 1H), 2.22-2.40 (m, overlapped, 2H), 2.49-2.64 (m, 1H), 2.72-2.91 (m, 1H), 3.26-3.40 (m, overlapped, 1H), 3.50-3.68 (m, overlapped, 1H), 3.62 (s, 3H), 4.05 (s, 3H), 4.09-4.17 (m, 1H), 4.17-4.25 (m, 1H), 4.35-4.45 (m, 1H), 5.62 (b, 1H), 7.44 (dd, *J* = 2.2, 9.3 Hz, 1H), 7.49 (s, 1H), 7.53 (d, *J* = 2.2 Hz, 1H), 7.65-7.78 (m, 3H), 7.98-8.06 (m, 2H), 8.41 (dd, *J* = 2.8, 9.3 Hz, 1H); ¹³C-NMR (CD₃OD, 75.5 MHz): δ 13.9, 18.8, 19.7, 20.2, 27.0, 29.7, 30.5, 31.8, 34.6, 37.7, 38.9, 41.1, 47.8, 52.3, 53.6, 56.9, 58.8, 58.9, 60.3, 83.8, 100.4, 102.2, 116.2, 121.6, 126.7, 129.8, 130.8, 133.3, 133.8, 143.5, 157.9,

M183-2

108

166.5, 168.5, 173.3, 173.9, 175.5, 175.5, 175.6. MALDI-TOF-spectrum: (M+H)⁺ calcd: 759.4, found: 759.7; (M+Na)⁺ calcd: 781.4, found: 781.7; (M+K)⁺ calcd: 797.4, found: 797.7.

5 Example 58



10 (S)-2-[[[(1R,2R,4S)-2-[(S)-1-[[[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-butyric acid (58).

15 The procedure described in example 42 was followed but with the use of L-2-amino-N-butyric acid tert.butyl ester instead of H-Nva-OtBu. The afforded compound was then reacted as described in example 43 which gave (1R,2R,4R)-2-[(S)-1-tert-butoxycarbonyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid methyl ester. Coupling of this compound with 55 as described in example 56 followed by esterhydrolysis as described in example 57 gave 58 as a colourless solid.


20 ¹H-NMR (300 MHz, CD₃OD): δ 0.82-0.99 (m, 9H), 0.82-1.40 (m, overlapped, 6H), 1.48-1.78 (m, 6H), 1.80-1.95 (m, 1H), 1.97-2.12 (m, 1H), 2.22-2.40 (m, overlapped, 2H), 2.51-2.64 (m, 1H), 2.71-2.90 (m, 1H), 3.16-3.39 (m, overlapped, 1H), 3.49-3.59 (m, 1H), 3.63 (s, 3H), 3.95 (s, 3H), 4.12-4.23 (m, 2H), 4.28-4.38 (m, 1H), 5.31 (b, 1H), 7.43 (dd, J = 2.2, 9.3 Hz, 1H), 7.47 (s, 1H), 7.51 (s, 1H), 7.66-7.89 (m, 3H), 25 7.99-8.07 (m, 2H), 8.42 (d, J = 9.1 Hz, 1H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 10.7, 18.8, 19.7, 25.8, 27.0, 27.0, 29.7, 30.5, 31.8, 37.7, 38.9, 41.2, 47.9, 52.3, 55.3, 56.9,

M183-2

109

58.8, 60.6, 83.6, 100.7, 102.2, 116.3, 121.5, 126.7, 129.8, 130.8, 133.7, 133.8, 143.9, 158.2, 166.4, 168.3, 173.3, 173.8, 175.2, 175.5, 175.6. MALDI-TOF-spectrum: (M+H)⁺ calcd: 745.4, found: 744.9; (M+Na)⁺ calcd: 767.4, found: 766.9; (M+K)⁺ calcd: 783.5, found: 782.9.

5

Example 59

10 (S)-2-[[[(1R,2R,4S)-2-[(R)-1-[(R)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-butyric acid (59)

The procedure described in example 54 was followed but with the use of Boc-D-cyclohexylglycine instead of Boc-L-cyclohexylglycine. The afforded compound was then reacted as described in example 55 followed by coupling with (1R,2R,4R)-2-((S)-1-tert-Butoxycarbonyl-pentylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid methyl ester as described in example 56. Removal of the ester group as described in example 57 gave compound 59 as a colourless solid.

20

¹H-NMR (CD₃OD, 300 MHz): δ 0.82-1.02 (m, 9H), 1.04-1.42 (m, 6H), 1.52-1.80 (m, 6H), 1.80-1.96 (m, overlapped, 1H), 2.00-2.14 (m, 1H), 2.29-2.46 (m, 2H), 2.51-2.65 (m, 1H), 2.68-2.84 (m, 1H), 3.24-3.39 (m, overlapped, 1H), 3.47-3.60 (m, 1H), 3.67 (s, 3H), 4.07 (s, 3H), 4.18-4.27 (m, 2H), 4.28-4.38 (m, 1H), 5.64 (app. bs, 1H), 7.44 (d, J = 2.3, 6.9 Hz, 1H), 7.42 (s, 2H), 7.67-7.81 (m, 3H), 8.04 (d, J = 7.8 Hz, 2H), 8.41 (d, J = 9.1 Hz, 1H); ¹³C-NMR (CD₃OD, 75.5 MHz): δ 10.8, 18.5, 19.6, 25.7,

M183-2

110

27.1, 27.1, 30.1, 30.6, 31.9, 37.3, 38.2, 41.1, 47.8, 52.3, 55.4, 56.9, 59.0, 59.1, 60.2, 83.8, 100.5, 102.2, 116.3, 121.6, 126.8, 129.8, 130.8, 133.6, 133.8, 143.7, 158.1, 166.5, 168.5, 173.4, 173.8, 175.4, 175.7, 175.7. MALDI-TOF-spectrum: (M+H)⁺ calcd: 745.4, found: 745.4; (M+Na)⁺ calcd: 767.4, found: 767.4; (M+K)⁺ calcd: 783.5, found: 783.3.

Example 60

N-Boc-4R-(2-phenyl-7-methoxyquinoline-4-oxo)proline (60).

10 To a stirred solution of N-Boc-trans-4-hydroxy-L-proline (3.9 g, 16.9 mmol) in DMSO (90mL) was added potassium tert.butoxide (4.5 g, 40.1 mmol). After 1 hrs 4-chloro-2-phenyl-7-methoxy quinoline (4.5g, 16.7 mmol) was added and stirred at RT for 12 hrs. The mixture was diluted with water (180 mL), washed with ethyl acetate (1x30mL) and neutralized with 1N HCl. The solid was filtered, washed with water and
15 dried giving (4.65g, 10mmol) of product. >95% purity by HPLC. M+H⁺ 464.2.

Example 61

2-(1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(7-methoxy-2-phenyl-quinoline-4-yloxy)-pyrrolidine-1-carboxylic acid tert.butyl ester (61).

20

To a solution of 1-amino-2-vinyl-cyclopropanecarboxylic acid ethyl ester (41 mg, 0.26 mmol), 60 (11 mg, 0.22 mmol), HATU (204 mg, 0.54 mmol) in DMF (4 mL) was added diisopropylethylamine (187 μ L, 1.08 mmol). After stirring at RT for 1 hrs, dichloromethane (4 mL) was added. The solution was washed with aqueous
25 NaHCO₃ (sat) and with two portions of water. The organic layer was dried and concentrated. The product was pure enough (>95 % by HPLC) to be used in the next step. M+H⁺ 602.2.

Example 62

30 1-[[4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (62).

M183-2

111

Compound 61 was kept in TFA-DCM 1:2 (3 mL) at RT for 60 min. Toluene (3 mL) was added. The sample was co-evaporated to dryness. Purity by HPLC >95%. M+H⁺ 502.4.

5 Example 63

1-[[1-[1-(2-Hydroxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (63).

10 To a solution of compound 62 (0.13 mmol) in THF (2 mL), was added a large excess of NaHCO₃ (s) and a solution of phosgene in toluene (1.6 M, 600 µL). After 10 min of agitation the slurry was filtered and concentrated to dryness. The solid was redissolved in dichloromethane and a large excess of NaHCO₃ (s) and 2-Amino-N-(2-hydroxy-indan-1-yl)-3,3-dimethyl-butyramide (0.65 mmol) was added. The slurry
15 was agitated for 24-40 hrs at RT. The slurry was filtered, concentrated and subjected to silica column chromatography (gradient elution from 100 % DCM to MeOH/DCM 2:98) to give the title compound (89.6 mg, 0.11 mmol). Purity by HPLC >95%. M+H⁺ 790.3.

20 Example 64

1-[1-[1-(2-Hydroxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propyl]-4-(6-methoxy-3-phenyl-naphthalen-1-yloxy)-pyrrolidin-2-yl]-2-vinyl-cyclopropanecarboxylic acid (64).

To a solution of 63 (76.7mg, 0.097mmol) in THF-MeOH 2:3 (2 mL) was added 1M
25 LiOH 5 equiv. The solution was kept at 60 °C for 60 min. After cooling to RT, HOAc 15-30 eq. was added followed by toluene (2 mL) and then concentrated to dryness. The residue was taken up in DCM and washed with water. The organic layer was dried and concentrated to give the title compound (72 mg, 0.094 mmol). Purity >95%
by HPLC M+H⁺ 762.2.

30

Example 65

M183-2

112

N-(2-Hydroxy-indan-1-yl)-2-[4-(6-methoxy-3-phenyl-naphthalen-1-yloxy)-2-(1-phenylmethanesulfonylaminoacarbonyl-2-vinyl-cyclopropyl)-pyrrolidin-1-yl]-3,3-dimethyl-butamide (65).

- 5 To solution of 64 (25 mg, 0.033 mmol) in chloroform (1 mL) was added benzenesulfonamide (10.5 mg, 0.066 mmol) followed by diisopropylethylamine (34 μ L, 0.197 mmol). The solution was stirred at RT for 10 min and then at -20 °C for 30 min. PyBOP (76 mg, 0.13 mmol) was then added as a solid. The solution was kept at -20 °C for 48 hours. The solution was then poured into aqueous NaHCO₃ (sat.) and
- 10 washed with water. The organic layer was dried, concentrated and subjected to purification by HPLC, affording the title compound as a white solid.

Example 66

Resin bound 2-*tert*-butoxycarbonylamino-3,3-dimethylbutyric acid (66).

- 15 To Argonaut resin PS-TFP (1.38 mmol/g, 10 g) and 2-*tert*-butoxycarbonylamino-3,3-dimethyl-butylric acid (4.5 g, 20.7 mmol) was added dichloromethane (40 mL) and DMF (10 mL). To this mixture was added DMAP (1 g, 8.28 mmol) and then DIC (9.5 mL, 60.7 mmol). After 3 hrs of agitation at RT the resin was filtered and washed
- 20 successively with DMF, THF, DCM, THF, DCM and ether and then dried in a vacuum.

Example 67

[1-(2-Hydroxy-indan-1-ylcarbonyl)-2,2-dimethyl-propyl]-carbamic acid *tert*-butyl ester (67).

- 25 To a portion of 66 (200 mg) in DCM aminoindanol (0.14 mmol) was added. The mixture was agitated for 2 hrs. The liquid was filtered of and the resin washed with 2x DCM. The combined liquids were combined and concentrated to dryness to afford
- 30 the title compound (20.5 mg, 0.055 mmol) Purity >95% by HPLC. M+H⁺ 363.15.

M183-2

113

^{13}C NMR δ_{C} (100 MHz; CDCl_3 ; Me_4Si) 27.0, 28.5, 34.2, 39.8, 50.8, 57.9, 68.2, 73.7, 124.8, 125.6, 127.4, 128.5, 140.4, 171.6. ^1H NMR δ_{H} (400 MHz; CDCl_3 ; Me_4Si) 1.07 (9H, s, CCH_3), 1.44 (9H, s, OCCH_3), 2.93 (1H, dd, J_{gem} 16.4 Hz, $J_{3,2}$ 2.3 Hz, CH_2), 3.15 (1H, dd, J_{gem} 16.4 Hz, $J_{3,2}$ 5.2 Hz, CH_2),

5

Example 68

2-Amino-*N*-(2-hydroxy-indan-1-yl)-3,3-dimethyl butyramide (68).

Compound 67 was kept in DCM-TFA 2:1 (2 mL) for 60 min at RT. The solution was co-evaporated with toluene to dryness.

10

Example 69

(2-*tert*-Butoxycarbonylamino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (69).

15

To a solution of 2-*tert*-butoxycarbonylamino-3,3-dimethyl butyric acid (500 mg, 2.16 mmol), Amino-cyclohexyl-acetic acid methyl ester (444 mg, 2.59 mmol) and HATU (2 g, 5.40 mmol) in DMF (20 mL) was added diisopropylethylamine (1.88 mL, 10.8 mmol). The solution was stirred for 1 hrs at r.t. and diluted with dichloromethane (40 mL). This solution was washed with aqueous. NaHCO_3 (sat.) and water (x2), dried and concentrated. The product was >95 % pure. $\text{M}+\text{H}^+$ 385.4.

20

Example 70

{1-[(Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propyl}-carbamic acid *tert*-butyl ester (70).

25

To compound 69 in EtOH-THF 1:2 was added a large excess of methylamine (30% in water) and left at rt. for 2 weeks. The solution was concentrated to dryness and the residue subjected to a short silica gel column eluted with 2% MeOH in dichloromethane to give a pure (>95%) product $\text{M}+\text{H}^+$ 384.5.

30

Example 71


M183-2

114

2-Amino-*N*-(cyclohexyl-methylcarbamoyl-methyl)-3,3-dimethyl-butamide (71).

Compound 70 was kept in dichloromethane-trifluoroacetic acid 2:1 for 1 h at rt and concentrated to dryness. The residue was dried in a vacuum for 16 hrs. Reversed
 5 phase C18 HPLC showed >95% purity $M+H^+$ 283.1.

Example 72




(1R,2S)-1-(((2S,4R)-1-((1S,2R)-2-Hydroxy-indan-1-ylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino)-2-vinyl-
 10 cyclopropanecarboxylic acid (72).

Compound 62 was treated as described for the preparation of 63 but with the use of (1S,2R)-cis-1-amino-2-indanol instead of 2-amino-*N*-(2-hydroxyindan-1-yl)-3,3-
 15 dimethyl butyramide followed by ester hydrolysis as described for the preparation of compound 64 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 649.1.

Example 73

M183-2

115




(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(Cyclohexylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (73).

5

N-(tert-butoxycarbonyl)-L-valine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. M+H⁺ 712.3.

10

Example 74



15


(1R,2S)-1-[[[(2S,4R)-1-[(1R)-2-Hydroxy-1-phenyl-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (74).

M183-2

116

Compound 62 was treated as described for the preparation of 63 but with the use of (R)-2-phenylglycinol instead of 2-amino-N-(2-hydroxyindan-1-yl)-3,3-dimethyl butyramide instead of 2-amino-N-(2-hydroxy-indan-1-yl)-3,3-dimethyl-butyramide followed by ester hydrolysis as described for the preparation of compound 64 which
5 gave the title compound. Purity by HPLC >95%. $M+H^+$ 637.1.

Example 75




(1R,2S)-1-[[[(2S,4R)-1-[[[(1S)-Cyclohexyl-(cyclohexylmethyl-carbamoyl)-methyl]-
10 carbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (75).

N-(tert-butoxycarbonyl)-L-cyclohexylglycine was attached to the resin as described for the preparation of compound 66 followed by reaction with
15 cyclohexanemethylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 752.4.

20 Example 76

M183-2


117



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-2-Cyclohexyl-1-(cyclohexylmethyl-carbamoyl)-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (76).

- 5 N-(tert-butoxycarbonyl)-L-cyclohexylalanine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexanemethylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave
- 10 the title compound. Purity by HPLC >95%. M+H⁺ 766.4.

Example 77



- 15 (1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(Cyclohexylmethyl-carbamoyl)-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (77).


- 20 N-(tert-butoxycarbonyl)-L-tert-butylglycine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexanemethylamine as described for the preparation of 67 and removal of the Boc group as described for

M183-2

118

68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 726.3.

5 Example 78



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(Cyclohexylmethyl-carbamoyl)-2-phenylethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (78).

10

N-(tert-butoxycarbonyl)-L-phenylalanine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexanemethylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 760.4.


15

Example 79



M183-2

119




(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-((1S,2R)-2-Hydroxy-indan-1-ylcarbamoyl)-3-phenyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (79).

5

N-(tert.butoxycarbonyl)-L-phenethylglycine was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-cis-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the
10 chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. M+H⁺ 810.4.

Example 80




15

(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-Benzylcarbamoyl-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (80).

M183-2

120

N-(tert-butoxycarbonyl)-L-valine was attached to the resin as described for the preparation of compound 66 followed by reaction with benzylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC
 5 >95%. $M+H^+$ 706.2.

Example 81

10 (1R,2S)-1-[(2S,4R)-1-[(1S)-1-[(1R)-2-Hydroxy-1-phenyl-ethylcarbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid (81).


15 N-(tert-butoxycarbonyl)-L-tert-butyglycine was attached to the resin as described for the preparation of compound 66 followed by reaction with (R)-2-phenylglycinol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 750.3.

20

Example 82

M183-2

121




(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-((1R)-Indan-1-ylcarbamoyl)-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (82).

5

(2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1R)-1-aminoindane as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the
10 chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (12.5 mg, 28 % yield), Purity by HPLC >90%. $M+H^+$ 732.2.

Example 83



15

(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-((1S)-Indan-1-ylcarbamoyl)-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (83).

20


(2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S)-1-

M183-2

122

aminoindane as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (22 mg, 49 % yield), Purity by HPLC >90% M+H⁺ 732.2.

Example 84




(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-(2-hydroxyethylcarbamoyl)-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]amino]-2-vinyl-cyclopropanecarboxylic acid (84).

(2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with 2-aminoethanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (3 mg, 8 % yield), Purity by HPLC >90% M+H⁺ 660.2.

Example 85

M183-2

123




(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-((1S, 2R)-2-Hydroxy-indan-1-ylcarbamoyl)-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (85).

5

(2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the
 10 chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (10 mg, 22 % yield), Purity by HPLC >90% $M+H^+$ 748.2.

Example 86



15

(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-((1R, 2S)-2-Hydroxy-indan-1-ylcarbamoyl)-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (86).

20


(2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1R,2S)-1-

M183-2

124

amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (11 mg, 24 % yield), Purity by
5 HPLC >75% M+H⁺ 748.

Example 87




(1R, 2S)-1-[[[(2S, 4R)-1-[[Cyclohexyl-(S)-((1S, 2R)-2-hydroxy-indan-1-ylcarbamoyl)-
10 methyl]-carbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-
amino]-2-vinyl-cyclopropanecarboxylic acid (87).

(2S)-*tert*.butoxycarbonylamino-cyclohexylacetic acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-
15 amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (7.5 mg, 16 % yield), Purity by HPLC >95% M+H⁺ 788.3.

20

Example 88




M183-2

125

(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1S, 2R)-2-Hydroxy-indan-1-ylcarbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (88).

- 5 (2S)-*tert*-butoxycarbonylamino-3,3-dimethylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which,
 10 after purification by HPLC, gave the title compound (12 mg, 26 % yield), Purity by HPLC >95% M+H⁺ 762.3.

Example 89




- 15 (1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1S, 2R)-2-Hydroxy-indan-1-ylcarbamoyl]-3,3-dimethyl-butylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (89).

- 20 (2S)-*tert*-butoxycarbonylamino-4,4-dimethylpentanoic acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which,
 25 after purification by HPLC, gave the title compound (14.2 mg, 30 % yield), Purity by HPLC >95% M+H⁺ 776.3.

Example 90

M183-2

126




(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1S, 2R)-2-Hydroxy-indan-1-ylcarbamoyl]-2-phenylethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (90).

5

(2S)-*tert*-butoxycarbonylamino-3-phenylpropanoic acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the
 10 chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (2.4 mg, 5 % yield), Purity by HPLC >95% M+H⁺ 796.2.

Example 91



15

(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-2-Cyclohexyl-1-[(1S, 2R)-2-hydroxy-indan-1-ylcarbamoyl]-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (91).

20


(2S)-*tert*-Butoxycarbonylamino-3-cyclohexylpropanoic acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-

M183-2

127

1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (12.3 mg, 25 % yield), Purity by HPLC >95% M+H⁺ 802.3.


Example 92



(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(S)-(Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (92).

Compound 62 was treated as described for the preparation of 63 but with the use of 71 instead of 2-amino-N-(2-hydroxy-indan-1-yl)-3,3-dimethyl-butyramide followed by ester hydrolysis as described for the preparation of compound 64 which, after purification by HPLC, gave the title compound (8.6 mg, 18 % yield). Purity by HPLC >95%. M+H⁺ 783.3.

Example 93



1-(2-Amino-4-methoxyphenyl)ethanone (93)

m-Anisidine (10.0 g, 82 mmol) was dissolved in CH₂Cl₂ (50 mL), and the solution was cooled to -50 °C. BCl₃ (1 M in CH₂Cl₂, 82 mL, 82 mmol) was added slowly during 20 min, after which the mixture was stirred at -50 °C for 30 min, followed by sequential addition of AcCl (6.0 mL, 84 mmol) and AlCl₃ (11 g, 82 mmol). The mixture was stirred at -50 °C for 1 h and was then allowed to assume rt. After stirring at rt overnight, the solution was heated at 40 °C for 4 h, after which the mixture was poured over ice. The aqueous mixture was made alkaline with 10 % NaOH (w/v) and extracted with EtOAc (4 x 200 mL). The combined organic phases were washed with brine, dried (MgSO₄), and evaporated to give a black solid, which was purified by flash column chromatography (ether/CH₂Cl₂ 20:80). The resulting solid was recrystallized from ether/hexane to give compound 93 as shiny tan leaflets (5.6 g, 42 %).

Example 94

15 *N*-(*tert*-Butyl)-*N*-isopropylthiourea (94)

To a solution of *tert*-butylisothiocyanate (5.0 mL, 39 mmol) in CH₂Cl₂ (200 mL) were added isopropylamine (4.0 mL, 47 mmol) and diisopropylethylamine (DIEA) (6.8 mL, 39 mmol), and the mixture was stirred at rt for 2h. The reaction mixture was diluted with EtOAc, washed with 10 % citric acid (2x), saturated NaHCO₃ (2x), H₂O (2x), and brine (1x). The organic layer was dried (MgSO₄) and evaporated to yield compound 94 (3.3 g, 52 %) as a white solid which was used without further purification.

Example 95

25 *N*-Isopropylthiourea (95)


Compound 94 (3.3 g, 20 mmol) was dissolved in conc. HCl (45 mL) and the solution was refluxed for 40 min. The mixture was allowed to cool to rt and then cooled in an ice bath and basified to pH 9.5 with solid and saturated NaHCO₃, after which the product was extracted into EtOAc (3x). The combined organic phases were washed

M183-2

129

with H₂O (2x) and brine (1x), dried (MgSO₄), and evaporated to yield crude compound 95 (2.1 g, 90 %) which was used without further purification.

Example 96




5

2-(Isopropylamino)-1,3-thiazole-4-carboxylic acid hydrobromide (96)

A suspension of compound 95 (2.1 g, 18 mmol) and 3-bromopyruvic acid (3.0 g, 18 mmol) in dioxane (180 mL) was heated to 80 °C. Upon reaching 80 °C the mixture became clear, and soon thereafter the product started to precipitate as a white solid. After 2 h of heating, the reaction mixture was cooled to rt and the precipitate was filtered off and collected. This yielded pure compound 96 (4.4 g, 94 %).

10

Example 97



15

N-(2-Acetyl-5-methoxyphenyl)-2-(isopropylamino)-1,3-thiazole-4-carboxamide (97)

A mixture of compound 96 (4.4 g, 16.5 mmol) and the aniline derivative 93 (2.75 g, 16.5 mmol) in pyridine (140 mL) was cooled to -30 °C (upon cooling, the clear solution became partially a suspension). POCl₃ (3.3 mL, 35 mmol) was added slowly over a 5 min period. The mixture was stirred at -30 °C for 1 h, and was then allowed to assume rt. After stirring at rt for 1.5 h the reaction mixture was poured over ice, and the pH was adjusted to about 9-10 using solid and saturated NaHCO₃. The crude product was extracted into CH₂Cl₂ (3x) and the combined organic phases were dried (MgSO₄) and evaporated. The crude dark-beige solid was purified by flash

20


25

M183-2

130

column chromatography (hexane/EtOAc 55:45) to give compound 97 (5.6 g, 76 %) as a pale yellow solid.

Example 98



5


2-[2-(isopropylamino)-1,3-thiazol-4-yl]-7-methoxyquinolin-4-ol (98)

A solution of t.BuOK (2.42 g, 21 mmol) in anhydrous t.BuOH (40 mL) was heated to reflux. Compound 97 (1.8 g, 5.4 mmol) was added portion-wise over a 5 min period, and the dark red solution formed was stirred at reflux for an additional 20 min. The mixture was cooled to rt, and HCl (4 M in dioxane, 8.0 mL, 32 mmol) was added, after which the reaction mixture was concentrated under vacuum. In order to assure that all of the HCl and dioxane were removed, the crude product was re-dissolved in CH₂Cl₂ twice and thoroughly evaporated to obtain the slightly impure HCl salt of compound 98 (1.62 g) as a brown solid. The product was dissolved in CH₂Cl₂ and washed with saturated NaHCO₃, after which the aqueous phase was extracted several times with CH₂Cl₂. The combined organic phases were dried (MgSO₄) and evaporated to give compound 98 (1.38 g, 81 %) as a light brown solid (> 95 % pure according to HPLC tests). ¹H-NMR (MeOH-*d*₄, 400 MHz): δ 1.30 (d, *J* = 6.0 Hz, 6H), 3.93 (s, 3H), 3.95-4.07 (m, 1H), 6.73 (s, 1H), 6.99 (dd, *J* = 2.4, 9.2 Hz, 1H), 7.26 (d, *J* = 2.4 Hz, 1H), 7.37 (s, 1H), 8.10 (d, *J* = 9.2 Hz, 1H).

Example 99

M183-2

131




(1*R*,4*R*,5*R*)-*N*-[(1*S*)-1-[[[(1*S*)-1-Cyclohexyl-2-(methylamino)-2-oxoethyl]amino]carbonyl]-2,2-dimethylpropyl]-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxamide (99)

5

To a solution of compound 32 (53 mg, 0.34 mmol) in DMF (9 mL) was added compound 71 (80 mg, 0.28 mmol) and DIEA (290 μ L, 1.66 mmol). The solution was cooled to 0 °C and HATU (127 mg, 0.33 mmol) was added. After stirring at 0 °C for 1 h and at rt for 1 h the solvent was evaporated, and the crude product was purified by flash column chromatography (EtOAc/toluene 2:1) to give compound 99 (110 mg, 92 %)

10

Example 100



(1*R*)-1-[[[(1*R*,2*R*,4*R*)-2-[[[(1*S*)-1-[[[(1*S*)-1-Cyclohexyl-2-(methylamino)-2-oxoethyl]amino]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]-4-hydroxycyclopentyl]carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid ethyl ester (100)

Compound 99 (60 mg, 0.14 mmol) was dissolved in dioxane (3.5 mL) and H₂O (2.5 mL) and the solution was cooled to 0 °C. LiOH (1 M, 280 μ L, 0.28 mmol) was added dropwise during 5 min, after which the reaction mixture was stirred at 0 °C for 40 min. The pH was adjusted to 7 using 1 M HCl, and the solvents were evaporated. The residue was suspended in DMF (5 mL) and 1-amino-2-vinyl-


20

M183-2

132

cyclopropanecarboxylic acid ethyl ester (32 mg, 0.17 mmol), and DIEA (146 μ L, 0.84 mmol) were added. After cooling to 0 °C HATU (64 mg, 0.17 mmol) was added and the mixture was stirred at 0 °C for 1 h and at rt for 1 h. The solvent was evaporated and the product was purified using flash column chromatography (EtOAc/MeOH 9:1) to give compound 100 (67 mg, 82 %) as a white solid.

Example 101




tert-Butyl (1*R*,2*R*,4*R*)-2-[[[(1*R*)-1-(ethoxycarbonyl)-2-vinylcyclopropyl]amino]carbonyl]-4-[[2-[2-(isopropylamino)-1,3-thiazol-4-yl]-7-methoxyquinolin-4-yl]oxy]cyclopentanecarboxylate (101)

The title compound was prepared according to the procedure described in example 103 method A but with the use of compound 34 instead of compound 100. (Note: 4 equivalents of Ph_3P and DIAD were used. Chromatography eluent: Toluene/EtOAc 1:1.)

Example 102

M183-2

133




(1R,2R,4R)-2-[[[(1R)-1-(Ethoxycarbonyl)-2-vinylcyclopropyl]amino]carbonyl]-4-[[2-[2-(isopropylamino)-1,3-thiazol-4-yl]-7-methoxyquinolin-4-yl]oxy]cyclopentanecarboxylic acid (102)

5

To a solution of compound 101 (20 mg, 30 μ mol) in CH_2Cl_2 (2 mL) was added TFA (2 mL) and Et_3SiH (10 μ L, 63 μ mol). After 2 h the volatiles were evaporated and the product was used without any purification step. Compound 102: 18 mg, quant. as a white solid.

10

Example 103



(1R)-1-[[[(1R,2R,4S)-2-[[[(1S)-1-[[[(1S)-1-Cyclohexyl-2-(methylamino)-2-oxoethyl]amino]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]-4-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]cyclopentyl]carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid ethyl ester (103)

15


M183-2

134

Method A: To a solution of compound 100 (59 mg, 0.10 mmol) in dry THF (4 mL) was added the quinoline 98 (49 mg, 0.16 mmol) and Ph_3P (65 mg, 0.25 mmol). After cooling to 0 °C DIAD (50 μL , 0.25 mmol) was added dropwise during 5 min. The solution was stirred at 0 °C for 1 h and at rt for 48 h. The solvent was evaporated and the remainder was purified using flash column chromatography ($\text{CHCl}_3/2 \text{ M NH}_3$ in MeOH 95:5) to give compound 103 (9 mg, 10 %) as a white solid.

Method B: Compound 102 was coupled to compound 71 according to the procedure in example 99 which gave the title compound (82%).

10 **Example 104**



(1R)-1-[[[(1R,2R,4S)-2-[[[(1S)-1-[[[(1S)-1-Cyclohexyl-2-(methylamino)-2-oxoethyl]amino]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]-4-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]cyclopentyl]carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid (104)


Compound 103 (8 mg, 9 μmol) was dissolved in a mixture of MeOH (150 μL) and THF (100 μL). A solution of LiOH (1 mg, 42 μmol) in H_2O (25 μL) was added and the mixture was stirred at 50 °C overnight. The solution was neutralized with HOAc and evaporated. The residue was suspended in CH_2Cl_2 and washed with H_2O . The organic phase was evaporated to give the title compound (8 mg, quant.) as a white solid.

M183-2

135

$^1\text{H-NMR}$ ($\text{MeOH-}d_4$, 400 MHz) (mixture of rotamers): δ 0.60-1.33 (m, 21H), 1.35-1.73 (m, 12H), 1.90-2.42 (m, 2H), 2.51-2.75 (m, 6H), 3.20-3.38 (m, 1H), 3.85 (s, 3H), 3.95-4.28 (m, 1H), 4.91-5.02 (m, 1H), 5.12-5.23 (m, 1H), 5.64-5.83 (m, 1H), 7.01-7.11 (m, 1H), 7.25-7.40 (m, 1H), 7.42-7.57 (m, 1H), 7.85-8.08 (m, 1H).


5

Example 105

(1S)-1-[(2S,4R)-2-(1-Methoxycarbonyl-butylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)]-pyrrolidine-carboxylic acid tert-butyl ester (105)

10

Reaction of 60 with Nva-OMe hydrochloride according to the method described in example 61 provided the title compound. Purity > 95% by HPLC, $\text{M}+\text{H}^+$ 578.24.

Example 106

15


(1S)-1-[(2S,4R)-2-[4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-pentanoic acid methyl ester (106)

M183-2

136

Compound 105 from above was kept in TFA-DCM 1:2 (3 mL) at RT for 60 min. Toluene (3 mL) was added. The sample was co-evaporated to dryness. Purity by HPLC > 95%. $M+H^+$ 478.21.

5 Example 107



(1S)-2-[[[(2S,4R)-1-[(1S)-1-(Cyclohexylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-pentanoic acid methyl ester (107)

10


To a solution of 106 (0.1 mmol) in THF (4 mL), cooled to 0 °C, was added a large excess of NaHCO_3 (s) and a solution of phosgene in toluene (0.2 mmol, 21 μL). After 10 min of agitation the slurry was filtered and concentrated to dryness. The solid was redissolved in dichloromethane and a large excess of NaHCO_3 (s) and 2-amino-N-cyclohexylmethyl-3-methyl-butyramide, described in example 73, (0.15 mmol) was added. The slurry was agitated 30 hrs at RT. The slurry was filtered, concentrated and subjected to silica column chromatography (gradient elution from 100 % DCM to MeOH/DCM 2:98) to give the title compound (30 mg, 0.042 mmol). Purity by HPLC > 95%. $M+H^+$ 716.40.

20

Example 108

M183-2

137




(1S)-2-[[[(2S,4R)-1-[(1S)-1-(Cyclohexylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-pentanoic acid (108)

5

To a solution of 107 (26 mg, 0.036 mmol) in THF-MeOH 2:3 (2 mL) was added 1M LiOH 1.5 equiv. The solution was kept at 60 °C for 60 min. After cooling to RT, HOAc was added followed by toluene (2 mL) and then concentrated to dryness to give the title compound (25 mg, 0.035 mmol). Purity > 95% by HPLC M+H⁺ 702.34.

10

Example 109



(1R,2S)-1-[[[(2S,4R)-1-[2-(2-Methoxy-phenoxy)-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (109)

15

To a solution of 62 (0.06 mmol) in THF (2 mL), was added a large excess of NaHCO₃ (s) and a solution of phosgene in toluene (0.078 mmol). After 10 min of agitation the slurry was filtered and concentrated to dryness. The solid was redissolved in dichloromethane and a large excess of NaHCO₃ (s) and 2-(2-


20

M183-2

138

methoxy-phenoxy)-ethylamine (15 mg, 0.09 mmol) was added. The slurry was agitated for 30 hrs at RT. The slurry was filtered, concentrated to dryness, redissolved in MeOH and subjected HPLC purification to give the title compound (10.6 mg, 0.015 mmol). Purity by HPLC > 95%. $M+H^+$ 695.17.

5

Example 110

(1R,2S)-1-[[[(2S,4R)-1-[2-(2-Methoxy-phenoxy)-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (110)


To a solution of 109 (10.6 mg, 0.0153 mmol) in THF-MeOH 2:3 (2 mL) was added 1M LiOH 10 equiv. The solution was kept at 50 °C for 60 min. After cooling to RT, HOAc 25 equiv. was added followed by toluene (2 mL) and then concentrated to dryness. The residue was taken up in ethyl acetate, filtered and concentrated to dryness to give the title compound (9.4 mg, 0.014 mmol). Purity > 95% by HPLC $M+H^+$ 667.14.

15

Example 111

M183-2

139




(1R,2S)-1-[[[(2S,4R)-1-[(1S,2R)-5-Hydroxy-4,5,6,7-tetrahydro-benzo[b]thiophen-4-yl-carbamoyl]]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (111)

5

The procedure described in example 109 was followed but with the use of 2-amino-4,5,6,7-tetrahydro-benzo[b]thiophen-5-ol instead of 2-(2-methoxy-phenoxy)-ethylamine, followed by hydrolysis of the ethyl ester as described in example 110 which gave the title compound (7.5 mg, 0.011 mmol). Purity > 95% by HPLC M+H⁺ 669.

10

Example 112



(1R,2S)-1-[[[(2S,4R)-1-[(3R)-3-Hydroxy-pyrrolidine-1-carbonyl]]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (112)

15


The procedure described in example 109 was followed but with the use of (R)-3-pyrrolidinol instead of 2-(2-methoxy-phenoxy)-ethylamine, followed by hydrolysis of

M183-2

140

the ethyl ester as described in example 110 which gave the title compound (4 mg, 0.007 mmol). Purity > 95% by HPLC $M+H^+$ 587.1.

Example 113




5

(1R,2S)-1-[[[(2S,4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-1-[(thiophen-2-yl-methyl)-carbamoyl]-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (113)

- 10 The procedure described in example 109 was followed but with the use of thiophene-2-methylamine instead of 2-(2-methoxy-phenoxy)-ethylamine, followed by hydrolysis of the ethyl ester as described in example 110 which gave the title compound (8 mg, 0.013 mmol). Purity > 95% by HPLC $M+H^+$ 613.08.

15 Example 114




(1R,2S)-1-[[[(2S,4R)-1-[(1,1-Dioxo-tetrahydro-1-λ⁶-thiophen-3-yl)-carbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (114)

M183-2

141

The procedure described in example 109 was followed but with the use of 3-aminotetrahydro-1H-1 λ^6 -thiophene-1,1-dione instead of 2-(2-methoxy-phenoxy)-ethylamine, followed by hydrolysis of the ethyl ester as described in example 110 which gave the title compound (13 mg, 0.02 mmol). Purity > 95% by HPLC M+H⁺ 635.05.


Example 115



2-Amino-3,3-dimethyl-N-thiophen-2-yl-methyl-butamide (115)

The title compound was prepared as described in example 67 but with the use of thiophene-2-methylamine instead of aminoindanole followed by removal of the Boc group as described in example 68.

Example 116




2-Amino-N-(6-hydroxy-4,5,6,7-tetrahydro-benzo[b]thiophen-5-yl)-3,3-dimethyl-butamide (116)

The title compound was prepared as described in example 67 but with the use of 2-amino-4,5,6,7-tetrahydro-benzo[b]thiophen-5-ol instead of aminoindanole followed by removal of the Boc group as described in example 68.


M183-2

142

Example 117**2-Amino-N-(2-diethylamino-ethyl)-3,3-dimethyl-butyramide (117)**


5

The title compound was prepared as described in example 67 but with the use of N,N-diethylethylenediamine instead of aminoindanole followed by removal of the Boc group as described in example 68.

Example 118**2-Amino-N-[2-(2-methoxy-phenoxy)-ethyl]-3,3-dimethyl-butyramide (118)**

15

The title compound was prepared as described in example 67 but with the use of 2-methoxyphenoxyethylamine instead of aminoindanole followed by removal of the Boc group as described in example 68.

Example 119

20


2-Amino-1-(3-hydroxy-pyrrolidin-1-yl)-3,3-dimethyl-butan-1-one (119)

The title compound was prepared as described in example 67 but with the use of (R)-3-pyrrolidinone instead of aminoindanole followed by removal of the Boc group as described in example 68.

M183-2

143

Example 120




2-Amino-N-(1,1-dioxo-tetrahydro-1-λ⁶-thiophen-3-yl)-3,3-dimethyl-butamide (120)

5

The title compound was prepared as described in example 67 but with the use of 2-methoxyphenoxyethylamine instead of aminoindanole followed by removal of the Boc group as described in example 68.

10 **Example 121**



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(2,2-Dimethyl-1-[(thiophen-2-yl-methyl)-carbamoyl]-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (121)

15

To a solution of 62 (0.06 mmol) in THF (2 mL), was added a large excess of NaHCO₃ (s) and a solution of phosgene in toluene (0.078 mmol). After 10 min of agitation the slurry was filtered and concentrated to dryness. The solid was redissolved in dichloromethane and a large excess of NaHCO₃ (s) and 115 (0.09 mmol) was added. The slurry was agitated for 30 hrs at RT. The slurry was filtered,


20

M183-2

144

concentrated to dryness, re-dissolved in MeOH and subjected HPLC purification to give the title compound (15.5 mg, 0.02 mmol). Purity by HPLC > 95%. $M+H^+$ 754.2.

Example 122




5

(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(2,2-Dimethyl-1-[(thiophen-2-ylmethyl)-carbamoyl]-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (122)

- 10 To a solution of 121 (14 mg, 0.017 mmol) in THF-MeOH 2:3 (2 mL) was added 1M LiOH 10 equiv. The solution was kept at 50 °C for 60 min. After cooling to RT, HOAc 20 equiv. was added followed by toluene (2 mL) and then concentrated to dryness. The residue was taken up in ethyl acetate, filtered and concentrated to dryness to give the title compound (13 mg, 0.017 mmol). Purity > 95% by HPLC $M+H^+$ 748.13.

15

Example 123



(1R,2S)-1-[[[(2S,4R)-1-[(1S,2R)-1-[1-(5-Hydroxy-4,5,6,7-tetrahydro-benzo[b]thiophen-4-yl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-


M183-2

145

phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid (123)

The procedure described in example 121 was followed but with the use of 116 instead of 115, followed by hydrolysis of the ethyl ester as described in example 122 which gave the title compound (4 mg, 0.005 mmol). Purity > 95% by HPLC M+H⁺ 782.16.

Example 124




(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(2-Diethylamino-ethylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (124)

The procedure described in example 121 was followed but with the use of 117 instead of 115, followed by hydrolysis of the ethyl ester as described in example 122 which gave the title compound (6 mg, 0.008 mmol). Purity > 95% by HPLC M+H⁺ 729.24.

Example 125

M183-2


146



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-[2-(2-Methoxy-phenoxy)-ethylcarbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (125)

The procedure described in example 121 was followed but with the use of 118 instead of 115, followed by hydrolysis of the ethyl ester as described in example 122 which gave the title compound (3 mg, 0.004 mmol). Purity > 95% by HPLC M+H⁺ 780.19.

Example 126




(1R,2S)-1-[[[(2S,4R)-1-[(3R)-1-(3-Hydroxy-pyrrolidine-1-carbonyl)-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (126)

The procedure described in example 121 was followed but with the use of 119 instead of 115, followed by hydrolysis of the ethyl ester as described in example 122 which gave the title compound (12.4 mg, 0.02 mmol). Purity > 95% by HPLC M+H⁺ 700.16.

M183-2

147


Example 127



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(1,1-Dioxo-tetrahydro-1-λ⁶-thiophen-3-yl-carbamoyl)-
5 2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-
carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (127)

The procedure described in example 121 was followed but with the use of 120
instead of 115, followed by hydrolysis of the ethyl ester as described in example 122
10 which gave the title compound (13 mg, 0.014 mmol). Purity > 95% by HPLC M+H⁺
748.13.

Example 128




(4R)-1-(*tert*-butoxycarbonyl)-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl-N¹-
15 (phenylsulfonyl)-L-norvalinamide (128)

To a solution of 60 (60 mg, 0.13 mmol) in DMF, HATU (124 mg, 0.325 mmol),
diisopropylethylamine (114 μL, 0.65 mmol) was added and agitated for 30 min at RT.

M183-2

148


A solution of 131 (0.157 mmol) in DMF was added. The slurry was agitated for 16 hrs at RT followed by concentration to dryness. The residue was taken up in DCM and washed with NaHCO₃ (sat.), and water. The organic layer was dried, concentrated and subjected to silica column chromatography (gradient elution from 100% DCM to 2%MeOH/DCM) to give the title compound (61 mg, 0.087mmol). Purity > 90% by HPLC. M+H⁺ 703.23.

Example 129

10 (4*R*)-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl-*N*¹-(phenylsulfonyl)-L-norvalinamide (129)

Compound 128 from above was kept in DCM-TFA 2:1 (2 mL) for 2.5 hr at RT. The solution was co-evaporated with toluene to dryness. Yield 100%. M+H 603.12

15

Example 130

Carbamic acid, [(1*S*)-1-[[[(phenylsulfonyl)amino]carbonyl]butyl]-, phenylmethyl ester (130)


20

5

10

15

(2S)-2-Amino-N-(phenylsulphonyl)pentanamide (131)



20

CN(C)C(=O)C[C@H](C1CCCCC1)C(=O)N(C)C(=O)N2C(=O)C[C@H](C2)Oc3cc(OC)c4ccccc4n3C5=CC=C(C=C5)C(=O)N(C)C(=O)N6C(=O)C[C@H](C6)C(=O)N(C)C(=O)N7C(=O)C[C@H](C7)C(=O)N(C)C(=O)N8C(=O)C[C@H](C8)C(=O)N(C)C(=O)N9C(=O)C[C@H](C9)C(=O)N(C)C(=O)N10C(=O)C[C@H](C10)C(=O)N(C)C(=O)N11C(=O)C[C@H](C11)C(=O)N(C)C(=O)N12C(=O)C[C@H](C12)C(=O)N(C)C(=O)N13C(=O)C[C@H](C13)C(=O)N(C)C(=O)N14C(=O)C[C@H](C14)C(=O)N(C)C(=O)N15C(=O)C[C@H](C15)C(=O)N(C)C(=O)N16C(=O)C[C@H](C16)C(=O)N(C)C(=O)N17C(=O)C[C@H](C17)C(=O)N(C)C(=O)N18C(=O)C[C@H](C18)C(=O)N(C)C(=O)N19C(=O)C[C@H](C19)C(=O)N(C)C(=O)N20C(=O)C[C@H](C20)C(=O)N(C)C(=O)N21C(=O)C[C@H](C21)C(=O)N(C)C(=O)N22C(=O)C[C@H](C22)C(=O)N(C)C(=O)N23C(=O)C[C@H](C23)C(=O)N(C)C(=O)N24C(=O)C[C@H](C24)C(=O)N(C)C(=O)N25C(=O)C[C@H](C25)C(=O)N(C)C(=O)N26C(=O)C[C@H](C26)C(=O)N(C)C(=O)N27C(=O)C[C@H](C27)C(=O)N(C)C(=O)N28C(=O)C[C@H](C28)C(=O)N(C)C(=O)N29C(=O)C[C@H](C29)C(=O)N(C)C(=O)N30C(=O)C[C@H](C30)C(=O)N(C)C(=O)N31C(=O)C[C@H](C31)C(=O)N(C)C(=O)N32C(=O)C[C@H](C32)C(=O)N(C)C(=O)N33C(=O)C[C@H](C33)C(=O)N(C)C(=O)N34C(=O)C[C@H](C34)C(=O)N(C)C(=O)N35C(=O)C[C@H](C35)C(=O)N(C)C(=O)N36C(=O)C[C@H](C36)C(=O)N(C)C(=O)N37C(=O)C[C@H](C37)C(=O)N(C)C(=O)N38C(=O)C[C@H](C38)C(=O)N(C)C(=O)N39C(=O)C[C@H](C39)C(=O)N(C)C(=O)N40C(=O)C[C@H](C40)C(=O)N(C)C(=O)N41C(=O)C[C@H](C41)C(=O)N(C)C(=O)N42C(=O)C[C@H](C42)C(=O)N(C)C(=O)N43C(=O)C[C@H](C43)C(=O)N(C)C(=O)N44C(=O)C[C@H](C44)C(=O)N(C)C(=O)N45C(=O)C[C@H](C45)C(=O)N(C)C(=O)N46C(=O)C[C@H](C46)C(=O)N(C)C(=O)N47C(=O)C[C@H](C47)C(=O)N(C)C(=O)N48C(=O)C[C@H](C48)C(=O)N(C)C(=O)N49C(=O)C[C@H](C49)C(=O)N(C)C(=O)N50C(=O)C[C@H](C50)C(=O)N(C)C(=O)N51C(=O)C[C@H](C51)C(=O)N(C)C(=O)N52C(=O)C[C@H](C52)C(=O)N(C)C(=O)N53C(=O)C[C@H](C53)C(=O)N(C)C(=O)N54C(=O)C[C@H](C54)C(=O)N(C)C(=O)N55C(=O)C[C@H](C55)C(=O)N(C)C(=O)N56C(=O)C[C@H](C56)C(=O)N(C)C(=O)N57C(=O)C[C@H](C57)C(=O)N(C)C(=O)N58C(=O)C[C@H](C58)C(=O)N(C)C(=O)N59C(=O)C[C@H](C59)C(=O)N(C)C(=O)N60C(=O)C[C@H](C60)C(=O)N(C)C(=O)N61C(=O)C[C@H](C61)C(=O)N(C)C(=O)N62C(=O)C[C@H](C62)C(=O)N(C)C(=O)N63C(=O)C[C@H](C63)C(=O)N(C)C(=O)N64C(=O)C[C@H](C64)C(=O)N(C)C(=O)N65C(=O)C[C@H](C65)C(=O)N(C)C(=O)N66C(=O)C[C@H](C66)C(=O)N(C)C(=O)N67C(=O)C[C@H](C67)C(=O)N(C)C(=O)N68C(=O)C[C@H](C68)C(=O)N(C)C(=O)N69C(=O)C[C@H](C69)C(=O)N(C)C(=O)N70C(=O)C[C@H](C70)C(=O)N(C)C(=O)N71C(=O)C[C@H](C71)C(=O)N(C)C(=O)N72C(=O)C[C@H](C72)C(=O)N(C)C(=O)N73C(=O)C[C@H](C73)C(=O)N(C)C(=O)N74C(=O)C[C@H](C74)C(=O)N(C)C(=O)N75C(=O)C[C@H](C75)C(=O)N(C)C(=O)N76C(=O)C[C@H](C76)C(=O)N(C)C(=O)N77C(=O)C[C@H](C77)C(=O)N(C)C(=O)N78C(=O)C[C@H](C78)C(=O)N(C)C(=O)N79C(=O)C[C@H](C79)C(=O)N(C)C(=O)N80C(=O)C[C@H](C80)C(=O)N(C)C(=O)N81C(=O)C[C@H](C81)C(=O)N(C)C(=O)N82C(=O)C[C@H](C82)C(=O)N(C)C(=O)N83C(=O)C[C@H](C83)C(=O)N(C)C(=O)N84C(=O)C[C@H](C84)C(=O)N(C)C(=O)N85C(=O)C[C@H](C85)C(=O)N(C)C(=O)N86C(=O)C[C@H](C86)C(=O)N(C)C(=O)N87C(=O)C[C@H](C87)C(=O)N(C)C(=O)N88C(=O)C[C@H](C88)C(=O)N(C)C(=O)N89C(=O)C[C@H](C89)C(=O)N(C)C(=O)N90C(=O)C[C@H](C90)C(=O)N(C)C(=O)N91C(=O)C[C@H](C91)C(=O)N(C)C(=O)N92C(=O)C[C@H](C92)C(=O)N(C)C(=O)N93C(=O)C[C@H](C93)C(=O)N(C)C(=O)N94C(=O)C[C@H](C94)C(=O)N(C)C(=O)N95C(=O)C[C@H](C95)C(=O)N(C)C(=O)N96C(=O)C[C@H](C96)C(=O)N(C)C(=O)N97C(=O)C[C@H](C97)C(=O)N(C)C(=O)N98C(=O)C[C@H](C98)C(=O)N(C)C(=O)N99C(=O)C[C@H](C99)C(=O)N(C)C(=O)N100C(=O)C[C@H](C100)C(=O)N(C)C(=O)N101C(=O)C[C@H](C101)C(=O)N(C)C(=O)N102C(=O)C[C@H](C102)C(=O)N(C)C(=O)N103C(=O)C[C@H](C103)C(=O)N(C)C(=O)N104C(=O)C[C@H](C104)C(=O)N(C)C(=O)N105C(=O)C[C@H](C105)C(=O)N(C)C(=O)N106C(=O)C[C@H](C106)C(=O)N(C)C(=O)N107C(=O)C[C@H](C107)C(=O)N(C)C(=O)N108C(=O)C[C@H](C108)C(=O)N(C)C(=O)N109C(=O)C[C@H](C109)C(=O)N(C)C(=O)N110C(=O)C[C@H](C110)C(=O)N(C)C(=O)N111C(=O)C[C@H](C111)C(=O)N(C)C(=O)N112C(=O)C[C@H](C112)C(=O)N(C)C(=O)N113C(=O)C[C@H](C113)C(=O)N(C)C(=O)N114C(=O)C[C@H](C114)C(=O)N(C)C(=O)N115C(=O)C[C@H](C115)C(=O)N(C)C(=O)N116C(=O)C[C@H](C116)C(=O)N(C)C(=O)N117C(=O)C[C@H](C117)C(=O)N(C)C(=O)N118C(=O)C[C@H](C118)C(=O)N(C)C(=O)N119C(=O)C[C@H](C119)C(=O)N(C)C(=O)N120C(=O)C[C@H](C120)C(=O)N(C)C(=O)N121C(=O)C[C@H](C121)C(=O)N(C)C(=O)N122C(=O)C[C@H](C122)C(=O)N(C)C(=O)N123C(=O)C[C@H](C123)C(=O)N(C)C(=O)N124C(=O)C[C@H](C124)C(=O)N(C)C(=O)N125C(=O)C[C@H](C125)C(=O)N(C)C(=O)N126C(=O)C[C@H](C126)C(=O)N(C)C(=O)N127C(=O)C[C@H](C127)C(=O)N(C)C(=O)N128C(=O)C[C@H](C128)C(=O)N(C)C(=O)N129C(=O)C[C@H](C129)C(=O)N(C)C(=O)N130C(=O)C[C@H](C130)C(=O)N(C)C(=O)N131C(=O)C[C@H](C131)C(=O)N(C)C(=O)N132C(=O)C[C@H](C132)C(=O)N(C)C(=O)N133C(=O)C[C@H](C133)C(=O)N(C)C(=O)N134C(=O)C[C@H](C134)C(=O)N(C)C(=O)N135C(=O)C[C@H](C135)C(=O)N(C)C(=O)N136C(=O)C[C@H](C136)C(=O)N(C)C(=O)N137C(=O)C[C@H](C1


M183-2

150

4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-({1-[(cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propyl}-amide)-2-[(1-phenylmethanesulfonylaminocarbonyl-2-vinyl-cyclopropyl)-amide] (132)

- 5 To solution of 92 (8.7 mg, 0.011 mmol) in chloroform (1ml) was added α -toluenesulfonamide (7 mg, 0.04 mmol) followed by diisopropylethylamine (21 μ L, 0.12 mmol). The solution was stirred at RT for 10 min and then at -20 °C for 30 min. PyBOP (46.5 mg, 0.08 mmol) was then added as a solid. The solution was kept at -20 °C for 48 hours. The solution was then poured into aqueous NaHCO₃ (sat.) and
- 10 washed with water. The organic layer was dried, concentrated and subjected to purification by HPLC, affording the title compound as a white solid (2.8 mg, 0.0049 mmol), Purity by HPLC > 95%, M+H⁺ 936.26.

Example 133



15

N-(2-Hydroxy-indan-1-yl)-2-[4-(6-methoxy-3-phenyl-naphthalen-1-yloxy)-2-(1-methanesulfonylaminocarbonyl-2-vinyl-cyclopropyl)-pyrrolidin-1-yl]-3,3-dimethyl-butylamide (133)


20

The title compound was prepared as described in example 132, using 64 as carboxylic acid starting material and methanesulfonamide instead of α -toluenesulfonamide. Yield 13%, Purity by HPLC > 95%, M+H⁺ 839.16.

Example 134

M183-2

151




4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-[[1-(cyclohexylmethyl-carbamoyl)-2-methyl-propyl]-amide] 2-[(1-phenylmethanesulfonylaminocarbonyl-2-vinyl-cyclopropyl)-amide] (134)

5

The title compound was prepared as described in example 132, using 73 as carboxylic acid starting material. Yield 2%. Purity > 95% by HPLC. $M+H^+$ 865.28.

10 Example 135



4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentane-1,2-dicarboxylic acid 1-[[1-(cyclohexylmethyl-carbamoyl)-2-methyl-propyl]-amide] 2-[(1-phenylmethanesulfonylaminocarbonyl-2-vinyl-cyclopropyl)-amide] (135)


15

N-(tert-Butoxycarbonyl)-L-valine was attached to Argonaut resin PS-TFP as described in example 66 followed by reaction with cyclohexanemethylamine as described in example 67 and removal of the Boc group as described in example 68. The afforded amine was used in a coupling reaction with compound 35 as described

M183-2


152

in example 39 followed by hydrolysis of the ethyl ester as described in example 40 which gave 1-[[2-[1-(cyclohexylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid. Reaction of this acid with α -toluenesulphonamide as
 5 described in example 132 gave the title compound. Yield 6%. Purity > 95% by HPLC. $M+H^+$ 864.32.

Example 136

10 4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-[[1-(cyclohexylmethyl-carbamoyl)-2-methyl-propyl]-amide] 2-[(1-phenylmethanesulfonylaminocarbonyl-butyl)-amide] (136)

The title compound was prepared as described in example 132, using 108 as
 15 carboxylic acid starting material. Yield 8%. Purity > 95% by HPLC. $M+H^+$ 855.28.

Example 137


M183-2

153

4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 2-[(1-benzenesulfonylaminocarbonyl-butyl)-amide] 1-[[1-(cyclohexylmethyl-carbamoyl)-2-methyl-propyl]-amide] (137)

- 5 The title compound was prepared as described in example 132, using 108 as carboxylic acid starting material and benzensulphonamide instead of α -toluenesulfonamide. Yield 21.5%. Purity > 95% by HPLC. $M+H^+$ 841.28.

Example 138



10


4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 2-[(1-benzenesulfonylaminocarbonyl-2-vinyl-cyclopropyl)-amide] 1-({1-[(cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propyl}-amide) (138)

- 15 The title compound was prepared as described in example 132, using benzenesulfonamide instead of α -toluenesulfonamide. Yield 26 %. Purity by HPLC > 95 %, $M+H^+$ 922.23.

Example 139

M183-2

154




4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 2-[(1-benzenesulfonylaminocarbonyl-butyl)-amide] 1-[[1-(2-hydroxy-indan-1-ylcarbamoyl)-2-methyl-propyl]-amide} (139)

5

To a solution of 129 (24.1 mg, 0.04 mmol) in DCM (2 ml), was added a large excess of NaHCO_3 (s) and a solution of phosgene in toluene (50 μL , 0.096 mmol). After 10 min of agitation the slurry was filtered and concentrated to dryness. The solid was redissolved in DCM and a large excess of NaHCO_3 (s) and 2-amino-*N*-(2-hydroxy-indan-1-yl)-3-methyl-butyramide, described in example 85, (0.1 mmol) was added. The slurry was agitated for 40 hrs at RT. The slurry was filtered, concentrated and subjected to HPLC purification, to give the title compound (1.6 mg, 0.0018 mmol). Purity > 95% by HPLC. $\text{M}+\text{H}^+$ 877.21.

15 Example 140



M183-2


155

4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 2-[(1-benzenesulfonylaminocarbonyl-butyl)-amide] 1-({1-[(cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propyl)-amide) (140)

- 5 The title compound was prepared as described in example 139 but using 71 instead of 2-amino-N-(2-hydroxy-indan-1-yl)-3-methyl-butyramide. Yield 2%. Purity > 95% by HPLC. $M+H^+$ 912.25.

Example 141

10



(1R,2S)-1-(((4R,2S)-1-(1-(1S)-Hydroxymethyl-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl)-amino)-2-vinyl-cyclopropanecarboxylic acid ethyl ester (141)

15


Treatment of compound 62 as described for the preparation 63 but with the use of (S)-tert-leucinol instead of 2-amino-N-(2-hydroxy-indan-1-yl) 3,3-dimethyl-butyramide provided the title product. $M+H^+$ 645.2.

20

Example 142

M183-2

156




(1R,2S)-1-[[[(4R,2S)-1-(1-(1S)-Formyl-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (142)

5

To a stirred solution of compound 141 (64 mg) in dichloromethane Dess-Martin periodinane (80 mg) was added at ambient temperature. After 4 hrs the slurry was filtered through basic alumina and concentrated to dryness. $M+H^+$ 643.2.

10 Example 143




(1R,2S)-1-[[[(4R,2S)-1-{1-[[[(1S,2R)-2-Hydroxy-indan-1-ylamino]-methyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (143)

15

To a solution of compound 142 in THF (2 ml) and HOAc (0.5 mL) polystyrene bound cyanoborohydride (2.36 mmol/g, 100 mg) and (1S,2R)-1-aminoindan-2-ol (18 mg) was added and agitated for 4 hrs. The mixture was filtered, concentrated and purified on a prep. HPLC. Purity by HPLC >90%. $M+H^+$ 776.5

M183-2


157

Example 144

5 (1R,2S)-1-[[[(4R,2S)-1-{1-[[[(1S,2R)-2-Hydroxy-indan-1-ylamino)-methyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (144)

To a solution of compound 143 in THF (2 mL) and MeOH (1 mL) 1N LiOH (0.2 mL) was added and the solution was kept at 60 °C for 1.5 hrs. The slurry was neutralized with 1N HCl to pH 7, concentrated and purified on a prep. HPLC giving pure product by HPLC >95%. M+H⁺ 748.4.

10

Example 145


15 (1R,2S)-1-[[[(4R,2S)-1-(1-[[[(1S)-(Cyclohexyl-methylcarbamoyl-methyl)-amino]-methyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (145)

M183-2

158

Treatment of compound 142 as described for the preparation of 143 but with the use of 2-amino-2-cyclohexyl-N-methyl-acetamide (17 mg) instead of (1S,2R)-1-aminoindan-2-ol followed by hydrolysis of the ethyl ester as described in example 144 provided the title product. Purity by HPLC >95%. M+H⁺ 769.5


5

Example 146

Acetic acid (1S,2R)-1-((2S)-2-amino-3,3-dimethyl-butylamino)-indan-2-yl ester
(146)

A solution of compound 67 (4g) was kept in pyridine-acetic anhydride 2:1 for 30 min. DCM was added and the solution was washed with citric acid (aq) and NaHCO₃ (aq). The organic layer was concentrated to dryness which gave the acetylated product >90% pure by HPLC. The afforded compound was then kept in a solution of 30% TFA in DCM for 1.5 hrs and then concentrated to dryness. Co-evaporation twice from toluene gave the title product >90% pure by HPLC.

15

Example 147

20

(2S,4R)-2-((1S,2R)-1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-hydroxy-pyrrolidine-1-carboxylic acid tert.butyl ester (147)


M183-2

159

A solution of HATU (6 g), diisopropylethylamine (6.8 mL), (1R,2S)-1-amino-2-vinyl-cyclopropanecarboxylic acid ethyl ester (1.5 g) and BOC-L-hydroxyproline (1.6 g) in dichloromethane was stirred for 1 hrs. The mixture was extracted with DCM-NaHCO₃ (aq) dried and concentrated. HPLC purity ca 90% M+H⁺ 369.1.

5

Example 148



(1S,2R)-1-[(2S,4R)-(4-Hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (148).


10

Compound 147 was kept in 30% trifluoroacetic acid in dichloromethane and 1% MeOH for 2 hrs before it was concentrated to dryness. The residue was re-dissolved in dichloromethane and during stirring 1N NaOH was added to pH 10-11. The organic layer was separated and concentrated which gave 1.6 g of the title product.

15

HPLC purity ca. 90% M+H⁺ 269.1.

Example 149



(1R,2S)-1-(((2S,4R)-1-[(1S)-1-((1S,2R)-2-Acetoxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-4-hydroxy-pyrrolidine-2-carbonyl)-amino)-2-vinyl-cyclopropanecarboxylic acid ethyl ester (149).


20

M183-2

160

To a stirred solution of compound 146 (1.81 g) in acetonitrile at 0 °C solid NaHCO_3 (800 mg) and p-nitrophenylchlorocarbonate (1.2 g) was added. The slurry was taken up to ambient temperature and stirred for another 30 min. To this slurry a solution of compound 148 (1.6 g) in acetonitrile (5 mL) diisopropylethylamine (1mL) was added.
 5 After 10 min the resulting mixture was concentrated, re-dissolved in ethyl acetate and washed with K_2CO_3 (aq) and then with 0.5 N HCl. Dried and concentrated which gave a >80% pure product by HPLC $\text{M}+\text{H}^+$ 599.6

Example 150




10 (1R,2S)-1-(((2S,4R)-1-((1)-1-((1S,2R)-2-Acetoxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-4-phenylcarbamoyloxy-pyrrolidine-2-carbonyl)-amino)-2-vinyl-cyclopropanecarboxylic acid ethyl ester (150)

15 To a stirred solution of compound 149 (20mg) in DCM and solid K_2CO_3 (200 mg) 20% phosgene in toluene (1 mL) was added. After 6 hrs the slurry was filtered and concentrated to dryness. To this residue a mixture of aniline (30 mg) DCM (3 mL) and solid NaHCO_3 (50 mg) was added and agitated for 10 hrs. The mixture was filtered, concentrated and purified on a prep. HPLC which gave the title product,
 20 >95% pure $\text{M}+\text{H}^+$ 718.6.

Example 151

M183-2

161




(1R,2S)-1-(((2S,4R)-1-[1-((1S,2R)-2-Hydroxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-4-phenylcarbamoyloxy-pyrrolidine-2-carbonyl)-amino)-2-vinyl-cyclopropanecarboxylic acid (151)

5

To a solution of compound 150 in THF-MeOH 2:1 (3 mL) was added 1N LiOH (0.2 mL). The solution was heated to 60 °C for 2 hrs. After cooling to ambient temperature acetic acid (0.5 mL) was added and the solution was concentrated to dryness. The remaining residue was purified on a prep. HPLC which gave the title product >95% pure M+H+ 648.5.

10

Example 152



(5S,3R)-3,4-Dihydro-1H-isoquinoline-2-carboxylic acid 5-(((1R,2S)-1-carboxy-2-vinyl-cyclopropylcarbamoyl)-1-[1-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-pyrrolidin-3-yl ester (152)

15

Treatment of compound 149 as described for the preparation of 150 but with the use of 1,2,3,4-tetrahydro-isoquinoline instead of aniline followed by hydrolysis of the ethyl


M183-2

162

ester as described in example 151 gave the title compound. Purity >90%. $M+H^+$ 688.6.

Example 153


5



10 (5S,3R)-3,4-Dihydro-2H-quinoline-1-carboxylic acid 5-((1R,2S)-1-carboxy-2-vinylcyclopropylcarbamoyl)-1-[1-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-2,2-dimethylpropylcarbamoyl]-pyrrolidin-3-yl ester (153)

15 Treatment of compound 149 as described for the preparation of 150 but with the use of 1,2,3,4-tetrahydro-quinoline instead of aniline followed by hydrolysis of the ethyl ester as described in example 151 gave the title compound. Purity >90%. $M+H^+$ 688.6.

Example 154




M183-2

163

(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-[(1S,2R)-2-Hydroxy-indan-1-ylcarbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(pyridin-3-ylmethylcarbamoyloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (154)

- 5 Treatment of compound 149 as described for the preparation of 150 but with the use of 2-pyridine-3-yl-ethylamine instead of aniline followed by hydrolysis of the ethyl ester as described in example 151 gave the title compound. Purity >90%. $M+H^+$ 663.5.

10 Example 155



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-[(1S,2R)-2-Hydroxy-indan-1-ylcarbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(methyl-phenethyl-carbamoyloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (155)


15

Treatment of compound 149 as described for the preparation of 150 but with the use of N-methylphenethylamine instead of aniline followed by hydrolysis of the ethyl ester as described in example 151 gave the title compound. Purity >90%. $M+H^+$ 690.6.

20 Example 156

M183-2

164




(1R,2S)-1-(((2S,4R)-4-Benzylcarbamoyloxy-1-((1S)-1-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-pyrrolidine-2-carbonyl)-amino)-2-vinyl-cyclopropanecarboxylic acid (156)

5

Treatment of compound 149 as described for the preparation of 150 but with the use of benzylamine instead of aniline followed by hydrolysis of the ethyl ester as described in example 151 gave the title compound. Purity >90%. $M+H^+$ 662.4.

10 Example 157




(1R,2S)-1-(((2S,4R)-1-((1S)-1-((1S,2R)-2-Hydroxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-4-phenethylcarbamoyloxy-pyrrolidine-2-carbonyl)-amino)-2-vinyl-cyclopropanecarboxylic acid (157)

15

Treatment of compound 149 as described for the preparation of 150 but with the use of phenethylamine instead of aniline followed by hydrolysis of the ethyl ester as described in example 151 gave the title compound. Purity >90%. $M+H^+$ 676.5.

M183-2


165

Example 158

5 (1R,2S)-1-(((4R)-1-([2-(*tert*-butoxycarbonyl)hydrazino]carbonyl)-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl)amino)-2-vinylcyclopropanecarboxylic acid ethyl ester (158)

To a solution of *tert*-butyl carbazate (0.3 mmol) and *p*-nitro phenyl chloroformate (0.3 mmol) in acetonitrile (6 ml) was added sodium hydrogen carbonate (0.48 mmol) as
10 solid. The solution was stirred at RT for 5 hrs and then cooled down to 0 °C. Compound 62 (0.3 mmol) dissolved in acetonitrile (10 mL) was mixed together with diisopropylethylamine (0.75 mmol) at 0 °C, and then added to the previous solution. The mixture was stirred at RT overnight and then concentrated to dryness. The
15 residue was dissolved in DCM and then washed with citric acid pH 4, followed by NaHCO₃ (aq) and water, dried over anhydrous sodium sulphate, filtrated and concentrated to dryness. The crude was dissolved in DCM and purified by column chromatography eluted with 0.1 to 0.2% MeOH/DCM to yield the title compound (101 mg). Purity >95% by HPLC, M+H⁺ 660.1.

20 Example 159



M183-2


166

(1*R*,2*S*)-1-(((4*R*)-1-[[2-(*tert*-butoxycarbonyl)hydrazino]carbonyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl)amino)-2-vinylcyclopropanecarboxylic acid (159)

Method A: To a solution of compound 158 (0.0115 mmol) in THF-MeOH 2:3 (2 ml) was added 1M LiOH (10 equiv) The solution was kept at 50 °C for 60 min. After cooling to RT, HOAc (20 equiv) was added followed by toluene (2 ml) and then concentrated to dryness. The residue was taken up in MeOH and then purified by Prep LCMS which gave the title compound (0.7 mg). Purity >95% by HPLC M+H⁺ 732.2.

Method B: To a solution of *tert*-butyl carbazate (0.07 mmol) and p-nitrophenyl chloroformate (0.07 mmol) in acetonitrile (3 ml) was added sodium hydrogen carbonate (0.112 mmol) as a solid. The solution was stirred at RT for 2.5 hrs and then cooled to 0 °C. Compound 160 (described below) (0.07 mmol) dissolved in acetonitrile (10 ml) was mixed together with diisopropylethylamine (0.175 mmol) at 0 °C, and then added to the previous solution. The mixture was stirred at RT overnight and then concentrated to dryness. The crude material was dissolved in MeOH and purified by Prep LCMS which gave the title compound (4.8 mg). Purity >95% by HPLC M+H⁺ 632.2

Example 160



(1*R*,2*S*)-1-[[[(2*S*,4*R*)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (160)


To a solution of compound 62 (0.067mmol) in THF-MeOH 2:3 (2 ml) was added 1M LiOH 10 equiv. The solution was kept at 50 °C for 2.5 hrs. After cooling to RT, HOAc

M183-2

167

20 equiv. was added followed by toluene (2 ml) and then concentrated to dryness. The residue was taken up in DCM and filtered from the salts which gave the title compound (0.07 mmol). Purity >95% by HPLC M+H⁺ 474.

5 Example 161




(1*R*,2*S*)-1-(((4*R*)-1-(hydrazinocarbonyl)-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl)amino)-2-vinylcyclopropanecarboxylic acid (161)

10

Compound (159) from above was kept in TFA-DCM 1:2 (3 ml) at RT for 60 min. Toluene (1 ml) was added. The sample was co-evaporated to dryness which gave the title compound (10.5 mg) as the trifluoroacetic acid salt. Purity by HPLC >95%. M+H⁺532.

15

Example 162



(1*R*,2*S*)-1-(((4*R*)-1-(hydrazinocarbonyl)-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl)amino)-2-vinylcyclopropanecarboxylic acid ethyl ester (162)


20

M183-2

168

Compound 158 (50 mg) was kept in TFA-DCM 1:2 (3 ml) at RT for 60 min. Toluene (1 ml) was added. The sample was co-evaporated to dryness and then taken up in DCM and washed with K_2CO_3 , dried over anhydrous sodium sulphate and concentrated to dryness which gave the title compound (41.8 mg). Purity by HPLC
5 >95%. $M+H^+$ 560.

Example 163



10 (1*R*,2*S*)-1-(((4*R*)-1-[(2-Benzylhydrazino)carbonyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolyl)amino)-2-vinylcyclopropanecarboxylic acid ethyl ester (163)


To a solution of compound 162 (0.037mmol) in MeOH:THF (4:1) was added benzaldehyde (0.0448 mmol). The solution was stirred at RT for 18 hrs. Borane-pyridine complex (0.37 mmol) was added followed by HCl (37%, 400 μ l). The
15 solution was stirred for 1.5 hrs and then filtrated and concentrated to dryness. The crude material was dissolved in MeOH and purified by Prep LCMS which gave the title compound (0.01 mmol). Purity by HPLC >95%. $M+H^+$ 650.

20 Example 164

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

M183-2


169




(1R,2S)-1-((4R)-1-((2-benzylhydrazino)carbonyl)-4-((7-methoxy-2-phenylquinolin-4-yl)oxy)-L-prolyl)amino)-2-vinylcyclopropanecarboxylic acid (164)

- 5 To a solution compound 163 (0.0101 mmol) in THF-MeOH 2:3 (3 ml) was added 1M LiOH 10 equiv. The solution was kept at 50 °C for 18 hrs. After cooling to RT the sample was neutralized with HCl and concentrated to dryness. The crude material was dissolved in DCM (2 ml) and a solution of TFA: TES 1:1 (1 ml) was added. The mixture was stirred for 3 hrs at RT and then concentrated to dryness. The crude
- 10 material was dissolved in MeOH and purified by Prep LCMS which gave the title compound (0.6 mg). Purity by HPLC >95%. M+H⁺ 622.

Example 165



- 15 (1R, 2S)-1-(((2S, 4R)-1-((1S)-1-Azidomethyl-3-methyl-butylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino)-2-vinylcyclopropanecarboxylic acid ethyl ester (165)




- 20 i) (2S)-Methanesulphonic acid 2-tert.butoxycarbonylamino-4-methyl-pentyl ester

M183-2

170


To a solution of ((1S)-1-hydroxymethyl-3-methyl-butyl)-carbamic acid tert-butyl ester (25 g, 115 mmol) in dichloromethane (500 ml) cooled by an ice-water bath was successively added diisopropylethylamine (35.7 g, 276 mmol) and methanesulphonyl chloride (15.81 g, 138 mmol). The resulting solution was stirred over night during
5 which time the mixture was allowed to gradually warm up to ambient temperature. The mixture was washed successively with water, 10 % citric acid (aq), water and saturated NaHCO₃ (aq), then dried with Na₂SO₄ and concentrated to a brown solid (32.6 g, 96 %) which was used in the next reaction without further purification.



10

ii) ((1S)-1-Azidomethyl-3-methyl-butyl)-carbamic acid tert.butyl ester

The mesylate from step i (32.6 g, 110 mmol) was treated with sodium azide (21.45 g, 330 mmol) in DMF at 80 °C for 24 hrs. The solvent was evaporated, the residue was
15 taken up in DCM, filtered and washed with saturated NaHCO₃ (aq). The solution was dried with Na₂SO₄ and concentrated to a brown oil which was purified by flash chromatography using a gradient of ethyl acetate and hexane to afford the title compound as a white solid (19.55 g, 73 %).



20

iii) (1S)-1-Azidomethyl-3-methyl-butylamine

((1S)-1-Azidomethyl-3-methyl-butyl)-carbamic acid tert-butyl ester (9.64 g, 39.78 mmol) was treated with TFA (30 ml) in DCM (150 ml) for 3 hrs, the mixture was
25 evaporated under reduced pressure and the residue was dissolved in ethyl acetate and washed with aqueous 1 M K₂CO₃, dried with Na₂SO₄ and concentrated to a yellow liquid (4.55 g, 80 %).

M183-2

171


Compound 62 was treated with phosgene as described in example 63 which gave the corresponding chlorocarbamate compound. The afforded chlorocarbamate (568 mg, 1.13 mmol) was dissolved in a solution of DCM-THF (1:1, 10 ml) and (1S)-1-azidomethyl-3-methyl-butylamine (401 mg, 2.82 mmol) and a large excess of

5 NaHCO₃ (s) was added. The resulting mixture was stirred for 18 hrs, filtered and washed with dilute citric acid (aq, pH 5). The organic layer was dried with Na₂SO₄ and evaporated to afford the desired product as a light yellow oil (837 mg, 99 %) sufficiently pure to be used in the next step.

M+H⁺ 670.1.

10

Example 166



(1R, 2S)-1-[[[(2S, 4R)-1-((1S)-1-Aminomethyl-3-methyl-butylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (166)

15

A solution of 165 (717 mg, 1.07 mmol) in THF (25 ml) was shaken together with PS-triphenylphosphine resin (diphenylphosphino polystyrene) (3.24 g, 1.65 mmol PPh₃/g) and methanol (2.5 ml) for 78 hrs. The mixture was filtered and the polymer

20 was washed repeatedly with DCM and methanol. The combined filtrates were evaporated to yield the title compound as a light beige solid foam (685 mg, 99 %) with more than 95 % purity as determined by reversed phase HPLC. M+H⁺ 644.1.

General procedure 1A for the preparation of compounds 167-173

25

To a solution of the acyl chloride (0.075 mmol) in DCM (0.5 ml) was added NaHCO₃ (s) (60 mg, 07 mmol) and a solution of the amine 167 (25 mg, 0.037 mmol) in THF (1 ml). The resulting mixture was stirred at room temperature over night , filtered and

M183-2


172

then shaken in the presence of PS-trisamine resin (tris-(2-aminoethyl) aminomethyl polystyrene) (3.91 mmol/ g, 50 mg, 0.2 mmol) for 5 hrs. The mixture was filtered and evaporated. The resulting solid residue was dissolved in MeOH-THF (2:1, 1.5 ml) and treated with 1 M LiOH (aq) (170 μ l) at 50 °C between 2 and 16 hrs. The reaction
 5 was monitored by HPLC-MS. The mixture was acidified with acetic acid and evaporated to dryness. The residue was dissolved in methanol and purified by reversed phase HPLC.

General procedure 1B for the preparation of compounds 167-173

10 To the acid (0.039 mmol) was successively added a solution of HATU (14.7 mg, 0.039 mmol) in DMF (0.5 ml), a solution of the amine 166 (20 mg, 0.031 mmol) in DMF (0.5 ml) and diisopropylethylamine (30 μ l, 0.155 mmol). The resulting mixture was stirred for 16 hrs then the solvent was evaporated and the residue was dissolved in DCM and washed with water and aqueous saturated NaHCO₃. The
 15 solvent was evaporated and the residue was dissolved in methanol-THF (2:1, 1.5 ml). To this was added 1 M LiOH (aq) (155 μ l) and the mixture was stirred at 60 °C for 3-5 hrs. Glacial acetic acid (50 μ l) was added and the mixture was concentrated, dissolved in methanol and purified by reversed phase HPLC.

20 Example 167




(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(3-Fluoro-benzoylamino)-methyl]-3-methylbutylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (167)
 25

M183-2

173

General procedure 1A was followed using 3-fluorobenzoyl chloride (12 mg) as acyl chloride which gave the title compound as a solid (13.6 mg, 50 %). $M+H^+$ 738.1.

Example 168




5

(1R, 2S)-1-[[[(2S, 4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-1-((1S)-3-methyl-1-[[[(pyridine-3-carbonyl)-amino]-methyl]-butylcarbamoyl]-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (168)

- 10 General procedure 1A was followed using nicotinoyl chloride (10.5 mg) as acyl chloride which gave the title compound as a solid (10 mg, 37 %). $M+H^+$ 721.1.

Example 169




- 15 (1R, 2S)-1-[[[(2S, 4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-1-((1S)-3-methyl-1-[[[(pyrazine-2-carbonyl)-amino]-methyl]-butylcarbamoyl]-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (169)

- 20 General procedure 1B was followed using pyrazine-2-carboxylic acid (5 mg) as acid which gave the title compound as a solid (5.7 mg, 25 %). $M+H^+$ 722.1.

Example 170

M183-2


174



(1R, 2S)-1-[[[(2S, 4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-1-((1S)-3-methyl-1-
 5 {[(thiophene-3-carbonyl)-amino]-methyl]-butylcarbamoyl)-pyrrolidine-2-carbonyl]-
 amino]-2-vinyl-cyclopropanecarboxylic acid (170)

General procedure 1A was followed using thiophene-3-carbonyl chloride (11 mg) which gave the title compound as a solid (4.3 mg, 16 %). $M+H^+$ 726.1.


10 Example 171



(1R, 2S)-1-[[[(2S, 4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-1-((1S)-3-methyl-1-
 15 {[(tetrahydro-furan-2-carbonyl)-amino]-methyl]-butylcarbamoyl)-pyrrolidine-2-
 carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (171)

General procedure 1B was followed using tetrahydrofuran-2-carboxylic acid (4.5 mg) as acid which gave the title compound as a solid (7.9 mg, 36 %). $M+H^+$ 714.1.

Example 172



20

M183-2


175

(1R, 2S)-1-[[[(2S, 4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-1-((1S)-3-methyl-1-[[[(5-phenyl-oxazole-4-carbonyl)-amino]-methyl]-butylcarbamoyl)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (172)

5

General procedure 1B was followed using 5-phenyl-oxazole-4-carboxylic acid (7.5 mg) as acid which gave the title compound as a solid (7.5 mg, 31 %). $M+H^+$ 787.1.

Example 173



10

(1R, 2S)-1-[[[(2S, 4R)-1-((1S)-1-[[[(Benzofuran-2-carbonyl)-amino]-methyl]-3-methyl-butylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (173)

15

General procedure 1B was followed using benzofuran-2-carboxylic acid (6.5 mg) as acid which gave the title compound as a solid (5.4 mg, 23 %). $M+H^+$ 760.1.

General procedure 2 for the preparation of compounds 174-176

20 To a solution of the sulphonyl chloride (0.075 mmol) in DCM (0.5 ml) was added NaHCO_3 (s) (60 mg) and a solution of the amine 166 (25 mg, 0.037 mmol) in THF (1 ml). The resulting mixture was stirred at room temperature for 18 hrs, filtered and then shaken with PS-trisamine (tris-(2-aminoethyl)aminomethyl polystyrene, 3.91 mmol/ g, ~50 mg) for 5 hrs.


25 The mixture was filtered and the polymer was washed successively with DCM, THF and methanol. The solid residue resulting from evaporation of the combined filtrates was dissolved in MeOH-THF (2:1, 1.5 ml) and treated with 1 M LiOH (aq) (170 μl) at 50 °C for reaction times varying from 18 hrs to one week depending on the actual

M183-2

176

structure. The reaction was monitored by HPLC-MS. The mixture was acidified with acetic acid and evaporated to dryness. The residue was dissolved in methanol and purified by reversed phase HPLC.

5 Example 174




(1R, 2S)-1-(((2S, 4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-1-((1S)-3-methyl-1-(phenylmethanesulphonylamino-methyl)-butylcarbamoyl]-pyrrolidine-2-carbonyl)-amino)-2-vinyl-cyclopropanecarboxylic acid (174)

General procedure 2 was followed using α -toluenesulphonyl chloride (14 mg) as sulphonyl chloride which gave the title compound as a white solid (4.9 mg, 17 %). $M+H^+$ 770.1.

15

Example 175



(1R, 2S)-1-(((2S, 4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-1-((1S)-3-methyl-1-[[5-methyl-isoxazole-4-sulphonylamino)-methyl]-butylcarbamoyl]-pyrrolidine-2-carbonyl)-amino)-2-vinyl-cyclopropanecarboxylic acid (175)


20

M183-2

177

General procedure 2 was followed using 5-methyl-isoxazole-4-sulphonyl chloride (14 mg) as sulphonyl chloride which gave the title compound as a white solid (1.6 mg, 6 %). $M+H^+$ 761.0.

5 Example 176



- 10 (1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(5-isoxazol-3-yl-thiophene-2-sulphonylamino)-methyl]-3-methyl-butylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (176)

- 15 General procedure 2 was followed using 5-isoxazol-3-yl-thiophene-2-sulphonyl chloride (19 mg) as sulphonyl chloride which gave the title compound as a white solid (3.0 mg, 10 %). $M+H^+$ 828.98.

20 Assays

20

The compounds of the invention are conveniently assayed for activity against the NS3 protease of flavivirus such as HCV using conventional in vitro (enzyme) assays or cell culture assays.

25

A useful assay is the Bartenshlager replicon assay disclosed in EP 1043399. An alternative replicon assay is described in WO 03064416.

A convenient enzyme assay involving the inhibition of full-length hepatitis C NS3 is essentially as described in Poliakov, 2002 Prot Expression & Purification 25 363 371. Briefly, the hydrolysis of a depsipeptide substrate, Ac-DED(Edans)EEAbu ψ [COO]ASK(Dabcyl)-NH₂ (AnaSpec, San José, USA), is
5 measured spectrofluorometrically in the presence of a peptide cofactor, KKGSVVIVGRIVLSGK, as described by Landro, 1997 Biochem 36 9340-9348. The enzyme (1 nM) is incubated in a buffer such as 50 mM HEPES, pH 7.5, 10 mM DTT, 40% glycerol, 0.1% n-octyl- β -D-glucoside, with 25 μ M cofactor and inhibitor at say 30 °C for 10 min, whereupon the reaction is initiated by addition of substrate, typically
10 0.5 μ M substrate. Inhibitors are typically dissolved in DMSO, sonicated for 30 s and vortexed. The solutions are generally stored at -20°C between measurements.

An alternative enzyme assay is described in WO 0399316 and employs an HCV NS3/4A protease complex FRET peptide assay. The purpose of this in vitro assay is
15 to measure the inhibition of HCV NS3 protease complexes, derived from the BMS, H77C or J416S strains, as described below, by compounds of the present invention. This assay provides an indication of how effective compounds of the present invention would be in inhibiting HCV proteolytic activity.

20 Serum is taken from an HCV-infected patient. An engineered full-length cDNA template of the HCV genome (BMS strain) was constructed from DNA fragments obtained by reverse transcription-PCR (RT-PCR) of serum RNA and using primers selected on the basis of homology between other genotype 1a strains. From the determination of the entire genome sequence, a genotype 1a was assigned to the
25 HCV isolate according to the classification of Simmonds et al. (See P Simmonds, KA Rose, S Graham, SW Chan, F McOmish, BC Dow, EA Follett, PL Yap and H Marsden, J.Clin. Microbiol., 31(6), 1493-1503 (1993)). The amino acid sequence of the nonstructural region, NS2-5B, was shown to be >97% identical to HCV genotype 1a (H77C) and 87% identical to genotype 1b (J4L6S). The infectious clones, H77C (1 a genotype) and J4L6S (1 b genotype) can be obtained from R. Purcell (NIH) and the
30 sequences are published in Genbank (AAB67036, see Yanagi,M., Purcell,R.H.,

Emerson, S.U. and Bukh. *Proc. Natl. Acad. Sci. U.S.A.* 94 (16) 8738-8743 (1997); AF054247, see Yanagi, M., St Claire, M., Shapiro, M., Emerson, S.U., Purcell, R.H. and Bukh, *Virology* 244 (1), 161 (1998)).

- 5 The BMS, H77C and J4L6S strains are used for production of recombinant NS3/4A protease complexes. DNA encoding the recombinant HCV NS3/4A protease complex (amino acids 1027 to 1711) for these strains were manipulated as described by P. Gallinari et al. (see Gallinari P, Paolini C, Brennan D, Nardi C, Steinkuhler C, De Francesco R. *Biochemistry*. 38(17):562032, (1999)). Briefly, a
- 10 three-lysine solubilizing tail was added at the 3'-end of the 3' NS4A coding region. The cysteine in the P1 position of the NS4A-NS4B cleavage site (amino acid 1711) was changed to a glycine to avoid the proteolytic cleavage of the lysine tag. Furthermore, a cysteine to serine mutation can be introduced by PCR at amino acid position 1454 to prevent the autolytic cleavage in the NS3 helicase domain. The
- 15 variant DNA fragment can be cloned in the pET21b bacterial expression vector (Novagen) and the NS3/4A complex can be expressed in *Escherichia coli* strain BL21 (DE3) (Invitrogen) following the protocol described by P. Gallinari et al. (see Gallinari P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkuhler C, De Francesco R., *J Virol.* 72(8):6758-69 (1998)) with modifications. Briefly, NS3/4A expression can
- 20 be induced with 0.5mM Isopropyl beta-D thiogalactopyranoside (IPTG) for 22hr at 20°C. A typical fermentation (10 l) yields approximately 80g of wet cell paste. The cells are resuspended in lysis buffer (10 mL/g) consisting of 25mM N-(2-Hydroxyethyl)Piperazine-N'-(2-Ethane Sulfonic acid) (HEPES), pH7.5, 20% glycerol, 500mM Sodium Chloride (NaCl), 0.5% Triton-X100, 1 ug/ml lysozyme,
- 25 5mM Magnesium Chloride (MgCl₂), 1 ug/ml DnaseI, 5mM beta-Mercaptoethanol (BME), Protease inhibitor - Ethylenediamine Tetraacetic acid (EDTA) free (Roche), homogenized and incubated for 20 mins at VC. The homogenate is sonicated and clarified by ultra-centrifugation at 235000 g for 1 hr at 4°C.
- 30 Imidazole is added to the supernatant to a final concentration of 15mM and the pH adjusted to 8. The crude protein extract is loaded on a Nickel Nitrilotriacetic acid (Ni-

M183-2

180

NTA) column pre-equilibrated with buffer B (25mM HEPES, pH8 20% glycerol, 500mM NaCl, 0.5% Triton-X100, 15mM imidazole, 5mM BME). The sample is loaded at a flow rate of 1mL/min. The column is washed with 15 column volumes of buffer C (same as buffer B except with 0.2% Triton-X100). The protein is eluted with 5 column volumes of buffer D (same as buffer C except with 200mM imidazole).

NS3/4A protease complex-containing fractions are pooled and loaded on a desalting column Superdex-S200 pre-equilibrated with buffer D (25mM HEPES, pH7.5, 20% glycerol, 300mM NaCl, 0.2% Triton-X100, 10mM BME). Sample is loaded at a flow rate of 1mU/min. NS3/4A protease complex30 containing fractions are pooled and concentrated to approximately 0.5mg/ml. The purity of the NS3/4A protease complexes, derived from the BMS, H77C and J4L6S strains, are typically judged to be greater than 90% by SDS-PAGE and mass spectrometry analyses.

15 The enzyme is generally stored at -80°C, thawed on ice and diluted prior to use in assay buffer. The substrate used for the NS3/4A protease assay, is conveniently RET S 1 (Resonance Energy Transfer Dipeptide Substrate; AnaSpec, Inc. cat # 22991)(FRET peptide), described by Taliani et al. in Anal. Biochem. 240(2):6067 (1996). The sequence of this peptide is loosely based on the NS4A/NS4B natural cleavage site except there is an ester linkage rather than an amide bond at the 20 cleavage site. The peptide substrate is incubated with one of the three recombinant NS3/4A complexes, in the absence or presence of a compound of the present invention, and the formation of fluorescent reaction product was followed in real time using a Cytofluor Series 4000. Useful reagents are as follow: HEPES and Glycerol (Ultrapur) can be obtained from GIBCO-BRL. Dimethyl Sulfoxide (DMSO) is 25 obtained from Sigma. Beta-Mercaptoethanol is obtained from Bio Rad.

Assay buffer: 50mM HEPES, pH7.5; 0.15M NaCl; 0.1% Triton; 15 % Glycerol; 10mM BME. Substrate: 2 uM final concentration (from a 2mM stock 20 solution in DMSO stored at -20°C). HCV NS3/4A type Ia (Ib), 2-3 nM final concentration (from a 30 5uM stock solution in 25mM HEPES, pH7.5, 20% glycerol, 300mM NaCl, 0.2%

M183-2

181

Triton-X100, 10mM BME). For compounds with potencies approaching the assay limit, the assay can be made more sensitive by adding 50 ug/ml BSA to the assay buffer and/or reducing the end protease concentration to 300 pM.

- 5 The assay is conveniently performed in a 96-well polystyrene black plate from Falcon. Each well contains 25ul NS3/4A protease complex in assay buffer, 50ul of a compound of the present invention in 10% DMSO/assay buffer and 25ul substrate in assay buffer. A control (no compound) is also prepared on the same assay plate. The enzyme complex is mixed with compound or control solution, typically for 1 min
- 10 before initiating the enzymatic reaction by the addition of substrate. The assay plate is generally read immediately using a spectrophotometer such as a Cytofluor Series 4000 (Perspective Biosystems). The instrument is conveniently set to read an emission of 340nm and excitation of 490nm at 25°C. Reactions are generally followed for approximately 15 minutes.

15

The percent inhibition can be calculated with the following equation.

$$100.- [(dF_{inh}/dF_{con}) \times 100]$$

- where dF is the change in fluorescence over the linear range of the curve. A
- 20 nonlinear curve fit is applied to the inhibition-concentration data, and the 50% effective concentration (IC₅₀) is calculated by the use software such as Excel XI-fit software using the equation:

$$y=A+((B-A)/(1+((C/x)^D))).$$

25


Various compounds of the invention exemplified above displayed IC₅₀s in the range 1nM to 6.9 micromolar and ED₅₀s in the sub-micromolar to micromolar range.

M183-2

182

Claims

1. A compound of the formula I:



5

wherein

A is COOR^1 , $\text{CONHSO}_2\text{R}^2$, CONHR^3 , or $\text{CR}^4\text{R}^{4'}$ wherein;

R^1 is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl;

R^2 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl;

10 R^3 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, $-\text{OC}_1\text{-C}_6$ alkyl, $-\text{OC}_0\text{-C}_3$ alkylcarbocyclyl, $-\text{OC}_0\text{-C}_3$ alkylheterocyclyl;

R^4 is $=\text{O}$, halo, amino, or OH ;

$\text{R}^{4'}$ is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl; wherein

15 R^2 , R^3 , and $\text{R}^{4'}$ are each optionally substituted with from 1 to 3 times with halo, oxo, nitrile, azido, nitro, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, $\text{NH}_2\text{CO}-$, Y-NRaRb , Y-O-Rb , Y-C(=O)Rb , Y-C(=O)NRaRb , Y-NRaC(=O)Rb , $\text{Y-NHSO}_p\text{Rb}$, $\text{Y-S(=O)}_p\text{Rb}$, $\text{Y-S(=O)}_p\text{NRaRb}$, Y-C(=O)ORb , Y-NRaC(=O)ORb ;

where Y is a bond or $\text{C}_1\text{-C}_3$ alkyl;

20 Ra is H or $\text{C}_1\text{-C}_3$ alkyl;

Rb is H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl or $\text{C}_0\text{-C}_3$ heterocyclyl;

p is 1 or 2;

20

M183-2

183

R^7 is C_1 - C_6 alkyl, C_1 - C_3 alkyl C_3 - C_7 cycloalkyl, or C_2 - C_6 alkenyl, any of which is optionally substituted with 1-3 halo atoms, amino or $-SH$;

$R^{7'}$ is H or taken together with R^7 to form a C_3 - C_6 cycloalkyl ring optionally substituted with $R^{7'a}$ wherein;

5 $R^{7'a}$ is C_1 - C_6 alkyl, C_3 - C_5 cycloalkyl, C_2 - C_6 alkenyl or J; any of which may be optionally substituted with halo;

q is 0 to 3 and k is 0 to 3; where $q+k \geq 1$;

W is $-CH_2-$, $-O-$, $-OC(=O)NH-$, $-OC(=O)-$, $-S-$, $-NH-$, $-NR^8$, $-NHSO_2-$, $-NHC(=O)NH-$ or $-NHC(=O)-$;

10 R^8 is a ring system containing 1 or 2 saturated or unsaturated rings each of which has 4-7 ring atoms and 0 to 2 hetero atoms selected from S, O and N, the ring system being optionally spaced from W by a C_1 - C_3 alkyl group; or R^8 is C_1 - C_6 alkyl, any of which R^8 groups can be optionally mono, di, or tri substituted with R^9 , wherein

15 R^9 is independently halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-Rb$, $Y-C(=O)Rb$, $Y-(C=O)NRaRb$, $Y-NRaC(=O)Rb$, $Y-NHSO_pRb$, $Y-S(=O)_pRb$, $Y-S(=O)_pNRaRb$, $Y-C(=O)ORb$, $Y-NRaC(=O)ORb$; wherein the carbocyclyl or heterocyclyl is optionally substituted with R^{10} ; wherein

20 R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or di- substituted with C_1 - C_6 -alkyl, sulfonyl, $(C_1$ - C_3 alkyl)sulfonyl, NO_2 , OH, SH, halo, haloalkyl, carboxyl, amide, $(C_1$ - C_3 alkyl)amide, or heteroaryl optionally substituted with C_1 - C_6 alkyl;

R^8 is H, C_1 - C_3 alkyl;

E is $-C(=O)-$, $-C(=S)-$, $-S(=O)_2-$, $-S=O-$, $-C=N-Rf$;

25 Rf is H, $-CN$, $-C(=O)NRaRa$; $-C(=O)C_1$ - C_3 alkyl;

X is $-NRx-$ where Rx is H, or C_1 - C_5 alkyl; or in the case where where E is $-(C=O)-$ X can also be $-O-$ or $-NRjNRj-$; wherein one of Rj is H, the other is H or J;

30 R^{11} is H, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-Rb$, $Y-C(=O)Rb$, $Y-(C=O)NRaRb$, $Y-$

M183-2

184

NRaC(=O)R_b , $\text{Y-NHSO}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{NRaR}_b$, Y-C(=O)OR_b , Y-NRaC(=O)OR_b ;

when $\text{R}^{7'}$ taken together with R^7 forms a $\text{C}_3\text{-C}_6$ cycloalkyl, then one of R_j , R_x , R_y or R^{11} can also be J;

- 5 J is a 3 to 10-membered saturated or unsaturated alkylene chain extending from the $\text{R}^7/\text{R}^{7'}$ cycloalkyl to R_j , R_x , R_y or R^{11} to form a macrocycle, which chain is optionally interrupted by one to three heteroatoms independently selected from: -O-, -S- or - NR^{12} - wherein 0 to 3 carbon atoms in the chain are optionally substituted with R^{14} ; wherein;

- 10 R^{12} is H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, or COR^{13} ;
 R^{13} is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl;
 R^{14} is independently selected from H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ alkoxy, hydroxy, halo, amino, oxo, thio, or $\text{C}_1\text{-C}_6$ thioalkyl;

Ru and R_z are independently H or $\text{C}_1\text{-C}_3$ alkyl;

- 15 m is 0 or 1; n is 0 or 1;

U is =O or is absent;

R^{15} is H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, $\text{C}_0\text{-C}_3$ carbocyclyl, $\text{NH}_2\text{CO-}$, Y-NRaR_b , Y-O-R_b , Y-C(=O)R_b , Y-(C=O)NRaR_b , Y-

- 20 NRaC(=O)R_b , $\text{Y-NHSO}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{NRaR}_b$, Y-C(=O)OR_b , Y-NRaC(=O)OR_b ;

G is -O-, - NR_y -, - NR_jNR_j -, ;

R_y is H, $\text{C}_1\text{-C}_3$ alkyl or J;

R^{16} is H; or $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, any of which

- 25 can be substituted with halo, oxo, nitrile, azido, nitro, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, $\text{NH}_2\text{CO-}$, Y-NRaR_b , Y-O-R_b , Y-C(=O)R_b , Y-(C=O)NRaR_b , Y-NRaC(=O)R_b , $\text{Y-NHSO}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{R}_b$, $\text{Y-S(=O)}_p\text{NRaR}_b$, Y-C(=O)OR_b , Y-NRaC(=O)OR_b ;


or a pharmaceutically acceptable salt or prodrug thereof.

30


2. A compound according to claim 1 with the formula lea-lee:

M183-2


185




lea




leb



lec



led




lee

where e is 1 or 2.


- 5 3. A compound according to claim 1 with the formula lfa-lfe

M183-2


186




Ifa




Ifb



Ifc




Ifd




Ife

where e is 0 to 2.


4. A compound according to claim 1, with the formula Ida-ldd




Ida



Idb



Idc



Idl




5

5. A compound according any preceding claim, wherein X is -NRx-

M183-2

187


6. A compound according to any preceding claim with the partial structure Ia, Ib or Iaa:



5 where e is 1 or 2

7 A compound according to any preceding claim, wherein E is $-C(=O)-$ or $-C=NR_f$.

10 8. A compound with the formula VI



wherein

R^7 , $R^{7'}$, R^8 , R^{11} , R^{15} , R^{16} , R_j , R_u , R_x , R_y , A , G , k , m , n , U are as defined in claim 1;
 q' is 0 or 1;

15 R_z is H, or together with the asterisked carbon forms an olefinic bond;

R_q is H or C_1 - C_4 -alkyl;

T is $-CHR^{11}-$ or $-NR_d-$, where R_d is H or C_1 - C_3 alkyl;


188

5

otherwise as defined in claim 1;

and pharmaceutically acceptable salts and prodrugs thereof

9. A compound according to claim 8 with the formula V1ea or V1eb:




10



10. A compound according to claim 8 with the formula Vifa.

M183-2

189



11. A compound according to claim 8 with the structure Vlda or Vldb




5


12. A compound according to any of claims 8 to 11, wherein Rz is H.
13. A compound according to any of claims 8 to 12 with the partial structure:

M183-2

190





14. A compound according to any of claims 8 to 12 with the partial structure





5

15. A compound according to claim 14, with the formula Vlaa or Vlab:



16. A compound according to claim 14, with the formula Vlac or Vlad:





10

17. A compound according to claim 14, with the formula Vlae-Vlaf

M183-2

191



18. A compound according to any of claims 8 to 17, where R_q is H or methyl.

5 19. A compound according to any preceding claim wherein R^{7'} is H and R⁷ is n-ethyl, n-propyl, cyclopropylmethyl, cyclobutylmethyl, 2,2-difluoroethyl, or mercaptomethyl.

20. A compound according to claim 19, wherein R⁷ is n-propyl or 2,2-difluoroethyl.

10

21. A compound according to any of claims 1 to 18 wherein R⁷ and R^{7'} together define a spiro-cyclopropyl or spiro-cyclobutyl ring, both optionally mono or di-substituted with R^{7'a} wherein;

15

R^{7'a} is C₁-C₆ alkyl, C₃-C₅cycloalkyl, or C₂-C₆ alkenyl, any of which is optionally substituted with halo or J.

22. A compound according to claim 21 wherein the ring is a spiro-cyclopropyl ring substituted with R^{7'a} wherein;

20

R^{7'a} is ethyl, vinyl, cyclopropyl, 1- or 2-bromoethyl, 1-or 2-fluoroethyl, 2-bromovinyl or 2-fluorethyl.

M183-2

192

23 A compound according to claim 21, wherein J is a 3 to 8-membered saturated or unsaturated alkylene chain optionally containing one to two heteroatoms independently selected from: -O-, -S- or -NR¹²-, wherein R¹² is H, C₁-C₆ alkyl, such as methyl, or -C(=O)C₁-C₆ alkyl, such as acetyl.

5 24. A compound according to claim 24 wherein J is a 5 to 8-membered saturated or unsaturated, all carbon alkylene chain.

25. A compound according to claim 23 or 24 wherein J is saturated or mono-unsaturated.






10 26. A compound according to claim 23, 24 or 25, wherein J is substituted with R¹⁴, wherein R¹⁴ is H or C₁-C₆alkyl.

27. A compound according to claims 23-26 with the formula Iga-Igf

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50


S

193



where e is 1 or 2.


- 28. A compound according to claims 23 to 26 with the structure Iha-Ihf.**




29. A compound according to claims 23-26 with the formula XIIIa, XIIIaa or XIIIb

M183-2

195






30. A compound according to claim 27, 28 or 29 with the partial structure



31. A compound according to claims 23 to 26 with the formula VIga-VIgc

M183-2




196




33. A compound according to claims 23 to 26 with the formula VIha-VIhc:

M183-2

197



33. A compound according to claim 31 or 32 with the partial structure:




5

34. A compound according to claim 32 or 33 with the partial structure:

M183-2

198



35. A compound according to claim 34, wherein Rq is methyl or H.
- 5 36. A compound according to any preceding claim, wherein A is $-CR^4R^{4'}$
37. A compound according to claim 36, wherein R^4 is C_1 - C_6 alkyl.
38. A compound according to claim 35, wherein R^4 is C_1 - C_3 alkylaryl or C_1 -
10 C_3 alkylheteroaryl.
39. A compound according to claim 37 or 38, wherein the alkyl moiety of R^4 is C_1 -
 C_3 alkanyl or C_2 - C_3 alkenyl.
- 15 40. A compound according to claim 41 or 42, wherein the aryl moiety of R^4 is optionally substituted phenyl.
41. A compound according to claim 38 or 39, wherein the heteroaryl moiety of R^4 is optionally substituted benzothiazole.
- 20 42. A compound according to claims 36 to 41, wherein $R^{4'}$ is $-NH_2$, fluoro or chloro.
43. A compound according to claims 36 to 41, wherein $R^{4'}$ is $-OH$.
- 25 44. A compound according to claims 35 to 41, wherein $R^{4'}$ is $=O$.
45. A compound according to claims 1 to 35, wherein A is $CONHR^3$.

46. A compound according to claim 45, wherein R^3 is optionally substituted C_0 - C_3 alkylaryl, C_0 - C_3 alkylheteroaryl, OC_0 - C_3 alkylaryl or OC_0 - C_3 alkylheteroaryl.

5 47. A compound according to claim 46, wherein R^3 is optionally substituted C_0 - C_3 alkylaryl or C_0 - C_3 alkylheteroaryl.

48. A compound according to claims 1 to 35, wherein A is $CONHSO_2R^2$.

10 49. A compound according to claim 48, wherein R^2 is optionally substituted C_1 - C_6 alkyl, preferably methyl.

50. A compound according to claim 48, wherein R^2 is optionally substituted C_3 - C_7 cycloalkyl, preferably cyclopropyl.

15

51. A compound according to claim 48 wherein R^2 is optionally substituted C_0 - C_6 alkylaryl, preferably optionally substituted phenyl.

52. A compound according to claims 1 to 35, wherein A is $COOR^1$.

20

53. A compound according to claim 52, wherein R^1 is H or C_1 - C_6 alkyl.

54. A compound according to claim 51 wherein R^1 is hydrogen, methyl, ethyl, or tert-butyl.

25

55. A compound according to any preceding claim, wherein W is $-OC(=O)NH-$, $-OC(=O)-$, $-NH-$, $-NR^8-$, $-NHS(O)_2-$ or $-NHC(=O)-$.

30

56. A compound according to claim 55 wherein W is $-OC(=O)NH-$ or $-NH-$.

M183-2

200

57 A compound according to claim 55 or 56 wherein R^8 is optionally substituted C_0 - C_3 -alkylcarbocyclyl or C_0 - C_3 -alkylheterocyclyl.

58 A compound according to claims 1 to 54 wherein W is -S- or preferably -O-.

59 A compound according to claim 58 wherein R^8 is C_0 - C_3 alkylaryl, or C_0 - C_3 alkylheteroaryl either of which is optionally mono, di, or tri substituted with R^9 , wherein;

R^9 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , OH, halo, trifluoromethyl, amino or amido optionally mono- or di-substituted with C_1 - C_6 alkyl, C_0 - C_3 alkylaryl, C_0 - C_3 alkylheteroaryl, carboxyl, aryl or heteroaryl being optionally substituted with R^{10} ; wherein

R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, C_1 - C_3 alkyl amide), sulfonyl C_1 - C_3 alkyl, NO_2 , OH, halo, trifluoromethyl, carboxyl, or heteroaryl.

60 A compound according to claim 59 wherein R^9 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, amino, di- $(C_1$ - C_3 alkyl)amino, C_1 - C_3 alkylamide, aryl or heteroaryl, the aryl or heteroaryl being optionally substituted with R^{10} ; wherein

R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino, mono- or di- C_1 - C_3 alkylamino, amido, C_1 - C_3 alkylamide, halo, trifluoromethyl, or heteroaryl.

61 A compound according to claim 60, wherein, R^{10} is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, amino optionally mono- or di substituted with C_1 - C_3 alkyl, amido, C_1 - C_3 -alkylamide, halo, or heteroaryl.

62. A compound according to any preceding claim wherein R^{10} is methyl, ethyl, isopropyl, tert-butyl, methoxy, chloro, amino optionally mono- or di substituted with C_1 - C_3 alkyl, amido, C_1 - C_3 alkylamide, or C_1 - C_3 alkyl thiazole.


M183-2

201

63 A compound according to claims 59 to 62, wherein R^8 is 1-naphthylmethyl, 2-naphthylmethyl, benzyl, 1-naphthyl, 2-naphthyl, or quinolinyln unsubstituted, mono, or disubstituted with R^9 as defined.

5 64 A compound according to claim 63 wherein R^8 is 1-naphthylmethyl, or quinolinyln unsubstituted, mono, or disubstituted with R^9 as defined.

65 A compound according to claim 63 wherein R^8 is:



10

wherein R^{9a} is C_1 - C_6 alkyl; C_1 - C_6 alkoxy; thio C_1 - C_3 alkyl; amino optionally substituted with C_1 - C_6 alkyl; C_0 - C_3 alkylaryl; or C_0 - C_3 alkylheteroaryl, C_0 - C_3 alkylheterocyclyl, said aryl, heteroaryl or heterocycle being optionally substituted with R^{10} wherein

15 R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or disubstituted with C_1 - C_6 alkyl, amido, C_1 - C_3 alkyl amide, heteroaryl or heterocyclyl; and




R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl) amide, NO_2 , OH, halo, trifluoromethyl, carboxyl.

20

66 A compound according to claim 63, wherein R^{9a} is aryl or heteroaryl, all optionally substituted with R^{10} as defined.

67 A compound according to 66, wherein R^{9a} is selected from the group consisted of :

25




M183-2

202

wherein R^{10} is H, C_1 - C_6 alkyl, or C_0 - C_3 alkyl- C_3 - C_6 cycloalkyl, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, amido, (C_1 - C_3 alkyl)amide, heteroaryl or heterocyclyl.

5 68. A compound according to claim 65, wherein R^{9a} is phenyl


69. A compound according to claim 68, wherein R^8 is:



10

wherein R^{10a} is H, C_1 - C_6 alkyl; C_1 - C_6 alkoxy; or halo; and R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl)amide, NO_2 , OH, halo, trifluoromethyl, carboxyl.

15 69. A compound according to claim 65, wherein R^8 is:



20

wherein R^{10a} is H, C_1 - C_6 alkyl, or C_0 - C_3 alkyl- C_3 - C_6 cycloalkyl, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, amido, (C_1 - C_3 alkyl)amide, heteroaryl or heterocyclyl; and R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl)amide, NO_2 , OH, halo, trifluoromethyl, or carboxyl.

M183-2

203

70. A compound according to any claim 65-70, wherein R^{9b} is C_1 - C_6 -alkoxy, preferably methoxy.

5 71. A compound according to any preceding claim, wherein Rx is methyl or preferably H.

72. A compound according to any preceding claim, wherein R^{11} is C_1 - C_6 alkyl, C_0 - C_3 alkyl/ C_3 - C_7 cycloalkyl, C_0 - C_3 alkylaryl or C_0 - C_3 alkylheteroaryl, any of which is optionally substituted with hydroxy, halo, amino, C_1 - C_6 alkoxy, C_1 - C_6 thioalkyl, 10 $COOR^{14}$, carboxyl, (C_1 - C_6 alkoxy)carbonyl, aryl, heteroaryl or heterocyclyl;

73 A compound according to claim 72, wherein the substituent is hydroxy or $COOR^{14}$.

15 74. A compound according to claim 73, wherein R^{11} is tert-butyl, iso-butyl, cyclohexyl, phenylethyl, 2,2-dimethyl-propyl, cyclohexylmethyl, phenylmethyl, 2-pyridylmethyl, 4-hydroxy-phenylmethyl, or carboxylpropyl.

20 75. A compound according to claim 74, wherein R^{11} is tert-butyl, iso-butyl, or cyclohexyl.

76. A compound according to claim 1 or 8, wherein Ru is methyl or preferably H.

25 77. A compound according to any preceding claim, wherein R^{15} is optionally substituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_0 - C_3 alkyl/ C_3 - C_7 cycloalkyl.

78. A compound according to claim 77, wherein R^{15} is cyclohexyl, cyclohexylmethyl, tert-butyl iso-propyl, or iso-butyl.

30 79. A compound according to claim 1 or 8, wherein m is zero and T is absent.

M183-2

204

80. A compound according to any preceding claim, wherein G is $-NR_y-$.
81. A compound according to claim 80, wherein R_y is methyl or preferably H.
- 5 82. A compound according to claim 80 or 81, wherein R_{16} is a nitrogen containing heterocycle which is N-linked to G.
83. A compound according to claim 82, wherein R_y is J.
- 10 84. A compound according to any of claims 1 or 8, wherein G is $-NR_JNR_J-$.
85. A compound according to claim 84, wherein m and n are zero.
86. A compound according to claim 84 or 85, wherein each R_J is H.
- 15 87. A compound according to claim 84 or 85, wherein one R_J is H and the other is J.
88. A compound according to any preceding claim, wherein R^{16} is C_1-C_6 alkyl, C_0-C_3 alkylheterocyclyl, C_0-C_3 alkylcarbocyclyl, any of which is optionally substituted with hydroxy, halo, amino, or C_1-C_6 alkoxy.
- 20 89. A compound according to claim 88, wherein R^{16} is methyl.
- 25 90. A compound according to claim 88, wherein R^{16} is 2-indanol, indanyl, 2-hydroxy-1-phenyl-ethyl, 2-thiophenemethyl, cyclohexylmethyl, 2,3-methylenedioxybenzyl, cyclohexyl, benzyl, 2-pyridylmethyl, cyclobutyl, iso-butyl, n-propyl, or 4-methoxyphenylethyl.

30

M183-2

205

91. A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable carrier therefore.
92. A pharmaceutical composition according to claim 91, further comprising an additional HCV antiviral, selected from nucleoside analogue polymerase inhibitors, protease inhibitors, ribavirin and interferon.
93. Use of a compound as defined in any of claims 1-90 in the manufacture of a medicament for the prophylaxis or treatment of flavivirus infections, including HCV.

Abstract of the Disclosure

- 5 Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds comprise a novel linkage between a carbocyclic or heterocyclic P2 unit and those portions of the inhibitor more distal to the cleavage site, which linkage which reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
219

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/SE05/000097

International filing date: 28 January 2005 (28.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: SE
Number: 0401288-6
Filing date: 19 May 2004 (19.05.2004)

Date of receipt at the International Bureau: 02 May 2005 (02.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.